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Abstract
Ability and willingness by HIV-positive individuals to maintain a high level of
adherence with complex antiretroviral treatment is critical to the success of Highly
Active Antiretroviral Therapy (HAART).
A sample ofHIV-positive individuals, accessing antiretroviral therapy from Lothian
based services, was assessed in order to determine if associations existed between
personality characteristics and level of adherence to treatment regimens.
Physiological and self-report measures of adherence were consulted. Personality and
coping style were evaluated using standardised assessments. Non-parametric
statistical tests were applied during the analysis.
Results indicated that there was evidence for an association between level of




When cases of AIDS were first diagnosed in 1979, and until quite recently, the
disease was considered to carry an almost certainly debilitating, downward course
leading to early death from opportunistic infections. Early medications used to treat
AIDS-related diseases, such as AZT (or Zidovudine), could only temporarily
suppress the levels ofHIV responsible for immune compromise. Benefits were often
only transient since circulating HIV remained in enormous quantities (termed viral
load), and also because the virus has a rapid and error-prone replication cycle that
allows it to quickly evolve resistance to any single antiretroviral medication. In 1996
the nature of HIV medical care, and the health outlook for patients, changed
dramatically with the advent of treatment regimens that added a new class of
antiretroviral medication (termed protease inhibitors) used in combination with
other antiretrovirals.
Highly active antiretroviral therapy (HAART), usually a protease inhibitor combined
with at least two other drugs, can suppress HIV viral load to undetectable levels,
increase indicators of immune system functioning such as CD4 lymphocytes1,
improves clinical health, and decreases AIDS-related mortality (Carpenter et al.,
1998). The success ofHAART requires the continual suppression ofHIV viral load
to such low levels that the virus cannot replicate rapidly enough to develop
medication resistance.
Early optimism regarding the widespread benefits of these medications is now
tempered by evidence that a significant proportion of individuals do not achieve or
sustain maximum reductions in viral load. Disease stage and previous antiretroviral
treatment history does influence response to current HAART treatment. However, an
especially critical determinant of treatment success is patient adherence. HAART
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regimens require that patients take multiple doses every day of each medication in
the combination. This can mean taking 20 or more pills a day, with each medication
in the regimen carrying specific dose-spacing requirements.
Depending on the combination, different medications within a particular treatment
regimen may need to be taken with food, without food, with water, or in temporal
sequence relative to other drugs in the combination. In a recent drug trial, failure of
patients to take even a single medication dose on 28 days during a 365-day clinical
treatment course, was strongly associated with treatment failure (Montaner et ah,
1998).
Helping patients achieve and maintain a successful response to HAART is very
significant for reasons related to both the patient's own well-being and the public
health. If adequate viral suppression is not achieved and sustained, the patient's HIV
infection can become permanently resistant to most current antiretrovirals. Those
who develop drug-resistant HIV can transmit these strains to others during high-risk
activities. Because research on chronic illness other than AIDS has shown that
patients have more difficulty adhering to complex regimens (Agras, 1989) or
regimens that include multiple medications (Blackwell, 1992), HAART regimens are
likely to prove especially difficult to adhere to. For medicine to bring about full
benefits for patients and the wider society in HIV care, it is essential to identify
factors that influence HIV treatment adherence and to then develop approaches to
promote adherence.
1 A CD4 lymphocyte is a small cell that is distributed by the bone marrow, but is developed in the thalamus of the brain. CD4
lymphocytes cause cellular immune responses. They are also referred to as CD4 cells, Helper T-Cells or simply T-Cells.
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1.1 HIV and AIDS
The following sections provide a general introduction to the main concepts behind
HIV/AIDS. This will include an analysis of the background to the HIV epidemic,
theories of causation, transmission of HIV, stages of HIV infection, and various
other issues which are important to consider in any introduction to HIV/AIDS as an
area of research.
1.1.1 Introduction to HIV/AIDS and issues of treatment
HIV stands for Human Immunodeficiency Virus. It was originally isolated in Paris in
May 1983 and belongs to a group of viruses called retroviruses. Viruses copy their
genetic material into the genetic material of human cells. This means that infected
cells stay infected for the rest of their lives. Through mechanisms, which are still not
understood, HIV prevents the immune system from working properly. Normally, the
body's immune system would fight off infection. HIV infects key cells (CD4 cells)
which co-ordinate the immune system's fight against infection. Many are actually
destroyed by being infected. Others, including CD4 cells, which are not themselves
infected, no longer work properly. The human immune system is immensely
complex and there are many ways in which it can be affected by a retrovirus such as
HIV. It is not clear what role (if any) other factors - known as co-factors - may play
in the development of immune damage. Although it is clear that HIV has a central
role in the development of AIDS, there remain unanswered questions about some of
the specific mechanisms by which it damages the immune system.
The definition of Acquired Immune Deficiency Syndrome (AIDS) has changed over
the years as a result of an increasing appreciation of the wide spectrum of clinical
manifestations of infection with HIV. Currently, AIDS is defined as an illness
characterised by one or more indicator diseases. Both in the presence or absence of
other causes of immune deficiency and with or without laboratory evidence ofHIV,
certain diseases when definitively diagnosed are indicative ofAIDS.
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1.1.2 Theories of origin of HIV
While discussion of the origins of HIV is interesting and potentially important
scientific debate, it is necessary to separate origins from cause. For example, the
identification of the origins ofHIV in African primates does not explain the cause of
the pandemic.
1.1.2.1 Types of retroviruses
HIV-1 and HIV-2 are just two members of a family of viruses called retroviruses.
Other viruses in this group are known to infect:
■ Humans, causing blood and nerve problems (HTLV-1)
■ Cats (FIV, which causes an AIDS-like illness in some cat species but not
others)
■ Monkeys (a variety of viruses called SIV - Simian Immunodeficiency Virus
- which causes an AIDS-like disease in some species ofmonkey)
■ Sheep (a retrovims which causes pneumonia).
1.1.2.2 The primate theory
HIV-1 is closely related to a version of SIV found in a species of chimpanzee.
Researchers have discovered a vims in these chimpanzees that appears to be a
'mosaic' vims which combines elements ofHIV with features of SIV. This vims is
between 70%-90% identical to HIV-1. Known as SIVcpz, this vims does not appear
to cause illness in the chimpanzee host. HIV-2 originated in the 'sooty mangabey'
monkey. As with SIVcpz in chimpanzees, this vims does not cause illness in sooty
mangabeys. Researchers believe that most African primates species have been
infected with a sexually transmitted form of SIV for thousands of years and that
these vimses no longer harm their hosts. However, when one type of SIV crosses
into a different species, it does cause illness. This theory suggests that HIV-1 and
HIV-2 may have been in the human population for anywhere between 25 and 100
years. It is thought that HIV successfully crossed the species barrier leading to the
current HIV epidemic in humans. The hunting and consumption of monkeys and
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apes by humans is thought to have led to HIV infection in humans. While it is likely
that forms of SIV have been infecting humans for a long time, virus mutations may
have led to the development of immunodeficiency viruses that were better able to
cross the species barrier and sustain infections in humans.
1.1.2.3 The polio vaccine link
This theory claims that HIV was spread from chimpanzees to humans through an
oral polio vaccine. The theory has been in circulation since the early 1990s. It is
argued that a polio vaccine, administered in central Africa in the late 1950s, was
cultured from primates infected with a version of SIV which subsequently infected
humans. The appeal of this theory relies on timing; administration of the vaccine
from 1957-1960 coincided with the first confirmed case ofHIV infection in Africa.
Independent analysis of the remaining stock of the vaccine has been conducted by a
number of researchers who conclude that there is nothing in the results to support the
theory that HIV was spread to humans via the polio virus clinical trials. They suggest
that HIV has been infecting humans for much longer than 40 years. Other theorists
have questioned this latest evidence and continue to support the polio vaccine
theory.
Scientific investigation of origins may help to understand how to combat HIV most
effectively. It is worth investigating populations who may have been exposed to HIV
for many years, such as those in Africa, in terms of understanding the actual history
ofHIV, its virulence, and possible immunity to it.
1.1.3 Transmission of HIV
HIV has been isolated from semen, vaginal secretions, lymphocytes, cell-free
plasma, cerebrospinal fluid, tears, saliva, urine and breast milk. However, not all
these fluids transmit infection, as the concentration of virus in them may be far too
low to be infectious. Particularly infectious are semen, blood (including menstrual
blood) and possibly cervical secretions.
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The main ways in which HIV is transmitted are:
■ Through unprotected anal or vaginal sexual intercourse. This is the
commonest mode of transmission of the virus throughout the world.
■ Through blood to blood contact. This mainly happens through the sharing of
injecting equipment among injecting drug users. In the past, before screening
was introduced, this also occurred through blood transfusions or from
infected blood products such as the Factor VIII used to treat haemophilia.
Very rarely, infection can occur through occupational accidents amongst
healthcare workers, such as needle-stick injuries or skin and mucosal
exposure to infected blood or body fluids. Fortunately, follow-up studies of
healthcare workers suffering percutaneous exposure to a known HIV
seropositive patient indicate a transmission rate of 0.32%.
■ Vertically, from an HIV-positive woman to her baby during the course of
pregnancy (in utero), at birth, or during breast-feeding. The average risk of
transmission during pregnancy is in the region of 10-15%, although it may be
greater if the mother has a high viral load (the amount of HIV in her blood
which indicates the rate at which the virus is reproducing in the body) or has
developed AIDS.
The virus is not spread by casual or social contact. There is no evidence that HIV is
spread by mosquitoes, lice, bed bugs, in swimming pools, or by sharing cups, eating
and cooking utensils, toilets and air space with an infected individual. In other
words, HIV infection and AIDS are not contagious.
1.1.4 Mechanism of action of the HIV virus
Although it is clear that HIV is the underlying cause of AIDS and AIDS-related
disease, it's origin, as already discussed, remains obscure. Serological evidence
suggests that HIV infection in central Africa pre-dates infection in North America.
Analysis of the HIV-1 genetic material, or genome, has suggested an origin in
chimpanzees while, in the case of HIV-2, genome similarity points to an origin in a
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species of monkey. In both cases the consumption of these 'bush meats' has been
incriminated in the transmission to the human host. HIV appears to have mutated
and shifted its host range and virulence, explaining how a new pathogenic retrovirus
could arise in humans. Its virulence may since have been amplified as a result of
travel, population dislocation and promiscuous sexual contact, with a resultant rapid
passage of the virus.
HIV is specifically known as a retrovirus. Retroviruses are so named because their
genomes encode an enzyme called reverse transcriptase, which allows DNA (the
virus 'blueprint') to be transcribed from RNA (a more basic form of DNA). Thus,
HIV can make copies of its own genome, as DNA, in host cells such as the human
CD4 'helper' white blood cells (lymphocytes). The viral DNA becomes integrated in
the lymphocyte genome, and this forms the basis for chronic HIV infection. Such
integration of the HIV genome into host cells is a formidable barrier to any antiviral
treatment that would not only suppress but also eradicate the infection. However the
basis of modern treatment is the use of combinations of antiretroviral agents which
has altered the mechanism of action of the HIV virus and transformed the prognosis
for HIV-positive individuals.
1.1.5 Early history and development of the HIV epidemic
In 1981 doctors in the USA began to notice a series of unusual infections in gay men
in Los Angeles, New York, and other big cities. These infections had previously
been extremely rare except amongst people whose immune systems had been
seriously weakened in some way. The most life-threatening seemed to be
Pneumocystis carinii pneumonia and Kaposi's sarcoma. However a whole range of
other severe infections and tumours had also been detected amongst gay men in
these cities.
In addition, doctors had begun to find persistently swollen lymph glands in otherwise
perfectly healthy gay men. The majority of these men stayed healthy for months or
16
years after diagnosis. However some went on quickly to develop the infections
mentioned above.
These problems were first reported in June 1981 by the U.S. Centre for Disease
Control (CDC). A CDC report brought the syndrome to the attention of doctors in
other U.S. cities. By late 1981 researchers were beginning to link these opportunistic
infections to damage to the immune systems of those who were affected. Even
though the condition became known early on as AIDS, its cause and modes of
transmission were not immediately obvious. The virus now known to cause AIDS in
a proportion of those infected was discovered in France in 1983 and given various
names. Since 1986 it has generally been referred to as HIV.
In 1984 a test for detecting antibodies to HIV was developed and this revealed that
only a relatively small proportion of people with HIV had gone on to develop AIDS.
AIDS was simply one end of a spectrum of different effects of HIV infection,
ranging from staying well through to life-threatening opportunistic illnesses.
In 1986 HIV-2 was discovered, and some researchers are claiming there may be
other different strains of the virus. Fortunately these all appear to behave in the same
way and this need not change advice about transmission, prevention, safer sex and
hygiene. HIV-2 has not been studied as extensively as HIV-1. However it seems that
it causes less severe immune damage than HIV-1 in the long term, and that people
with HIV-2 may on average stay healthy for longer than those with HIV-1. In
particular HIV-2 has been isolated in people with West African connections.
95% of all new HIV infections occur in developing countries and continents, the
epidemic being concentrated in sub-Saharan Africa and south-east Asia. It is now
recognised that cases of AIDS were first seen in Central Africa in the 1970s even
though at that time it was not recognised as such. Prevalence is at its highest among
prostitutes (50-90%) and those attending departments for sexually transmitted
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diseases and antenatal clinics (60-70%). In the developing world, HIV is spread
mainly by heterosexual intercourse.
In North America and the UK the first wave of the epidemic occurred in homosexual
men. Even though infections amongst men who have sex with men still arise, an
increasing proportion of new infections are occurring amongst intravenous drug
users sharing needles and equipment. There is also an increase amongst
heterosexuals in both the USA and the UK. Thus the nature of the epidemic in the
UK is changing with more heterosexual transmission. In the UK 12% of adult cases
of AIDS have occurred in women, 70% of which have resulted from heterosexual
intercourse. In 2000 there were more new annual infections ofHIV than ever before
and for the first time more were occurring as a result of heterosexual sex than men
having sex with men (SCIEH, 2000).
The advent of an effective antibody test in 1984 has created more clarity regarding
the changing prevalence and natural history of HIV infection. It has been observed
that the proportion of individuals infected needs to be high before cases of AIDS
start to become apparent. It also highlights the importance of health education
campaigns early in the epidemic, when the seroprevalence ofHIV is low. Once cases
of AIDS start to appear the epidemic drives itself and a much greater effort is
required in terms of control and medical care.
Within countries a considerable variation in seroprevalence rates for HIV can
become apparent. Over 70% of cases of AIDS and HIV infection within the UK
occur and are observed in London and the surrounding area. Among different groups
geographical differences are also noticed. For example, the rates among injecting
drug users are higher in Edinburgh than in London, and for gay men higher in
London than anywhere else in the UK.
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1.1.5.1 Prevalence and Patterns ofHIV Infection in Lothian
In 1985 a high prevalence ofHIV was discovered in injecting drug users in Lothian,
which led Edinburgh to be dubbed "The AIDS capital ofEurope".
Figure 1 (page 21) shows the large numbers found to be infected when the test for
HIV became available in 1985 and testing of stored blood showed that the majority
of drug users had become positive in 1983 and 1984. In total, 1,684 people have
been tested and/or treated in Lothian to June 2002. Of these, 684 are known to have
died; 392 of these were drug users. After 1985 and 1986, when special clinics were
set up to counsel and test intravenous drug users (IDUs) who might have been at
risk, the numbers rapidly fell, probably because HIV had infected all those at risk in
the IDU population. HIV had probably saturated the population of an estimated
2,000 injectors at that time. Since the early 1990s the numbers being tested positive
have remained fairly static, with between 60 and 80 cases diagnosed in Lothian each
year. Most of those diagnosed latterly have acquired HIV through sexual
transmission, either heterosexual or homosexual.
Figure 2 (page 21) shows the incidence of both AIDS cases and deaths in all groups.
In common with reports from all over the developed world, when combination
therapy became readily available in 1987, the incidence of opportunistic infections,
leading to an AIDS diagnosis rapidly declined as did deaths overall. Until 1987 the
number of new infections were matched by the number of deaths, so that the
absolute number ofHIV positive people in Lothian remained relatively static. Since
1987, the number of people attending clinics for treatment, and the numbers
receiving treatment, have steadily risen. Similarly, concerns have been raised about
escalating cost, about the possibility of complacency over transmission, and the
possibility of transmission of resistant virus.
Figure 3 (page 22) shows the frequencies of individuals by risk group, who are
currently receiving treatment. In March 2002, the month for which these latest
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figures are available, there were over 450 people receiving combination therapy. The
majority were on 3 drug regimes, but an increasing number (170) of people were
observed on regimes containing more than 3 drugs. This is one indication of the
struggle that clinicians are experiencing in trying complex regimes with people who
have first attended ill, and therefore need highly potent regimes, or in patients who
have tried a number of regimes in the past and have developed resistance. Much of
the latter can be ascribed to adherence problems, for a number of reasons, which will
be explored in later sections of this introduction.
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The use of highly active antiretroviral therapy (HAART) as a treatment strategy in
resource-rich countries has resulted in an increase in life expectancy. In combination
with the increase in new HIV infections, this means that the prevalent pool of those
infected, and potentially infectious, is increasing. This presents a continuing
challenge for health promotion and a re-statement of the importance of safe sex
techniques, particularly condom use.
1.1.6 Treatment of HIV infection
The treatment of HIV infection can be largely divided into: 1) specific antiviral
agents that inhibit viral replication, and 2) measures that either treat or prevent
(prophylaxis) it's complications - namely opportunistic infections and tumours.
Advances in the treatment of HIV infection have resulted in marked falls in the
number of reported new AIDS cases and deaths in the developed world since 1996.
The main reasons for this have been effective antiretroviral therapy regimens which
substantially inhibit HIV replication and allow durable improvements in the immune
system. In those who are severely immunosuppressed the treatment and prophylaxis
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of opportunistic infections remains important. The most effective way to prevent
first episodes or recurrence of opportunistic infections is treatment with
antiretroviral drugs. One strategy to provide more potent suppression of HIV, and
more durable suppression by delaying the emergence of resistant virus, is the use of
combination therapies. Clinical trials over recent years have clearly demonstrated the
superiority of combination therapies over monotherapies in achieving improved
clinical outcomes.
1.1.6.1 The theory of early intervention
Until recently, the issue of when to start treatment for HIV/AIDS has been
dominated by the theory of early intervention. The idea of early intervention is to
provide prompt medical treatment relatively early in the course of HIV infection,
before clinical illness has developed, with the aim of preventing or delaying the
appearance of symptoms. It is considered a form of prophylaxis against developing
symptomatic HIV disease or AIDS.
There are three possible approaches to early intervention:
■ Using anti-HIV drug combinations
■ Using immune stimulants or therapeutic vaccines
■ Using prophylaxis against opportunistic conditions
It is also worth noting that many people regard maximising their general state of
health as an excellent early intervention, although it does not strictly fit the exact
definition of early intervention. This may range from giving up smoking or other
drugs, taking exercise, or improving diet, to stress reduction, relaxation, and other
alternative therapies. No scientific studies to date have provided strong evidence
that, in themselves, these pursuits make a direct difference.
Since the mid-nineties, antiretroviral therapy has taken centre stage in HIV
treatment. There was a strong push to 'hit hard, hit early' in order to prevent damage
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to the immune system and the illnesses that follow. It is also felt that current drugs
have a greater chance of reducing viral load to undetectable levels if the treatment
starts when viral load is relatively low (below 50,000 copies).
However, over the last three years there has been a shift away from early treatment
in the asymptomatic phase of HIV infection, for several reasons. There is growing
concern about the long-term toxicities of HAART and long-term side effects may
lower quality of life. Secondly, the clinical benefits of treatment begun before the
onset of advanced disease remain largely unproven. Finally, preliminary evidence
from several large studies shows no advantage to starting treatment with a CD4
count2 above 350 compared with starting treatment with a CD4 count between 200-
350, at least in the short-term (1-2 years). There is uncertainty as to how long the
drugs should be taken for and resistance may develop if the treatment fails. This may
leave a person cross-resistant to many of the drugs now available. During early 2001,
revised British and US guidelines moved away from early treatment strategies in
people with chronic infection.
Two different blood tests are used to monitor the progress of the virus, CD4 count
and viral load count. Because CD4 count and viral load are directly influenced by
antiretroviral drugs, both counts have also been used as a measure of an individual's
adherence to their medication regimen.
1.1.6.2 CD4 Count
CD4 cells are the white blood cells (lymphocytes) in the immune system which are
targeted by HIV. A CD4 count measures the number of these cells contained in a
cubic millimetre of blood. The lower the CD4 count, the more damage the immune
system has sustained from HIV infection. An individual with a CD4 count less than
200 cells/mm3 would be described as severely immunosuppressed.
24
1.1.6.3 Viral Load
Viral load count is a measure of the amount of HIV in the blood (the number of
copies ofHIV in 1 millilitre of blood plasma). Reducing viral load has been shown
to reduce the risk of dying from AIDS. It has also been shown to improve the health
of people with AIDS-related illnesses. Reducing viral load and keeping it down is
the aim of antiretroviral therapy. The aim of treatment should be to achieve and
maintain undetectable viral load (below 50 copies/ml of blood plasma). For people
who have taken several anti-HIV regimens, the aim of treatment may be to boost
CD4 cell count rather than to achieve undetectable viral load. To strive for
undetectable viral load may mean using many drugs which may in turn produce
severe side-effects.
1.1.6.4 Antiretroviral therapy for HIV/AIDS
HIV contains nine genes, which carry all the information needed to make new
viruses. When HIV locks onto a CD4 lymphocyte its genetic material is absorbed
into the cell. HIV then makes a copy of its genetic information. This is called a
provirus. HIV uses an enzyme of its own, called reverse transcriptase, to do this.
Drugs called reverse transcriptase inhibitors can stop the virus from making these
copies. The provirus, or copy, is then inserted into the genetic code of the host cell.
HIV uses another of its enzymes, called integrase, to do this. The provirus is put into
the genetic code, or genome, by cutting the genome and slipping in the HIV
provirus. Drugs are being developed to stop integrase from doing this.
Some of HIV's genes can instruct the cell to use its own machinery to make new
viruses. When the cell receives these instructions, it makes another copy of the
provirus that is bound up in its genetic material. This copy is then used to generate
the production of new viruses from materials supplied by the cell. In effect, the cell
2 CD4 Count - The number of CD4 cells in a microlitre of blood plasma. HIV attacks CD4 cells and their number falls as the
infection gets more serious.
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has been hijacked by HIV and turned into a virus factory. Each cell can produce
dozens, if not hundreds, of virions (virus copies).
The new viral building blocks need to be assimilated. Another HIV enzyme, called
protease, is produced to do this job. Drugs called protease inhibitors can stop this
process. If viruses can be assembled they are packaged in the cell wall of the host
cell. They are pushed through the cell wall and are then free to enter the bloodstream
and pass into other cells.
Thus antiretroviral drugs target specific stages of the HIV life cycle, preventing it
from reproducing itself. There are currently three classes of antiretroviral agents,
each attempting to disable the virus at a different stage of it's life cycle: the
nucleoside and non-nucleoside reverse transcriptase inhibitors and the protease
inhibitors.
1.1.6.4.1 Reverse transcriptase inhibitors
Reverse transcriptase is a unique characteristic of retroviruses such as HIV. Once
HIV releases its genetic material into a human host cell, the reverse transcriptase
enzyme helps assimilate the protein building blocks in the cell to make more copies
of viral DNA. Reverse transcriptase inhibitors block this process.
The main class of reverse transcriptase inhibitors comprises the nucleoside analogue
drugs. Nucleoside reverse transcriptase inhibitors include: AZT, ddl, ddC, abacavir,
3TC and d4T. Non-nucleoside reverse transcriptase inhibitors include: nevirapine,
delavirdine, and efavirenz.
1.1.6.4.2 Protease inhibitors
Protease inhibitors also act against the enzyme that HIV uses to break up large
proteins into the smaller proteins from which the new viral particles are produced.
New HIV particles produced in the presence of protease inhibitors are immature and
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non-infectious. The protease inhibitor drugs include: indinavir, saquinavir,
ritonavir, nelfinavir, and amprenavir.
1.1.6.5 Combination therapy
HIV makes numerous mistakes when it copies itself. Unlike human cells it is unable
to detect these errors or remove them. Many of these copies are so faulty that they
cannot infect other cells, or they will only reproduce very slowly. These copies of the
HIV virus are those that are targeted by antiretroviral drugs. However, some viral
copies will develop genetic changes which allow them to make copies even when
antiretroviral drugs are around. This is known as drug resistance.
Every antiretroviral drug works against a slightly different part ofHIV's protease or
reverse transcriptase enzymes. Each enzyme is made up ofmany pairs of chemicals
called amino acids. Sometimes these amino acids will be placed in different
positions as a result of faulty copying. This gives the virus the ability to continue
making copies even when high levels of an antiretroviral drug are present. However
another antiretroviral drug may have more success in stopping reverse transcriptase
from working because it's target is a different set of amino acids on the 'mutant'
virus. It is for this reason that a combination of drugs in therapy is more effective
than using one drug in isolation to fight the virus.
Combination therapy can use different drugs, which attack the same enzyme, or it
can use a combination of drugs, which attack several different enzymes
simultaneously. It is not known which approach is best in the long-term.
Combinations of two or more drugs have been shown to substantially reduce the risk
of disease progression and death. The best results are usually seen with combinations
that include a protease inhibitor and reverse transcriptase inhibitors. Currently,
combinations of at least three anti-HIV drugs (triple therapy) are the standard of
treatment. Individuals considering treatment need to discuss the most suitable drug
combination with their doctor. A number of factors need to be examined including
27
current state of health, potential side effects, and how taking the drugs will fit into
their lifestyle. The best combination for anyone is that which best fits their lifestyle
and achieves maximum suppression ofHIV.
1.1.6.6 Side effects of antiretroviral therapy
The drugs used in combination therapy are particularly powerful drugs, many of
which have strong side-effects. Additionally, the more drugs an individual takes in
combination, the greater the chance of unwanted interactions between them. The
side-effects ofmost drugs are well established. Information on toxicities is gathered
during clinical trials and reports from prescribing doctors. However, many drugs
used by people with HIV are relatively new and the urgent need for effective
medications has meant that many anti-HIV drugs are released onto the market after
only a relatively small number of people have taken them for a relatively short
period of time. Information on side-effects and adverse drug interactions can be less
complete than with other medications.
In the age of HAART, drug side-effects are a common cause of ill-health among
people with undetectable viral load or asymptomatic HIV disease. Allergic side-
effects occur when the immune system reacts to a drug by causing symptoms such as
a rash or a fever. Allergic reactions will occur despite the dose of drug taken.
Starting at a low dose can desensitise the immune system to the allergic reaction.
Allergic reactions can be so serious that they become life-threatening. Other side-
effects may be caused directly by unwanted effects of the drug itself, rather than by
the immune system's response. A wide range of potential side-effects is possible and
may include: anaemia, nausea, diarrhoea, bloating, abdominal discomfort, headache,
dizziness, general malaise, fatigue, and reduced sex drive.
Side-effects such as nausea, vomiting, diarrhoea, abdominal pain, and headache and
dizziness, tend to be associated with the time at which drug levels reach their peak in
the blood. Given the frequency of daily doses, this is why side-effects may occur
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regularly at certain times of the day. The inconvenience of these side-effects may be
reduced by adjusting the time at which particular medications are taken throughout
the day. However this will depend on individual eating schedules and the need to
take medications with food or on an empty stomach. Frequently, even more drugs
need to be taken to deal with unwanted side-effects, such as anti-nausea or anti-
diarrhoea medicines. This can exacerbate the frequency of pill-taking episodes and
make medication adherence even more problematic.
Other side-effects, associated with the long-term use of antiretrovirals, include
lipodystrophy, wasting of the arms, legs and face, and metabolic abnormalities
including high blood lipids, insulin resistance and high lactate levels. Coping with
side-effects can become a constant challenge for individuals taking antiretroviral
therapy. Consequently, they can make it very difficult for people to successfully
adhere to therapeutic levels of antiretroviral regimens.
1.1.6.7 Resistance to antiretroviral drugs
Resistance can develop against all current antiretroviral drugs and is a major factor
contributing to therapy failure. Resistance occurs when HIV mutants emerge which
can reproduce in the presence of a drug. The mutated virus forms the basis of a new
virus population because they can reproduce despite the antiretroviral drug being
present. Once resistance to one drug has emerged, this virus population may also be
resistant to other drugs not yet taken. This is called cross-resistance. Drug resistant
viruses can be transmitted and 10-15% of patients presenting with primary HIV
infection already have mutations associated with drug resistance (Gottlieb, 2000).
Opportunity for resistance is greatly reduced if every prescribed dose of
antiretroviral drug is taken. A missed dose causes blood concentrations of the drug
to fall, making it easier for mutant viruses to reproduce. Patients who achieve
sustained falls in plasma viral load to <400 copies/ml are less likely to develop
mutations associated with drug resistance than those who do not. The more often
doses are missed, the more likely it is that resistant viruses will emerge. Resistance
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testing is possible, and can guide a choice of therapy in individuals changing
treatment and in those recently infected.
Poor adherence to combination therapy is a major contributor to developing
resistance to antiretroviral drugs.
1.1.6.8 AIDS, survival and mortality in the HAART era
Since mid-1996 the widespread use of HAART has seen a dramatic decline in the
number of AIDS-related deaths in many countries. A concommitant increase in the
number of people living with HIV and AIDS has also been observed. Research
presented at the 39th Interscience Conference on Antimicrobial Agents and
Chemotherapy suggests that the incidence of AIDS-defming events has fallen
dramatically across Europe during the HAART era. Data from 7,200 participants of
an HIV positive cohort found that 31% became ill within a year in 1994, but that this
rate had fallen to 3% by 1998 (Reiter et al, 1999). This period was marked by the
gradual introduction of anti-HIV therapies. Death rates also fell between September
1994 to March 1998 from 23.3 deaths to 4.1 deaths per 100 persons. The decline in
mortality was most striking among people with very low CD4 counts. Among people
with CD4 counts between 50-99, the death rate fell from 20% to 7% during the study
period. Among people with CD4 counts below 50, the death rate fell from 60% to
8%. Increased survival was strongly associated with combination therapy. For people
not on treatment the death rate was 65.4%. For those on dual and triple combinations
of treatment, the death rates were 7.5% and 3.4% respectively. The lowest death rate
was observed among those who commenced treatment with a triple combination
(Mocroft et al, 1998). A study of 421 people with HIV attending the Royal Free
Hospital in London who commenced HAART, found that incidence of death among
patients on treatment was l/6th of pre-HAART levels, while the incidence of new
AIDS-defming illnesses and hospital admissions was 1 /7th and l/5th respectively
(Mocroft et al, 2000).
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American research also reveals the dramatic impact of antiretroviral therapy on the
health and survival of people with HIV. The number of AIDS-related deaths in New
York City for example, fell by 63% between 1995 and 1997. The actual number of
deaths has fallen from over 7,000 to 2,625 per year. However, this decline in the
number of AIDS deaths has slowed. In the USA there were 17,047 deaths from
AIDS in 1998 compared with 21,222 in 1997. The slowing of the decline in deaths




1.2.1 Introduction to treatment adherence
Getting people to take their medication as prescribed has always been a problem for
medicine and a concept long known to health psychology (Buckalew & Sallis, 1986;
Ley, 1997). Whether or not medications are taken, forgotten or discarded very often
depends upon the differences and diversities of the individual lives of patients. Thus
medication adherence is widely perceived to be beyond the influence of clinicians.
This section considers the issue of non-adherence among individuals with chronic or
life-threatening conditions including HIV/AIDS.
1.2.2 Adherence and chronic illness - the research base
The magnitude of the problem of poor adherence to long-term medical regimens for
chronic disease has been well documented over the last 30 years or more. The rates
have changed little over that time period (Dunbar-Jacob, Dwyer & Dunning, 1991).
Various research studies have suggested that as much as 80% of patients would not
follow their treatment programme sufficiently in order to achieve therapeutic benefit
(Dunbar-Jacob, Burke and Puczynski, 1995). Furthermore, the problem of non-
adherence crosses age groups, diagnoses, and socioeconomic variables as well as
various treatment regimens (Goodall & Halford, 1991). Meichenbaum and Turk
(1987) estimated slightly improved estimates of medication non-adherence, across
various illnesses, typically ranging from 30% to 60%. However, the non-adherence
percentage rate was observed to be greatest when the patients studied were reported
as symptom-free. This is of particular relevance when applied to HIV/AIDS where
individuals can be asymptomatic for considerably lengthy periods of time.
Medication remains the most widely studied regimen with the vast majority of
studies occurring in chronic disease. One of the most commonly studied is
hypertension. Average rates of adherence among people with hypertension tend to
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average about 64% (Dunbar-Jacob, Dwyer and Dunning, 1991) and even with great
attention to improving these rates over the past two decades, significantly little
change has occurred. Highest rates have tended to be observed in family practice
sites with hospital out-patient clinics showing the smallest proportion of adherent
patients (Dunbar, Dunning, Dwyer, Burke & Snetselaar, 1991). Adherence rates
among people with other chronic disorders are similarly problematic. 40% to 60% of
people with rheumatoid arthritis adhere to medication targeting inflammation of the
joints (Hicks, 1985), among people with chronic pulmonary disease more than 50%
report missing or discontinuing medication (Dolce et al, 1991), and in patients
receiving organ transplants adherence rates of 57% to 85% have been reported
(Rovelli et al, 1989; Schweitzer et al, 1990).
Although adherence to medication regimens has been most widely studied, there is
also evidence that making changes in other health-related behaviours, such as diet
and exercise, is even more difficult (Lynch D.J. et al, 2000; Lynch D.J. et al, 1992).
The rates reported for other specific diseases are similar to those stated above.
Despite as few as 20% and as many as 80% of people adhering to a specific
treatment medical regimen within a specific sample, overall adherence studies
appear to suggest that a crude estimate of between Vi to 3A of patients across a broad
range of diseases adhere to treatment, at least sufficiently enough to obtain
therapeutic benefit. These rates of adherence are problematic whether the disease is
symptomatic or not (e.g., rheumatoid arthritis vs. hypertension or asymptomatic HIV
infection) and whether the disorder is or is not more immediately life-threatening
(e.g., organ transplantation vs. hypercholesterolemia3). The research into adherence
and chronic illness will be returned to in Section 3 of this chapter, which also
considers the extent of the role ofpersonality characteristics.
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1.2.3 Research into adherence to HAART
The strict medication regimens of HAART make adherence a constant problem for
HIV infected individuals4. Currently, HIV clinics, care services and HIV prevention
organisations are all developing initiatives focussed on confronting the problem of
adherence to HAART. The issue of who is best placed to address this problem
remains largely open. There is therefore an opportunity for clinical psychology to
apply research skills to this area and potentially offer suggestions for intervention.
Any enthusiasm to respond to the problem is fully justified given the crucial role of
adherence in the long-term success of antiretroviral therapy. Ultimately, the
challenge adhering to HAART has to be met by the patients themselves, as it is they
who are left with the task of taking medications on a daily and routine basis. This
would imply that only self-help in its most basic form would ensure that the process
takes place as it should.
Recent evidence has suggested that most people with HIV cope relatively well with
the demands of adherence to HAART (AIDS Treatment Update, Adherence special
issue, 1999). In a qualitative study of HAART (Anderson & Weatherburn, 1998),
participants described their experiences of learning to live with the pills. Individual
stories were characterised by the process of adjusting to the routines of their daily
lives; integrating the treatment schedule meant making the pills as routine as
everything else. Most participants described daily routines with varying degrees of
acceptance, frustration and resentment. However all shared a common commitment
3
Hypercholesterolemia - A genetic disease in which too much cholesterol is present in the blood. There is no cure but it can
be controlled by diet regimens.
4 The experience of an individual, from the thesis research sample, reflects the strict requirements of a HAART regimen:
Mr 'A' is 52 years old and, although currently unemployed, is a part-time voluntary worker. He is on a current combination
therapy of four different antiretroviral drugs; Abacavir (12 per day), saquinavir (3 per day), Ritonavir (3 per day) &
Efavirenz (3 per day). Mr A takes a total of 21 antiretroviral pills every day. He has specific instructions to take these pills
twice per day, at 1 Oam & 10pm. In addition some of these pills are to be taken with food and some not. IfMr A deviates from
any of these instructions the drugs may not have any therapeutic benefit. Mr A finds some of the pills almost too large to
swallow even with a drink. He reports that he misses a dose about once or twice every week. He sometimes takes his pills at a
different time than that specified - around four times every month. He cites routine interruptions and forgetfulness as common
reasons for not adhering accurately to his regimen. He has no currently reported adverse drug side-effects, but the daily
inconvenience of taking his medication, especially during work, has resulted in him considering a 'drug holiday'. In addition
to his antiretrovirals, Mr A takes a further 7 prescription pills every day for anxiety, anti-sickness, and to boost thiamine and
folic acid levels. In total Mr A takes 28 pills every day for the foreseeable future.
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to taking the pills and to making whatever adjustments to life that were necessary.
Furthermore, in a recent national study (Anderson & Weatherburn, 1999), almost all
(97%) of those who were taking HAART agreed with the statement that 'HIV is still
a very serious condition'. 94% said that 'HIV can become resistant to treatments,
especially if they are not taken properly'. Therefore, not only is HIV still perceived
to be a serious medical condition, but the consequences of non-adherence are also
understood to be very serious.
The incentives for adhering to HAART are unusual among treatments for chronic
diseases. The general research literature on adherence to medications proposes that a
willingness to take treatment depends on assessment of the severity of the illness and
susceptibility to it. In other words, if you do not think that your illness is very
serious, or think that it will not affect you much, you are unlikely to take medications
properly. The vast majority of people with HIV are in no doubt where they stand
with these issues. Consequently, although rates of adherence average around 50% in
many other conditions (Blackwell, 1996), people with HIV miss a dose much more
rarely. The contrast with research into other illnesses draws attention to how
comparatively well people with HIV are doing in adhering to their medications.
Nevertheless, due to the life-threatening mechanism ofHIV infection, a particularly
high level of adherence is essential if viral suppression is to be sustained. HIV
disease is associated with all the predictors of low adherence: long duration of
treatment, preventative rather than curative treatment, asymptomatic periods, and
frequent and complex medication dosing. Non-adherence is related to viral
resistance (Condra et al, 1995), a problem that affects not only the individual under
treatment but also public health concerns about future treatment and containment of
HIV infection. This then makes non-adherence a major problem among patients
treated for HIV infection. Before the HIV era, adherence levels above 80% were
seen as satisfactory, but now the target is 100%. A number of recent studies have
reported on the levels of adherence to HIV therapies (Belzer, Fuchs, Luffman and
Tucker, 1999; Gordillo et al, 1998; Kastrissios, Suarez and Katzenstein, 1998). They
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have adopted various means ofmeasuring adherence including self-report, pill count,
pharmacy refill records and plasma drug concentrations. The data from these studies
suggests that a consistent minority of individuals do not adhere at maximum levels.
These studies are mostly cross-sectional in design meaning a shortage of evidence of
adherence over time. It is therefore unclear whether some patients never adhere or
whether all patients sometimes do not adhere. On average, rates of adherence to
antiretroviral therapy range from 50% to 70%. Table 1 (page 39) presents a list of
recent studies that have documented rates of adherence to HIV antiretroviral
treatment.
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1.2.4 Reasons for non-adherence in HIV and other life-threatening illnesses
In general, beyond life-threatening or chronic illnesses, as the population continues
to age and cost-containment pressures increase, healthcare professionals will
constantly be challenged to find ways to empower patients to play a greater role in
the management of their illnesses. Obviously, one avenue towards achieving this is
by patients being trusted to adhere to their medication regimens. Medication
regimens are dispensed with the fundamental expectation that they will be taken
exactly as prescribed. Non-adherence has negative consequences for the patient, the
clinician, the provider, and even the medical researchers who work to establish the
value of the medication for the target population. The current composite issues
surrounding the particularly high rates of non-adherence in chronic illnesses,
especially HIV/AIDS, are well illustrated in an early paper by Sackett and Snow
(1979). They reported that 77% of patients demonstrated degrees of compliance with
their medication regimen when the treatment was designed to cure a disease, and
only 63% of patients complied when treatment was aimed at prevention.
Furthermore, when medication was to be taken over a long period, as is the case with
HIV/AIDS, compliance rates dropped dramatically to around 50% for either
prevention or cure.
As can already be assumed, many factors are involved in patient non-adherence:
disease characteristics, medication side-effects, duration of treatment, frequency of
dosing, complexity of treatment, severity of the disease, socioeconomic factors and
psychosocial variables. Adherence is less likely over long treatment periods, and
even when daily doses require relatively minor increases from one pill to four pills
(Kramer, 1995). Schedules calling for medication to be taken four or more times a
day appear to create an unnatural division of the day for most people, increasing the
potential for non-adherence. The majority of patients may also be trying to please
their physicians, typically giving the often convincing impression that they have
been following, or intend to follow, the physician's medication directives.
Unsurprisingly, overly anxious patients forget more of what they are told by their
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physician. Studies have reported that 40% to 60% of patients could not correctly
report what their physician expected of them 10 to 80 minutes after their
consultation (Ley & Spellman, 1976). If the information presented is consistent with
previously held beliefs about the disease and about what medication can and cannot
do, patients are more likely to adhere to the medication regimen (DiMatteo and
DiNicola, 1982).
People with HIV do not usually miss doses because of a lack of motivation to take
treatments or because they choose to give greater priority to other aspects of their
lives. 'Drug holidays' for special reasons are often taken, but deliberate non-
adherence is rare. A study in San Francisco (Chesney, 1997) reported that the most
common reasons for missed doses were forgetfulness (40%), sleeping through time
of dose (37%), absence from home (34%), routine interruptions (27%) and
distractions (22%). Another very important reason for lack of adherence is a poor
tolerability of the drugs.
In summary, forgetfulness and failure to plan ahead would appear to be the main
reasons for non-adherence. Forgetting happens for many reasons - being too busy,
being distracted by work or pleasure. Sleeping through a dose is evidence of failure
to plan ahead. Change, interruption or intrusion into a routine undermines
expectations and diverts reminders to take medications. As individuals' lives are so
unpredictable and variable, it becomes almost impossible to predict who will or will
not be adherent.
1.2.5 Developing a psychological approach to non-adherence to HAART
By increasing an understanding of adherence factors in HIV, research can become
more systematic and interventions may then be generated and subsequently
evaluated. Dunbar-Jacob et al (1995), and more recently Sherr (2000), suggest that
medical adherence, in general, can be studied from four main perspectives: (1) the
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patient or person, (2) the preparation or medication, (3) the healthcare provider and
(4) the setting or environment.
1.2.5.1 Patient characteristics
The least relevant factors appear to be demographic strata. Age (with the exception
of adolescence), gender, marital status (with the exception of dietary adherence), and
socioeconomic status have not been consistently related to adherence. The impact of
culture or ethnicity on adherence is under researched. However, some studies that
examined these issues have reported significant differences in adherence patterns
across cultures (Dolce et al, 1991). One study has found that a specific cultural
cohort of patients (Hispanic) were more likely to comply with medication
recommendations when their clinicians demonstrated some understanding of their
cultural norms and practices (Ruiz and Ruiz, 1983). There has been a recent increase
in the number of studies addressing the impact of specific cognitive coping
strategies, such as denial, learned resourcefulness, and helplessness, on patient
adherence specific to HIV. These studies have produced significant associations and
will be discussed later. Selective cognitive elements have been associated with
adherence in other illnesses. Sherbourne et al (1992) noted that avoidant coping was
associated with adherence. Research within the Common Sense Model of Illness, has
noted that cognitive constructions of the illness, or the model the patient holds of
their disease and its course, are also associated with adherence (Baumann et al,
1989). Self-efficacy has also been associated with adherence in cancer treatment
(Lev, 1997). Personality characteristics have been the least studied factors in
research into medication adherence. A wider discussion of the research into
personality and adherence will be returned to further into this report. A summary of
the most relevant patient characteristics, predictive or non-predictive of adherence
can be referred to in Table 2 (page 43).
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1.2.5.2 Medication regimen characteristics
Across all medical disorders, regimen features are particularly important influences
on adherence. Several dimensions of the regimen appear to be most critical. The
more frequently the regimen needs to be repeated throughout the day, the greater the
probability of non-adherent episodes. Also, the greater the number of separate
regimens (e.g., diet plus drug as opposed to drug alone) the more likely adherence
will be affected. Regimens requiring lifestyle behaviour changes complicate
adherence further. With particular reference to HIV/AIDS, another critically
important factor is the duration of the regimen. Adherence declines over time (Sherr,
2000). Patients on long-term treatment regimens are more likely to default with
regard to their dosing circumstances.
1.2.5.3 Healthcare provider characteristics
Providers and their practices influence patient adherence. Their skills in
communicating, and explaining dosing and regimens clearly, checking that
instructions are understood, reviewing questions, queries and problems on a regular
basis, are all key factors. Simplified instructions, specific statements and support for
the process are vital.
1.2.5.4 Setting or environment characteristics
The effects of challenging social circumstances have been examined, such as those
of prison settings (Mostashari et al., 1998), individuals with low levels of literacy
(Kalichman S.C. et ah, 1999) and that of the homeless and drug users (Sorensen,
Mascovich, Wall and DePhilipps, 2000). Preconceived views of these groups need to
be addressed, and the impact of particular settings on the individual's ability to carry
through a therapeutic level of regimen adherence. There is evidence that these
adverse social situations are not necessarily predictors of non-adherence.
Furthermore, the practical and procedural aspects of the clinical practice, such as the
location of clinics and the minimisation ofwaiting times, may play an important role
in whether or not patients return for consultations and follow advice on treatment.
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1.2.6 Psychological models of adherence
The above perspectives on issues of adherence can be allowed to invoke and inform
a number of theories in order to help understand adherence from a psychological
perspective.
1.2.6.1 Cognitive models
Cognitive models suggest that adherence is associated with cognitive variables.
These variables would include memory, forgetting, recall, decision-making and
comprehension of the regimens involved. Interventions aimed at addressing these
cognitive aspects would be assumed to improve adherence to antiretroviral therapy.
There is evidence to suggest that cognitively based interventions can significantly
improve adherence. Person-centred interventions would include cognitive cues to
avoid forgetting, memory aids, cognitive re-framing of decision-making processes
and increasing a patient's understanding of the medication regimen. Johnson (2000),
in a study of 96 HIV outpatients, reported that one coping strategy (cognitive
reappraisal) and one appraisal style (helplessness/hopelessness) were significant,
independent predictors of both treatment adherence and psychological well-being. It
was also concluded that the prediction of treatment adherence and psychological
well-being was significantly improved by using these two predictors together.
Interventions aimed at the preparation would consist of audio or visual cues to
remind the person to medicate, and the simplification of dosing practicalities such as
packaging to improve access to medication.
From the perspective of the provider, cognitive strategies would incorporate an
improved education of dosing and regimens, reducing anxiety provoking settings
and reinforcing that simplified instructions have been thoroughly understood.
Variations in provider behaviour as a result of particular cognitions and beliefs have
been found to be associated with adherence outcome. For example, the likelihood of
a physician prescribing antiretroviral treatment has been associated with the strength
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of the physician's belief in the patient's ability to adhere (Roberts & Volberding,
1998). Just as in patients, it is also feasible that lack of knowledge, forgetfulness and
unfamiliarity with treatments may also affect clinicians. Provider oriented
interventions such as clear record-keeping, computerised information and clear
policy directives have been shown to be effective.
1.2.6.2 Social concepts
Employment, social support (or isolation), familial factors, age, financial and
availability factors have also been used to help explain a lack of adherence. There
may be an interaction between employment and cognitive factors in that busy
employees are more likely to forget medication and thus affect adherence. There is
also anecdotal evidence that in resource-poor settings, with costly and less accessible
treatments, adherence is less of a problem than when medication is widely available.
A wide range of challenging social circumstances have been examined and reported
in the literature on adherence to antiretroviral therapy. The interaction between
psychosocial factors and adherence is documented in the literature considerably
more than an exploration of the cognitive factors involved.
A revealing study by deBoer (1999) examined the psychosocial responses of 70
HIV-positive gay men taking a powerful new antiretroviral treatment. Aside from
'forgetting', participant narratives revealed four commonly reported reasons for
adherence lapses: chemical dependence relapse, needing to rebel, maintaining
needed benefits (secondary gain) from illness status, and testing the treatment. Pre-
treatment and pre-infection level of functioning also appeared important, as those
who had mastered previous developmental tasks appeared more able to devote
resources toward battling the disease and planning for the future. Salient issues
associated with better adherence to treatment included resolution of family of origin
issues and consolidation of personal, sexual, and vocational identity. Failure to have
achieved a positive sexual identity, a meaningful vocational life and important
interpersonal bonds prior to treatment or infection, heightened the vulnerability to re-
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experience traumatic themes, which in turn manifested as a lower level of adherence
to drug treatment. Results also indicated an association between higher income and
higher adherence. Interestingly, the study also revealed that 'forgetting' was at times
associated with wishful thinking. This highlights the combined interaction between
cognitive and psychosocial factors in medication adherence.
In a study of illness behaviour, psychosocial and clinical variables among
asymptomatic HIV infected individuals, significantly higher levels of medication
adherence were observed in participants in a non-intravenous drug use category and
who also had better social support. This study also reported significantly elevated
CD4 cells among the high adhering group. Psychosocial variables resulted in
influencing the tendency to interpret illness in a maladaptive way in HIV-infected
subjects. Psychological stress and low CD4 cell count were the main predictors of
the affective dimension of illness behaviour measured in this study (Grassi et al,
1999).
1.2.6.3 Psychodynamic models
A psychodynamic perspective would suggest that factors below the consciousness of
the individual, where access is limited, mitigate against adherence. Such factors
would include unconscious fears and anxieties. There is currently little empirical
evidence to support this model, although interventions based upon limited
qualitative data, would focus on the belief systems of the individual and an in-depth
understanding of the circumstances surrounding their illness. From the provider
perspective, doubts and hesitations about the medication and its efficacy would most
probably be examined.
1.2.7 Measuring adherence
Adherence is essentially a process variable that should be evaluated in all
therapeutic outcome studies and in any clinically prescribed treatment that requires a
self-management component. This can be very difficult to achieve. Relief from
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symptoms or the achievement of therapeutic goals may suggest that the patient is
correctly following the treatment plan. However, it is no confirmation that this is
indeed the case and therapeutic outcome is not necessarily a good measure of
adherence.
Numerous methods of assessing adherence in chronic illness have been reported in
the literature, although none are sufficiently accurate for a true standard to be
identified and universally applied across treatments. As Table 3 (page 49) shows, a
number of methods have been reported in the HIV research base for the
measurement of adherence. An overview follows of some specific assessment
methods used in chronic illnesses in general.
1.2.7.1 Self-report measures
Self-report appears to be the most commonly used method with evidence that this
approach is reasonably reliable (Caron, 1985). Self-report measures are relatively
easily administered and inexpensive to apply. Common approaches to self-report
include patient interviews, structured questionnaires, and daily diaries. The majority
of research studies examining medication adherence report the use of interview
methods. Brief interviews that assess global estimates of adherence have been
published (Morisky, Green and Levine, 1986; Shea, Misra, Ehrlich, Field and
Francis, 1992). Limited psychometric data are available on these instruments, and
they have rarely been compared with more accurate daily estimates of adherence.
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Table 3: Measures of adherence in recent studies
Study N Adherence measure
Singh et al. (1996)
Watson & Farley (1999)
Eldred et al. (1998)
Kastrissios et al. (1998)
Kastrissios et al. (1998)
Haubrich et al. (1999)
Gordillo et al. (1998)
Kalichman et al. (1999)
Hecht et al. (1998)























Patient self-report & pill counts




Patient & doctor report
t Electronic devices can be used as monitors in the longitudinal assessment of proxies for medication
adherence
Concerns have also been raised that the nature of the questions used in the self-
report interview may affect reported adherence (Burke et al, 1992; Dunbar et al,
1991). Questionnaires are also commonly used self-report measures of adherence in
HIV, often integrating an assessment of other socio-demographic and psychological
variables, such as social support health beliefs and questions addressing the patient-
doctor relationship (see Gordillo et al, 1998, for a comprehensive methodology of
adherence assessment). The literature on dietary and exercise adherence also
frequently documents the use of such an approach (for example, Block et al, 1986;
Schechtan, Barzilai, Rost and Fisher, 1991). Daily records or diaries are not well
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documented in the research as measures of adherence in HIV. Commonly used
among individuals with diabetes and dietary treatment regimens, they have the
advantage of circumventing any reliance on recall required by the use of interviews
and questionnaires. They also have the potential to modify the patient's behaviour as
a function of self-monitoring. However, they do require that the patient be trained in
effectively keeping accurate daily records. Despite this, monitoring adherence by
diary appears to require further examination in relation to antiretroviral regimens
before any informed judgement can be made as to its reliability as an adherence
measure.
1.2.7.2 Physiological measures
A variety of physiological measures have been used as a gauge of adherence. For
HIV medication adherence, such measures as the level of the drug or its metabolites
in the blood plasma concentrate or urine, viral load and CD4 count have all been
examined. Physiological measures rarely provide an assessment of the daily
variability in adherence, but tend to identify those people who have been adherent
within a relatively recent time period, close to the time of assessment. In the short-
term, these measures do not identify the level of adherence, but simply classify a
person as having followed or not followed some of the regimen. Physiological
measures also risk being affected by individual differences in drug metabolism and
the effects of antiretroviral drug resistance on CD4 counts and viral loads.
Nevertheless, physiological measures remain common guides as to the adherent
individual. It is also not uncommon for physiological measures to be used
concurrently with self-report measures in order to increase the power of the
assessment.
1.2.7.3 Pill counts and pharmacy refills
Pill counts and pharmacy refdls are unique to the assessment of medication
adherence. They have been used in a number of studies of adherence to HIV
medication. Pill counts consist of counting the number of pills remaining from a
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prescription over a defined time period and comparing that with the number of pills
that should have remained. This difference is subtracted from the number of pills
dispensed to determine the number that were taken. From this mathematics an
adherence percentage can be calculated. Pill counts have been found to overestimate
adherence in some studies of chronic illness (for example in hypertension, Rudd et
al, 1990). Pharmacy refills (or pharmacy records) perform like pill counts, except the
time the medication is refilled is compared with the time it should have been refilled
if the patient had taken all of the medication. Adherence is estimated in a similar
manner to the pill count estimate. This is a potentially accessible method of
adherence assessment in antiretroviral therapy, since individuals with HIV tend to
receive all their medication from the same pharmacy, thus ensuring a tightly
controlled dispensing situation.
Many techniques are available for the assessment of adherence although none have
been shown to be perfect. Those methods providing the most complete picture of
adherence tend to be expensive and more difficult to access; whereas those
providing the most detail surrounding adherence events are often the most subject to
error. Existing methods are, however, sufficient to provide evidence of effective
intervention, and over a certain period of time can identify estimated levels of
adherence among individuals.
1.3 Personality
1.3.1 The integration of personality and adherence research
This section constitutes a broad review of the literature on the interactions between
personality and HIV/AIDS. Reference to personality concepts do not arise frequently
in the research behind HIV/AIDS, although some studies have applied models of
personality to HIV risk behaviours, appraisal and coping styles, and quality of life
issues. This section examines the available literature across some of these areas and
concludes with a comprehensive critical examination of the limited role of
personality in HIV/AIDS adherence research.
1.3.2 The role of personality in HIV risk behaviour
Most research into personality and HIV/AIDS is reported in the literature in the
context of understanding the role of personality characteristics in HIV risk
behaviour. A disturbing trend in the HIV epidemic has been the persistence of high-
risk behaviours among individuals who are HIV infected. Knowledge ofHIV and its
transmission is insufficient in deterring certain individuals from engaging in HIV
risk behaviours, suggesting that certain personality characteristics may increase the
likelihood of engaging in high risk behaviour. Such individuals, who report high
rates of sex and/or drug risk behaviours, include HIV infected drug users (Novotna
et al, 1999), patients presenting at HIV primary care clinics (Erbelding et al, 2000),
and HIV infected men who have sex with other men (Kohl et al, 1999).
There has been little empirical investigation of the influence of personality
characteristics on HIV risk behaviour. However, in a revealing study Hutton and
Treisman (2001) examined this area based on their own clinical observations and a
review of the dimensional nature ofpersonality5.
5 Most personality theories depict individuals along dimensions of extroversion-introversion and stability-instability (Costa
6 Widiger, 1994; Eysenck, 1990).
Footnote continued overpage
52
They observed that of the four personality temperaments, unstable extroverts are the
most prone to engage in HIV risk behaviour. They estimated 60% of their patients,
referred to psychiatry, presented with this type of temperament. Their actions tended
to be unpredictable and inconsistent, and they displayed a large discrepancy between
thought and action. Regardless of intellectual ability or understanding of HIV,
unstable extroverts were most likely to engage in behaviour associated with high risk
of HIV infection. Their over-arching goal is to achieve immediate pleasure or pain
removal, however risky and regardless of circumstances in an effort to eliminate low
mood. Unstable extroverts in their sample were less likely to plan ahead and carry
condoms and more likely to have unprotected vaginal or anal sex. They were more
fixed upon the reward for sex and remarkably inattentive to the risk of acquiring an
STD if they did not use a condom. Similarly, unstable extroverts were more
vulnerable to drug and alcohol abuse, being drawn to these substances as a quick
route to pleasure. They were also more likely to become injecting drug users because
the experience is more intense, and less likely to defer this intensity in the interest of
safety.
The second most common personality type observed by Hutton and Treisman, which
they estimated represented about 25% of their patients, is that of the stable extrovert.
Stable extroverts are also present-oriented and pleasure seeking, however their
emotions are less intense and not as easily provoked. This emotional flatness is
thought to generate a kind of indifference to HIV risk, as opposed to a drive to seek
Extroversion-introversion refers to the individual's basic tendency to respond to stimuli with either excitation or inhibition.
Extroverts are: 1) present-oriented; 2) feeling-directed; and 3) reward-seeking. Extroverts are sociable, crave excitement, take
risks, and act impulsively. They tend to be care-free, inconsistent and optimistic. By contrast, introverts are: 1) future & past-
oriented; 2) cognition-directed; and 3) consequence avoidant. Logic and function predominate over feelings. They will not
engage in a pleasurable activity if it might pose a threat in the future. They tend to be orderly, reliable and rather pessimistic.
The second personality dimension, stability-instability, befines the degree of emotionality or lability. The emotions of stable
individuals are aroused slowly and minimally, and return quickly to baseline. By contrast, unstable individuals have intense
mercurial emotions and act upon them in impulsive and irrational ways.
If the two dimensions of introversion-extroversion and stability-instability are juxtaposed, four personality types emerge:
stable introverts, unstable introverts, stable extroverts and unstable extroverts.
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pleasure at any cost. Stable extroverts may be at risk because they are too confident
to believe that they will become HIV infected.
Introverts were found to be less common among their HIV clinic patients. Preference
for cognition over feeling, and an avoidance of negative consequences, is thought to
render them more likely to engage in protective and preventive behaviours. Hutton
and Treisman estimated 14% of their HIV infected psychiatric patients presented
with a blend of introversion and instability. Unstable introverts are typified by
anxiety, low mood and pessimism. They typically seek out drugs and engage in
sexual behaviours not for pleasure, but for relief or distraction from pain. They have
more concern about the future and adverse outcomes. Stable introverts, comprising
1% of the sample, are typified by controlled, even-tempered personalities, and were
least likely to engage in risky HIV behaviour. In fact, they hypothesized that such
patients were infected with HIV as a result of a blood transfusion or an occupational
needle-stick injury.
A number of empirical investigations would support the clinical observations of
Hutton and Treisman, with regard to the influence of extroversion and emotional
instability upon HIV risk behaviour. High extroversion has been associated with
sexual promiscuity, desire for sexual novelty and multiple sex partners (Eysenck,
1976; Trobst et al, 2000). Emotional instability is related to unsafe sex practices
(Fontaine, 1994) and substance abuse (McCormick et al, 1998).
1.3.3 Personality and adherence to treatment in chronic or life-threatening
illness
Before any analysis of a specific interaction between personality and adherence to
HIV therapy per se, it is relevant to firstly consider a review of the literature on how
personality and adherence may have a relationship in terms of life-threatening illness
in general. Appraisal of the literature in this area reveals a comparatively large
research base upon which to construct a more explicit framework for exploring the
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HIV/AIDS experience of personality and adherence factors. In an effort to reflect the
wide diversity of research in this particular area some of these, often novel, studies
are discussed below.
Literature reviews have typically concluded that personality factors are unrelated to
adherence to general treatment programs. Therefore the following studies have been
selected in order to represent, as much as possible, a cross-section of the research,
early and recent, into the role of personality on adherence in chronic or life-
threatening illnesses.
1.3.3.1 Personality, adherence and cancer
Evidence from research examining applications of Bandura's (1986) theory of self-
efficacy in oncology suggests relationships between self-efficacy and cancer
prevention, and self-efficacy and adaptation to cancer (Lev, 1997). The research
found that strong perceptions of self-efficacy predicted intention to stop smoking,
increased participation in screening programs, and adjustment to cancer diagnosis.
Lev (1997) concluded that increased self-efficacy was associated with increased
adherence to treatment.
Pugliese et al (1995) examined personality, inner experience and compliance in
advanced cancer patients treated with external pumps for delivery of chemotherapy
drugs. This study has particular power in that demographic strata including age, sex
and level of education were controlled for in terms of their influence on response to
treatment. Pugliese and colleagues note that personality variables of 'coping' and
'awareness' were positively associated with treatment compliance. Remaining
personality variables held constant throughout the course of chemotherapy, across
both compliant and non-compliant patients. They also found that a decrease in the
inner experience variables of 'acceptance' and 'expectation', with regards to
treatment, was observed in patients with low compliance. This study demonstrates
55
evidence for a clear link between personality characteristics and adherence in long-
term treatment for chronic illness.
An earlier, and intriguing, study by Lansky (1983), considered the psychological
correlates of compliance in a sample of 31 children receiving orally delivered steroid
treatment for lymphocytic leukaemia. What makes this study appear quite unique is
that demographic data and psychological test responses of patients and their parents
were correlated with urinary assays (drug concentrations in urine being a measure of
compliance). Results indicated that while the rate of compliance was the same for
boys and girls, the psychological correlates were very different. Parental personality
traits and attitudes were more involved with boy's compliance than with girl's.
Parent variables that were positively correlated with compliance in boy's were
hostility, anxiety and obsessive-compulsive behaviour. Parents were also more likely
to describe compliant boys as vulnerable. Such traits, usually considered to be
maladaptive, certainly appeared to facilitate boy's compliance. Parents seemed to
have less worry and concern about their daughters and presumably gave them more
responsibility for their own medication. This not only provides further evidence for
the role of personality in medication adherence, it also raises the issue of a
potentially powerful effect of 'secondary' personality characteristics (by virtue of
patients' family or carers) on treatment adherence and outcome.
1.3.3.2 Personality, adherence and diabetes mellitus
Gentili et al (2000) have analysed personality traits to study different behaviour in
compliance conduct with insulin therapy in Type 2 diabetic patients. Adaptation and
coping strategies were also considered. Results revealed that participants who
showed more fear, insecurity and initial resistance towards insulin therapy appeared
more rigid and conforming in relation to treatment. These individuals also revealed
more personality aspects compatible with the presence of passive-aggressive and
avoidant traits.
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In a study examining the association between 'hardiness' and compliance in elderly
patients with diabetes, Ross (1991) discovered that a significant correlation existed
between hardiness and compliance variables. This suggests that the degree of
hardiness in individuals with diabetes may predict compliance to a prescribed
diabetic regimen.
As mentioned, most studies conclude that personality factors are unrelated to
adherence to treatment programmes. Although evidence for this appears to be largely
unreported in the literature around HIV/AIDS, Hepburn et al (1994) do provide
support for this disassociation in relation to diabetes. In a large study of 303 insulin-
dependent patients, no significant correlations were observed between personality
variables and measures of compliance, either physiological or by patient self-report.
Thus, a contradiction is evident in the literature concerning the actual role
personality may or may not play in predicting adherence. The vast individual
differences between chronic illnesses will most likely ensure that such discrepancies
are durable facets of any research into the personality and adherence interaction.
Another important feature of this particular study is that it indicates the difficulties in
accurately measuring patient adherence to treatment. This concept warrants a fuller
critique and will be returned to for further discussion later in this research thesis.
1.3.3.3 Personality, adherence and organ transplantation
Explicit psychological factors and adherence issues are not widely commented on in
the literature on solid organ transplantation candidates, and how they are evaluated
for treatment. In this contentious aspect of medicine, medical review boards have
been established that consider medical, psychosocial, and financial factors in
choosing appropriate candidates for transplant surgery. Psychological evaluation can
furnish clinically useful baseline data regarding the patient's emotional and cognitive
functioning, and identify other individual and familial variables that may affect
patient adherence and the outcome of transplantation. Such research, for example by
Shapiro et al (1995), has attempted to predict compliancy problems and morbidity
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after heart transplantation. Although not explicitly measuring personality
characteristics per se, this study evaluated a number of prospective psychosocial risk
factors in adult patients undergoing heart transplantation to determine their
associations with morbidity, mortality and compliance. Compliance problems and
episodes of organ rejection were discovered to be significantly associated with
substance abuse history, evidence of personality disorder, and a global measure of
psychosocial risk. Survival was not associated with any of the predictor variables.
Research like this suggests that an evaluation of broader psychosocial factors can
help identify patients at increased risk of issues of problematic compliance.
Therefore, while pure personality characteristics in isolation may not reliably predict
poor adherence (see Hepburn et al, 1994), widening the area of measurement to
consider a possible interaction with psychosocial factors may be a prudent inclusion
to research into adherence and life-threatening illness.
Unfortunately, as in HIV, there has not been any systematic and comprehensive
review of the literature on personality-driven predictors of non-adherence in organ
transplant patients thus far. Non-adherence impairs both quality of life and life span
as it is a major risk factor for graft rejection episodes and is responsible for many
deaths after the initial recovery period. Therefore, to best select potential organ
recipients, it would appear to be the ideal that patients who are very likely to show
non-compliant behaviour could be identified already before receiving organ
transplants. For a literature overview demonstrating the necessity of pre-operative
psychosocial screening regarding predictors for post-transplant compliance, the
reader is directed to Bunzel and Laederach-Hofmann (2000).
1.3.3.4 Personality, adherence and renal failure
Studies into renal failure and haemodialysis adherence have arguably received most
interest from psychologically-minded clinicians, as the author observes the
introduction of psychological models of personality into the literature research base
of this field of psychological medicine. By applying the Five-Factor Model of
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Personality6, various studies (for example: Christensen and Smith, 1995; Moran et
al, 1997; Weibe & Christensen, 1997) have sought to identify personality correlates
of adherence and health outcomes. The research has shown that in general, health
beliefs and, more specifically, traits of conscientiousness, interact to predict
physiological measures of medication adherence. However, findings have also
suggested that an interaction of high conscientiousness and high perceived severity
of illness was associated with poorer patient adherence.
Vives et al (1999) examined the impact of social-clinical factors over personality
dimensions. They also sought empirical evidence of the relationship between
internal locus of control experience and higher levels of treatment adherence in
patients with renal failure. The impact of socio-demographic and clinical factors
showed no significant statistical differences with regard to treatment adherence,
health perception and the dimensions of personality. They found no statistically
significant association between the dimensions of personality and adherence.
However, there was a tendency to correlate the dimension of locus of internal control
with adherence to treatment. The results of this study may be somewhat misleading
as a health locus of control scale7 constituted the only actual measure of personality.
The study therefore raises issues around how to measure not only adherence, but also
personality in a medical sample. Reliable measurement of these variables shall be
returned to for further discussion later in Chapter 2.
6 The Five-Factor Model ofPersonality (McCrae and John, 1992) - There is increasing recognition of the utility of the five-
factor taxonomy in elucidating personality correlates of health-related outcomes. One such application is the usefulness of five
factor personality measurement in understanding patient adherence to a prescribed medical regimen. A conceptual
examination of the five-factor taxonomy suggests that Dimension III, labeled Conscientiousness, by Costa & McCrae (1992),
may be the most accurate trait descriptor of those qualities of the individual thought to be important in terms of adherence
behaviour. The Conscientiousness factor has been interpreted as 'will to achieve', 'dependability' and 'self-control' by various
five-factor theorists (Digman, 1990). The dimension reflects a highly purposeful, well organized and self-disciplined style.
It has been suggested that level of conscientiousness in childhood predicts survival in middle to old age (Friedman et al.,
1993). The mechanisms underlying this association could not be determined. However, individual differences in health-related
behaviours, including adherence, are one plausible mediator of the relationship between conscientiousness and survival.
7 The Vives et al (1999) study applied Wallston's Multidimensional Health locus of control scale as the only measure of
personality. It measures across three dimensions: 1) Internal locus of control, which evaluates the belief that one can control
one's own health, 2) Power locus of control, which evaluates the belief that one's own health is controlled by the environment,
and 3) Locus of control due to chance, which evaluates the belief that one's health depends on factors absolutely beyond
control. As an application of locus of control in adherence research, their results are interesting. However, the measures
employed would not appear to constitute a thorough analysis of personality dimensions per se. The expected aims of the study
(i.e., an analysis of personality and adherence in renal failure) should perhaps be interpreted with caution.
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1.3.3.5 Personality, adherence and severe mental illness
Factors associated with non-compliance with outpatient visits to psychiatric services
have also been addressed in a number of studies. Centorrino et al (2001) found
significantly higher visit adherence among patients in an acute stage of illness, when
the visit entailed psychotherapy rather than pharmacotherapy, and when patients had
a personality disorder. Similarly, Matas, Staley, and Griffin (1992), in a thirty-month
review of outpatient psychiatry referrals, constructed a profile of the typical non¬
adherent patient with some similar findings. Significant differences between
compliant and non-compliant patients were examined in a sample of 874 referrals.
Non-compliant patients comprised 18% of the sample and were significantly more
likely to be single, male, previously unmarried, unemployed, and diagnosed with
substance abuse or personality disorder.
Poor adherence with long-term antidepressant medication has also been associated
with a sensation-seeking personality (Ekselius, Bengtsson and von Knorring, 2000),
although it is noteworthy that this study also acknowledges the need for improved
methods in ascertaining actual level of adherence among patients.
1.3.3.6 Personality, adherence and life-threatening illness - a research
summary
The above examples of research into the interaction between personality factors and
adherence to treatment regimens have been discussed in order to present the salience
of the problem across a wide range of chronic and life-threatening conditions. The
influence of personality and adherence variables span across a broader range of
medical and psychiatric circumstances. Examples are too numerous to mention
within the confines of this thesis, however the author can direct the interested reader
to applied research into adherence in areas ranging across cardiac rehabilitation
(Hershberger, Robertson and Markert, 1999; Sromberg, Brostrom, Dahlstrom and
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Fridlund, 1999), cystic fibrosis8 (Geiss et al, 1992), asthma (Haida, Ito, Makino and
Miyatrioto, 1995), and maternal phenylketonuria9 (Waisbren, Hamilton, StJames,
Shiloh, 1995). As would be expected, research is also widespread among non life-
threatening conditions outside pure medicine, for example, in orthodontics (Sergl,
Klages and Zentner, 2000) and opthalmology (Bennet, et al, 1998).
In summarising the general themes within the literature around demographic,
psychosocial and explicit personality variables, and their association with treatment
adherence in life-threatening illness, a number of tentative conclusions can be
drawn. The research allows us to argue that a therapeutic level of adherence is
associated with various psychological features, including: a positive adjustment to,
and acceptance of, an illness, positive coping strategies, increased self-efficacy,
functional levels of anxiety, positive health beliefs, conscientiousness, internal locus
of control and general 'hardiness'. Non therapeutic levels of adherence can be
associated with the inverse perspective of the above factors, and various under-
researched, explicit personality variables such as hostility, sensation-seeking traits,
and pathological extremes of personality, including personality disorder. Substance
abuse also appears to feature highly in non-therapeutic adherence along with socio-
demographic variables such as being single, living alone, poor social support and
unemployment.
A review of the literature has also indicated the increasing attempts to apply
theoretical models of personality to the research into adherence. This more
scientifically robust approach may have arise from the contradictory, and
unsatisfactory, results of the earlier research studies examining the influence of
personality on regimen adherence. The research base described thus far, highlights
8 Cystic fibrosis - A hereditary disorder of the exocrine glands. Infection affects mucus-producing glands. It is marked by
production of very thick mucus, excess sweating (with loss of electrolytes), and an overactive nervous system. Treatment
consists of dietary regimens and antibiotic medication.
9
Pnenylketonuria (PKU) - An inherited disorder in which the enzyme that breaks down the amino acid pnenylalanine is
defective. Build up of phenylalanine in the body leads to central nervous system damage and learning disabilities. Treatment is
by special dietary regimens.
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the results of studies around well-established life-threatening illnesses and
conditions. It also informs us that personality is a relatively recent avenue for
scrutiny among those with an interest in improving treatment adherence in a range of
illnesses. It is therefore no surprise to discover that a considerable paucity of
comment exists in the application of this research to the comparatively new disease
that is HIV/AIDS. Relative to the other conditions described above, and given the
particularly crucial role of adherence in the long-term success of antiretroviral
therapy, not to mention the scale of the HIV epidemic, it appears obvious that
researchers should concentrate more effort on studying predictors of non-adherence
to HIV therapy. A review of the limited literature that already exists in relation to
psychological, and explicitly personality, variables influencing adherence to
antiretroviral therapy, follows in the next section.
1.3.4 Demographic, psychosocial, and personality variables influencing
adherence to antiretroviral therapy - a review of the literature
A review of the literature surrounding personality factors and their influence on
adherence in life-threatening illness, has shown that much research has been
conducted producing often contradicting results. Some studies have shown clear
associations between personality concepts and adherence while others have not.
Relative to other life-threatening illnesses, studies on psychological predictors of
adherence in HIV are limited. Even less examined is the specific potential
interaction of personality variables with adherence to antiretroviral therapy. [The
reader is re-directed to Table 2. for a summary of this research and salient findings]
From a review of the literature reflecting current thinking in adherence to
combination therapies, there is an explicit and universal conviction that, for
therapeutic success on antiretroviral therapy, viral suppression must be achieved and
sustained over time. This implies that individuals must maintain low viral loads
through good, if not perfect, adherence. Practically, this will require >90%
consumption of the prescribed medications. The price to pay for sub-therapeutic
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doses will be resistance to HIV antiretrovirals, putting the success of future
combination therapies at risk, thus compromising the life of the individual.
A reappraisal of Sherr's (2000) review of the literature surrounding adherence in
HIV therapy, reminds us that non-adherence can be understood in terms of four
distinct levels of psychological thinking: cognitive models, psychodynamic models,
social concepts and personality concepts. Furthermore, adherence research can be
practically approached from four perspectives: the patient, the preparation, the
provider, and the environment. This section constitutes a review of the limited
literature surrounding personality concepts and how they affect adherence from the
perspective of the patient.
1.3.4.1 Demographic and psychosocial variables and adherence to
antiretroviral therapy
It has been demonstrated that certain demographic and HIV risk groups have poorer
access to therapy [for example, African- Americans (Moore, Stanton, Gopalan and
Chaisson, 1994) and injecting drug users (Solomon et al, 1995)]. However, less data
is available on the influence of these factors on adherence to HIV therapy. Certain
demographic characteristics have been associated with decreased adherence.
Gordillo et al (1998) assessed socio-demographic and psychological variables
influencing adherence in a large cohort of 366 HIV-infected individuals. They report
unsatisfactory adherence is significantly more common among younger individuals
(<32 years old), whereas the best adherence rates are observed in individuals aged
between 32 and 35 years old. Intravenous drug users and those below 23 years of age
had the poorest compliance with the prescribed treatment. A recent study (Catz,
Heckman, Kochman and DiMarco, 2001) addressed the specific difficulties faced by
older adults (mean age = 53.4 years) with HIV infection. Less education, poorer
relationships with physicians, greater alcohol use and higher levels of somatisation
uniquely predicted adherence problems in this cohort.
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In another study of HIV-infected individuals, it was observed that women miss a
higher percentage of clinic visits than men (Kissinger et al, 1995). They concluded
that women may face particular gender-specific barriers to treatment such as finding
childcare facilities. Homosexuals and heterosexuals appear to demonstrate similar
adherence rates, and those with a lower socioeconomic status are typically less
adherent. The specific components of lower socioeconomic status associated with
adherence are unstable or poor housing, low income, low level of education, and (in
the U.S.) a lack ofmedical insurance (Coons et al., 1994; Singh et al., 1994). Having
a job is also associated with better compliance, as is the perception of a good social
support (Gordillo et al., 1998).
Poor social relationships and activities have been associated with lower adherence.
Kissinger et al. (1995) speculated that HIV infection is a potential cause of social
isolation. Social isolation may therefore be thought of as a risk factor for decreased
compliance in HIV-infected individuals.
1.3,4.2 Psychological variables and adherence to antiretroviral therapy
The presence of a psychiatric illness is commonly associated with decreased
adherence in patients with mental illness, elderly status, and HIV infection (Broers,
Morabia and Hirschel, 1994; Carney, Freedland, Eisen, Rich and Jaffe, 1995; Coons
et al., 1994). In a prospective study of HIV-infected individuals, adherent patients
(defined as ^0% adherence) had significantly less depression than non-adherent
patients (Singh et al., 1994). In another large study (Broers et al, 1994), 81%
adherence was observed in those without psychiatric diagnoses, compared with 53%
adherence in those with a psychiatric disorder. Depression is the most commonly
cited psychiatric problem among HIV-infected individuals, with prevalence rates
ranging from 17-30% (Fernandez and Ruiz, 1989).
Patient attitudes and beliefs related to decreased adherence have been found to
include acceptance or perception of the disease, and perceived lack of benefit of
treatment (Samel, Libman and Steger, 1992). Similarly, a belief that antiretrovirals
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prolong life is strongly associated with increased adherence. These beliefs can also
be risk factors among patients with other types of chronic illness. A study by Catz et
al. (2001) surveyed patients' own perceptions of barriers to treatment on HAART
regimens. The most frequently reported barriers to adherence reflected general
concerns about treatment as a reminder of one's HIV status, not wanting other
people to know one's HIV status, and difficulty remembering to ask one's health
care provider questions about treatment. Consistent with adherence findings in other
chronic diseases, depression, severity of side-effects, perceived self-efficacy to
adhere to antiretroviral regimens, and social support were each related to adherence
in univariate statistical analyses. In mulitvariate analysis, social support and
treatment self-efficacy predicted non-adherence. Participants who perceived less
emotional support and those who were less confident of their ability to adhere, were
most likely to report inconsistent use of HAART. This study, along with that by
Gordillo et al (1999), appear to have been the only recent investigations into
psychological influences (specifically patient beliefs and perceptions) on adherence
in HIV. Few studies of people living with antiretroviral therapy have emphasised the
patients' perception of their illness and medication, their understanding of the
rationale for treatment and the patient-doctor relationship. Most of the remaining
studies in this particular area have exclusively concentrated on socio-demographic
data and characteristics of the actual medication. Other life-threatening illnesses,
such as those already discussed, have received considerably more attention in
relation to psychological determinants of treatment adherence.
Considering that psychological factors per se, have received little investigation in
relation to adherence and antiretroviral therapy, it comes as little surprise to learn
that personality characteristics and their interaction with adherence ability have not
yet been explicitly examined in the context ofHIV. However, if adherence is related
to the personal ability and willingness to take complex antiretroviral regimens
correctly, there is no doubt that personality variables should play an important role.
Given the extent of the research into how personality characteristics may place
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individuals at risk ofbecoming HIV infected10 (refer to: 1.3.2 The role ofpersonality
in HIV risk behaviour), it is even more surprising to discover the paucity of research
into how particular personality characteristics may reduce ability to adhere to the
demanding drug regimens of antiretroviral therapy.
The following study aims to address some of the absences in the literature
surrounding the role of personality characteristics in predicting non-adherence to
antiretroviral therapy. The existing research base in personality, adherence and other
life-threatening illnesses can inform research questions in the area ofHIV.
10 Prevalence rates of personality disorders among HIV-infected (19-36%) and HIV at-risk (15-29%) individuals are high and
significantly exceed rates found in the general population (10%) [Jacobsberg, et al., 1995; Johnson et al, 1995; Perkins, et al,
1993; Weisman, 1993]. Antisocial personality disorder is the most common and is a risk factor for HIV infection. Individuals
with personality disorder, particularly antisocial personality disorder, have high rates of substance abuse and are more likely to
inject drugs and share injecting equipment compared with those without an Axis II diagnosis [Brooner, et al., 1993;
Dinwiddie, 1996]. Approximately half of intravenous drug users meet criteria for a diagnosis antisocial personality disorder
[Kleinman, et al., 1994]. Antisocial personality disorder individuals are also more likely to have higher numbers of lifetime
sexual partners, to engage in unprotected anal sex, and contract sexually transmitted infections compared with individuals
without antisocial personality disorder [Ramrakha et al., 2000],
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1.4 Research question & statement of hypothesis
1.4.1 General research question
What are the overall general profiles of adherent and non-adherent HIV-infected
individuals receiving antiretroviral therapy in terms of:
i) general personality characteristics?
ii) attitudes to their illness and healthcare?
1.4.2 Specific research hypothesis
Therapeutic and non-therapeutic levels of regimen adherence to HIV antiretroviral
therapy are associated with:
i) personality style
ii) coping styles




Before commencement of the study a research protocol was submitted for ethical
approval by the Lothian Research Ethics Committee, Edinburgh. The research was
granted ethical approval by the Psychiatry/Clinical Psychology Research Ethics Sub-
Committee on 12 April 2002. Please refer to Appendix I for a summary of this
process including relevant correspondence between the researcher and ethics
committee.
2.1 Participants
Participants were recruited from an out-patient Regional Infectious Diseases Unit
(RIDU), and an out-patient Genito-Urinary Medicine (GUM) clinic in the Lothian
region. In-patients at the RIDU were also invited to participate in the study. All
participants who were at least 18 years old with an HIV positive status, and in
receipt of antiretroviral therapy for the duration of a three month period (from 1st
January 2002 until 30th March 2002), were considered eligible for this study.
Participants were recruited during March, April and May 2002. HAART patients are
asked to attend regular appointments to monitor their progress on treatment
regimens. The frequency of these appointments varies from patient to patient. The
three month recruitment period was therefore imposed in order to reach all eligible
patients with information about the study. It also ensured that adequate time had
elapsed to allow the medication to have a measurable impact on physiological
variables, and to enable later comparisons of theses measures between 'good' and
'poor' adherers. Participants with gross cognitive deficits were ineligible (for
example problems with vision or memory caused by HIV infection or opportunistic
infection of the central nervous system or eyes).
A total of 320 patients were offered information about the research (see Appendix
Ic: Patient Information Sheet). Of this population, 240 were in attendance at the
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RIDU and 80 were patients attending GUM. Patients were identified as eligible for
the study from a printed database record of patients of both clinics. Anonymous,
sealed envelopes, each containing a patient information sheet, participant consent
form and return envelope, were distributed to reception staff at the RIDU and GUM
clinic. Reception staff at each clinic were also given a printed list of eligible patients
due to attend their particular department over the 3 month recruitment period. On
arrival for their appointments, patients were offered a sealed information pack and
asked to consider whether or not they wished to participate. Of the 320 eligible
persons on HAART regimens who were approached, only 26 (8%) agreed to
participate, and 16% of patients declined the offer to receive information. Most
individuals approached but not recruited indicated that they did not have the time to
participate or were not interested in doing so.
2.2 Procedure
Once patients had read the information provided about the study, and following the
provision of written informed consent (refer to Appendix Id: research participant
consent form), patients were contacted by letter or phone and were scheduled
appointments for individual interview sessions to complete a battery of
questionnaires within 3 weeks of their recruitment at medical departments.
Participants were scheduled appointments to meet with the researcher between April
and July 2002. Participants were seen at either the RIDU (to coincide with their next
medical consultation) or at the premises of the Community HIV Service. Two
participants were visited at home as it was inconvenient for them to travel. One
participant was seen on the RIDU in-patient ward due to a deterioration in health.
All participants were invited to re-read the patient information sheet and any queries
were answered at the outset of each appointment. A brief outline of the research
objectives was verbally presented to each participant.
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All measures were administered using a semi-structured interview format in order to
minimize the duration of appointments. The length of appointments ranged from 50
minutes to 110 minutes. Each participant was interviewed once. The researcher was
present for the duration of all appointments should participants require assistance in
their completion ofmeasures. Once completed, each participant and their completed
measure were allocated a unique participant identification number. This ensured
participant anonymity and enabled completed measures to be cross-referenced for
the analysis. Participant information and completed measures were, at all other
times, stored in a locked filing cabinet to ensure full confidentiality of research
materials.
2.3 Measures
The following measures were administered to each participant:
2.3.1 Socio-demographic and adherence self-report assessment
A specific questionnaire was constructed for use in the study in order to collect data
on socio-demographic information, and the participants' self-report of their own
level of adherence and associated difficulties (for a sample copy of this data
collection questionnaire please refer to Appendix II: Socio-demographic and
adherence self-report questionnaire).
2.3.1.1 Socio-demographic data
Socio-demographic data included: gender, date of birth, age, employment status,
sexual orientation, marital status, route of HIV infection, date of HIV diagnosis,
AIDS diagnosis status, history of illegal drug use, alcohol use, and prescription drug
use. The socio-demographic data allowed the production of descriptive statistics
regarding the sample population.
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2.3.1.2 Adherence self-report data
The adherence section of the questionnaire was designed to both elicit specific
information concerning current antiretroviral medication, and guide a more informal
discussion of adherence issues particular to each individual. The questionnaire
assisted data collection regarding: knowledge of CD4 count and viral load,
knowledge of drug resistance, current antiretroviral regimens, previous gaps in
therapy, frequency ofmissed or delayed doses, reasons for missed or delayed doses,
drug side-effects, and personal general comments about combination therapy.
The adherence section of the questionnaire asked participants to indicate the number
of antiretroviral medication pills in their prescribed regimen that they had missed
over the previous 3 months. A short to medium-term pattern of medication
adherence could then be assessed. From the data, calculation indicated whether
participants reported perfect adherence or could be classified as missing doses on a
daily, weekly or monthly basis during the 3-month period.
2.3.2 Psychological (personality) assessment
Two distinct psychological assessment instruments were used to elicit information
on participants' personality styles and a range of psychological factors affecting the
course of participants' medical treatment for HIV. Both are grounded in a
biopsychosocial theory of personality developed by Theodore Millon (Millon, 1983).
The assessments are from a range of measures commonly referred to as 'the millon
inventories'.
2.3.2.1 Millon Index ofPersonality Styles (MIPS)
The Millon Index ofPersonality Styles (Millon, Weiss, Millon and Davis, 1994) was
chosen to examine personality style. The MIPS is a 180-item, true/false
questionnaire (Appendix III: MLPS test booklet), designed to measure personality
styles of normal and reasonably functioning adults between the ages of 18 and 65+
years. Items were endorsed by respondents on a separate answer sheet (Appendix IV:
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MIPS answer sheet). The MIPS consists of 24 scales grouped into 12 pairs. Each
pair contains two juxtaposed scales. For example, the 'Retiring' and 'Outgoing'
scales are considered a pair.
As Table 4 shows, the 12 pairs ofMIPS scales are organised into three major areas:
Motivating Aims, Cognitive Modes, and Interpersonal Behaviours. The 'Motivating
Aims' sub-scale assesses an individual's orientation toward obtaining reinforcement
from the environment. The 'Cognitive Modes' sub-scale examines styles of
information processing. The 'Interpersonal Behaviours' sub-scale considers on¬
going social roles and relationships and includes variations on the factors used in the
five-factor model (Tupes and Christal, 1992). In addition to the 12 pairs of content
scales, the MIPS contains three validity indicators: Positive Impression, Negative
Impression, and Consistency. The MIPS also contains a composite of overall
psychological adjustment called the Adjustment Index.
Table 4: Organisation ofthe MIPS Scales
Validity indicators Motivating Aims Cognitive Modes Interpersonal
Behaviours
Consistency Enhancing Extraversing Retiring
Positive Impression Preserving Introversing Outgoing








The MIPS is usefully applied to settings in which clinicians seek to identify,
understand, and assist normally functioning adults. The scale measures normal
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personality style, not clinical disorders, and has a rich theoretical foundation in a
model of personality that is deeply rooted in a biopsychosocial theory (Millon,
1969/1983; 1990; 1991). The MIPS was selected as the most appropriate measure of
personality for this study, firstly because, along with the MBMD (the second
psychological measure in this study), it is intrinsically linked to a sound theoretical
model ofpersonality.
The five-factor model of personality has recently often been used in elucidating
personality correlates of health-related outcomes (Smith and Williams, 1992).
However, the five-factor model is largely devoid of theory, having its roots in the
statistical analysis of lists of adjectives used by ordinary people to describe others
(Goldberg, 1993). Nonetheless, validity11 for both models is reinforced by the
finding that the MIPS appears to factor into five dimensions that are consistent with
the five-factor model of personality (Millon, 1997). This finding is important
because of the parallels between the theoretically derived MIPS scales and the
empirically derived five-factor model. The decision to use a theoretically based
model of personality is summed up by a quote from Weiss who argues that,
"
future research on the five-factor model should seek to place that model into
the larger nomological network of established personality theories to further our
understanding ofthe structure ofnormalpersonality. "
(Weiss L.G., 1997)
The second reason for choosing the MIPS was the fact that it is quick to administer;
an important consideration which allowed potentially richer information to be
elicited from the informal semi-structured adherence interview. The length of time
11 The MIPS scales have been validated against other measures of similar personality styles and constructs. Such data are
presented in the MIPS technical manual (Millon et at, 1994) in the form of correlations with six widely used personality
measures and one measure of depression.
Internal consistency and test-retest reliability of MIPS scales has been found to be very good. Median split-half reliabilities
were r = .82 and r = .80 for an adult and college sample, respectively. Test-retest stability over 2 months was estimated in
samples of 50 adults and 110 college students. Correlations corrected for variability of scale scores at first testing ranged from
.73 to .91 in the adult sample (median = .85) and .78 to .90 in the college sample (median = .84) [Millon et al., 1994],
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spent interviewing each participant varied considerably therefore quickly
administered psychometric assessments were essential. The MIPS was
predominantly applied to participants in order to examine hypothesis 2.
2.3.2.2 Millon Behavioural Medicine Diagnostic (MBMD)
The Millon Behavioural Medicine Diagnostic (Millon, Antoni, Millon, Meagher and
Grossman, 2001) is a substantially up-graded version of the Millon Behavioural
Health Inventory or MBHI (Millon, Green and Meagher, 1979/1982). Both
inventories were designed to,
" .provide the critical psychological information doctors need to treat the whole
patient."
(Millon T. et al., 2001)
The MBMD (Appendices V & VI: MBMD test booklet and answer sheet) is a 165-
item, self-report inventory with 29 Clinical scales, three Response Patterns scales,
one validity indicator, and six Negative Health Habits indicators. It is designed to
assess psychological factors that can influence the course of treatment ofmedically
ill patients. The MBMD was developed in consultation with doctors, psychologists,
nurses and other health professionals who work with the physically ill. As a result, it
reflects issues that are relevant to a thorough understanding of the attitudes,
behaviour and concerns ofmedical patients. The inventory was developed for use in
clinical practice, hospitals, outpatient settings and in research. It is especially useful
when applied to patients in which psychosocial factors may play a role in the course
of disease and treatment outcome.
The MBMD assesses several important psychosocial characteristics that the MBHI
does not provide explicit information on. These include information about:
■ the presence of psychiatric indicators that may influence patients' adjustment
to their medical condition
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■ coping styles that reflect recently derived personality disorders (Millon and
Davis, 1996)
■ psychological factors related to cognitive appraisals (e.g., self-esteem and
general efficacy), resources (e.g., spiritual and religious), and contextual
factors (e.g., functional abilities)
■ lifestyle behaviour (e.g., alcohol and substance abuse, eating patterns,
inactivity and exercise)
■ patients' communication styles (tendency toward disclosure, social
desirability, and devaluation)
■ predicting patient adherence, medication abuse, and use of medical services,
which can be useful for healthcare management decisions and triaging mental
health treatment
Since the development of the MBHI in 1982, numerous clinical studies in diverse
hospital settings have shown that patients who receive cognitive-behavioural
interventions require fewer medical services than those who receive standard care.
Research informed interventions can reduce healthcare costs significantly and
ultimately enhance patient adherence to treatment regimens. This research has
included the use of the MBHI and MBMD in studying adjustment and health
behaviour in straight, gay and bisexual populations of men and women living with
HIV (Antoni and Emmelkemp, 1995; Byrnes-Pereira, Antonio, Davidson and
Simon, 2000; Starr et al., 1996).
Given the HIV specific research base, and the inclusion of scales assessing coping
styles and issues of adherence, the MBMD was therefore chosen as an appropriate
measure for examining the hypothesis. Like the MIPS, the MBMD is also easy and
quick to administer. Fundamentally, both measures are derived and developed from
the same theory of personality, making comparisons of results particularly
meaningful, and especially in a theoretical context. This was viewed a sensible
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approach to the research question, and is given emphasis by a quote from a review
article on patient adherence and chronic illness by Wiebe and Christensen,
" research has examined the utility ofusing standardizedpersonality inventories
as predictors of adherence however, many of these studies have not been
theoretically driven and have lacked an organizing framework to guide
measurement attempts."
(Wiebe J.S. and Christensen A.J., 1997)
The reader is referred to Appendices VII & VIII for full descriptions of the MIPS
and MBMD scales. All MIPS scales were used in the research. Not all MBMD
scales were considered necessary to apply within the assessments (for example
those assessing negative health habits such as smoking, lack of exercise and diet).
The focus of the study remained on the personality issues surrounding individuals'
approach to their healthcare.
2.3.3 Note on adherence assessment
From the introduction to this area of research it is noted that adherence can be
assessed in a variety of different ways (refer to Table 1: Summary of recent studies
of adherence to HIV antiretroviral therapy). For this study three different methods
were considered as a measure ofpatient adherence:
i) Self-report ofprevious 3-month adherence
ii) Viral load
iii) MBMD Treatment Prognostics Scale - 'Problematic Compliance'
Upon analysis of the viral load data, it was observed that of the participants who had
reported missing any antiretroviral dose in the past 3 months (n=19), only 3 (16%)
had detectable viral loads (>400 copies/ml). It became apparent that, given the
sample size (N=25), participants could not be classified as 'good' or 'poor' adherers
on viral load alone. The Problematic Compliance scale of the MBMD proved to be a
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useful post-hoc reference for adherence, but as it was one of the measures acting as
an independent variable in the study it was not used to classify adherence per se. In
line with the reliability reported in other studies of adherence (please refer to Table
2.), it was therefore decided to apply patient self-report as the primary function of
adherence, and it was the main dependent variable in this study. Viral load and the
Problematic Compliance indicator will be discussed later in this report.
A review of the literature on research using self-report as an adherence measure
(Catz et al., 2000; Gordillo et al., 1999), advised that the cut-off point for
determining good or poor adherence should lie between 80-90% adherence. This was
a potentially vague boundary, however the inability to use viral load as an adherence
measure suggested that 90% was too high a cut-off point. It was felt that the use of
the semi-structured interview, which provided the opportunity to carefully probe
respondents honest self-report of adherence, would compensate for the loss of viral
load indicators. Therefore in line with previous research into medication adherence
and life-threatening illness it was decided to refer to an 80% adherence cut-off point.
A review of the research also indicated that, in the case of HIV/AIDS, this 80% cut¬
off corresponds to a reported frequency of missed doses of >1 dose/week. This then
acted as the boundary for classifying participants as either 'good' or 'poor' adherers
upon their self-report of adherence during the semi-structured interview.
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3 Results
3.1 Descriptive results analysis
Descriptive statistical analysis was applied to much of the data collected using the
demographic and adherence self-report semi-structured interview schedule. The
results of this initial analysis are displayed below.
3.1.1 Demographic-related self-report data
A total of 25 participants completed measures. All questionnaires were completed in
full with no omissions from the data collected. The sample comprised 16 males
(64%) and 9 females (36%) who fell into a variety of age ranges. Such data are
presented graphically in Figures: 4 & 5 (pages 78 & 79).
(All frequencies correspond to the number ofparticipants meeting each condition).















Data on the following variables are also included in the following charts: marital
status, sexual orientation, route of HIV infection, time since diagnosis, and
frequency ofAIDS diagnosis.
(Of all the participants 56% were single, 20% married, 8% divorced and 16%
cohabiting. 56% identified as being heterosexual and 44% as homosexual.)
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A surprisingly high number of individuals in this sample (28%) reported not
knowing how they became infected with HIV. In Lothian, out of those currently
receiving antiretroviral therapy (458) only 15 individuals are reported as becoming
HIV positive through unknown routes. This might suggest that some participants in
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this study were unwilling to disclose their route of infection and chose to give a
response of unknown.


















The semi-structured interview scheduled also included an item on the presence of an
AIDS diagnosis. As mentioned earlier, there has been some variation in the exact
medical status or series of conditions that are necessary for a diagnosis of AIDS.
Before coming to a diagnosis of AIDS, doctors consider a variety of symptoms and
tests. There is no single test for AIDS. They may look for one of the opportunistic
infections or cancers in the presence of an underlying immune deficiency. Tests may
also be carried out to try to seek a positive diagnosis ofPneumocystis carinii, one of
the AIDS-defining illnesses. Five respondents initially reported that they thought had
previously been diagnosed as having AIDS, but were unsure whether or not their
consultant had ever done this, reflecting the ambiguity in the diagnosis. All five
individuals (20%) eventually concluded that they had been diagnosed with AIDS at
some point and that, as far as they were aware, they still had the diagnosis. Figure 9
(page 82) presents the incidence of AIDS diagnoses within the sample.
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3.1.2 Adherence-related self report data
The semi-structured interview schedule also permitted the collection of data, by self-
report, related to individuals' particular antiretroviral dosing regimens. The
interview was designed to obtain an accurate recording of medication factors, and
assess to what extent participants were adhering to their particular medication
regimen. At some point, all except two of the participants reported that they had
experienced significant gaps in their treatment regime. These gaps were often
referred to as 'drug holidays', and were all noted taken for at least a duration of three
months. Participants' reasons for taking these breaks from treatment were in relation
to experiencing adverse side effects to a previous antiretroviral combination. Gaps
represented a treatment free period before beginning an altered treatment regimen,
hopefully with less disagreeable side effects.
The data related to medication regimens included: time since HIV diagnosis, the







taken per day. This information is presented below in summary Table 5, reporting
means for males and females under each condition.
(Once again, all frequencies correspond to the number ofparticipants meeting each
condition)
Table 5: Time since HIV diagnosis and number ofpills taken per day (Means)









Male Mean 42 12.0 3 11
N=16










Most participants were taking at least three different antiretrovirals in combination
on a daily basis. This would be observed across a wider sample of those on HIV
therapy. Advances in drug development and effectiveness have allowed many pills,
in the past taken separately, to be combined into one pill for ease of administration.
Nevertheless some individuals in this study were taking in excess ofmore than three
different pills in any combination. In addition, four respondents were taking in
excess of a cumulative total of 16 pills per day12. The frequency of individuals
taking different antiretrovirals in each daily combination, and the total number of
pills taken, is best demonstrated graphically (please refer to Figures 10 & 11, pages
84 & 85).
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Figure 10: Number of individuals by frequency ofantiretroviral types in
combination taken per day
□ 1 type 1
■ 2 types 4
□ 3 types 11
□ 4 types 8
■ 5 types 1
No. of different antiretroviral types taken
per day
The cumulative number ofpills taken daily was observed to fluctuate across the
individuals sampled.
12 One participant in the study was on a daily regimen of 15 antiretrovirals. In addition he also took prescription medications
for the treatment of HIV-related infections and various other ailments. Medication outside his combination therapy consisted
of 13 pills per day. The total number of pills taken every day by this individual came to 28.
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Figure 11: Number of individuals by total number ofantiretroviral pills* taken
each day
No. pills taken every day
f This total is exclusive ofotherprescription medications
Despite, as mentioned earlier, the recent medical advances leading to the physical
combination of different antiretrovirals into less pills, a strong positive correlation
(r=0.694; n=25; p<0.0l) was observed between the numbers of different
antiretrovirals taken and the cumulative daily pill intake.
Antiretroviral treatments are observed to vary considerably in relation to the
complexity of the regimen. Not only are there variations in the number of pills taken
by individuals, the time of dosing throughout the day also varies, as does advice
from consultants on whether to take pills with or without food. Very often pills not
taken with food are instead to be taken between 1-2 hours before or after eating. The
regime varies according to the individual circumstances of the medication, the
patient and the aetiology of the infection. The analysis included a consideration of
the complexity of treatment regimens on adherence. A further examination of the
interaction between adherence and regime complexity occurs later in the report,
although the frequencies of individuals on any particular level of regimen
complexity are detailed in Figure 12 (page 86). The legend indicates the number of
pills taken at any one dose and the additional instructions for proper medicating.
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□ x2 daily with
food
□ x3 daily with
food
Ix2 daily 1-2 hrs
before/after
food
□ x3 daily 1-2 hrs
before/after
food
f Graph legend refers to the regimen for any one particular antiretroviral drug. Please note that dosing
requirements are repeatedfor other drugs in the regimen
As can be seen from Figure 12, the majority of respondents were taking a
combination of antiretroviral medications within a 'twice daily' treatment regimen.
Most individuals receiving HAART in the Lothian region were known to be on a
combination of at least three different drugs, therefore in terms of the number of
discrete antiretrovirals taken by each individual, this suggested that the participants
in this study comprised a representative sample.
Once it was established how the sample presented in terms of level of regimen
complexity, information was collated from the interview material to establish the
extent to which doses within each individual regimen were missed or not taken
according to instruction. Doses were considered as 'missed' if they were not taken at
all, and in the case of delayed doses if they were taken outside a time-frame of a Zz
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hour13 either side of the specific dosing time of the regimen. For example, on a
regimen expecting a combination of antiretrovitals to be taken at 8.00am and again
at 8.00pm, the morning dose would be 'missed' if it was actually taken after 8.30pm.
The frequency of such occurrences across the sample is displayed in Figure 13.
Figure 13: Number of individuals by self-reported number of doses missed


















No. of doses missed
The self-report of number of missed doses over the previous three months was the
basis for the dependent adherence variable. The decision to establish a cut-off point
for good and poor adherence was based upon previous research into adherence in
HIV therapy (please refer to methodology). Therefore, upon a study of the above
chart, the frequencies of individuals who met each condition are to be found in Table
6.
13 The use of a half-hour parameter either side of the specified dosing time was imposed following a
literature review which indicated that previous studies into HIV medication adherence had identified
this 'therapeutic window' as the appropriate time to medicate.
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Table 6: Number ofindividuals by categorisation of'good' and 'poor'
adherence
Good adherence Poor adherence
<1 missed dose per week >1 missed dose per week
No. ofparticipants meeting 16 9
each condition
The final part of the adherence section of the semi-structured interview enabled
some qualitative information to be gathered concerning the reasons why these doses
are occasionally missed (refer to Figure 14, page 90). Participants would typically
begin their response by simply stating that they 'don't know' why these doses would
have been missed. However the interview process enabled effective probing on this
issue and most participants, with the exception of three, were guided towards the
identification of discrete, individual explanations for missed or delayed doses.
Responses by self-report varied across participants, although a closer inspection of
the reasons given allowed each to be grouped under a range of main reasons for
missed doses (please refer to Figure 14).
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Main reason for missing a
dose
□ Forgetting






Most respondents stated that forgetfulness accounted for the majority of missed
doses. Some participants volunteered several different reasons and appeared quite
clear about the situations leading to their own experience of missed dosing. It was
noted that several participants claimed that, over the last 3 months, they had missed
doses through apparent 'laziness'. As one respondent, on an 8.00am/8.00pm dosing
time, described,
"
I deliberately slept through the alarm, I knew I had to take it [the medication] but
I was really tired and just couldn't be bothered getting up doesn't normally
ever happen but I was just so fed up
This incident was classified as 'inconvenience' as the main reason for the participant
missing the dose. Similarly, another respondent reported missing six doses over two
days for the following reason,
"I just decided I'd had enough that day didn't take any that day or the
following day I've been undetectable [viral load] for quite a while and took
some time off".
Again, this response was classified as 'inconvenience', although both examples are
suggestive of an underlying psychological factor perhaps indicating that these
individuals had almost had enough of meeting the demands of their particular
treatment regimen and felt driven to rebel against it.
Demographic results from the semi-structured interview were cross-tabulated with
the results self-report adherence measure. The resulting contingency tables were
analysed by applying a chi-squared statistic to determine the presence of any
association between reported frequencies of occurrence of descriptive demographic
or treatment regimen data, and level of regimen adherence. No significant
associations were discovered upon this analysis.
3.1.3 Personality and adherence-related data
By this stage of the investigation, each participant had been categorised as either a
'good' or 'poor' adherer to antiretroviral treatment. Viral load output was returned to
in order to establish if any of the self-reported poor adherers demonstrated levels of
detectable viral load (>400 copies/ml) in the previous 6 months (February to July
2002). Four individuals within the sample (16%) were noted to have had viral loads
>400 copies/ml in the previous 6 months. Previously, an examination of the last 3
months' data had revealed 3 individuals (12%) with elevated viral loads. However,
examination of the last 6 months' viral load data was very revealing as 3 out of the 4
individuals with detectable viral load were also identified as poor adherers on the
basis of self-report within this study. This finding reinforced the self-reported data of
poor adherence as a more reliable function of adherence in general.
Before personality and adherence measures were examined for any meaningful
associations between them, the occurrences of the different personality styles among
good and poor adherers were considered.
Figure 15 (page 91) is a visual representation of the incidence of each personality
style measured by the MIPS across good and poor adherers.
90
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All personality styles were cross-tabulated with level of adherence. Each resulting
contingency table was then subjected to a chi-square (x2) statistical analysis to
establish any existence of a statistical association between adherence level and
personality style. However, as x 2 does not measure the strength of a statistical
association, a measure of strength of association for categorical data, the phi
coefficient (<j>), was also applied to the data. The following associations between
level of adherence and personality style were discovered:




Adherence Good Count 2 7 9
Expected count 4.7 4.3 9.0
Poor Count 11 5 16
Expected Count 8.3 7.7 16.0
Total Count 13 12 25




Pearson X 2 4.996 1 0.025
* 0.447 0.025 (approx. sig)
X2 = 5.00; df = 1; p<0.05
(|) = 0.447; p<0.05
It can be concluded that there is a statistical association between adherence and an
accommodating personality style. Based on the results, good adherers are statistically
more likely to have an accommodating personality style.
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Adherence Good Count 2 7 9
Expected count 4.7 4.3 9.0
Poor Count 11 5 16
Expected Count 8.3 7.7 16.0
Total Count 13 12 25




Pearson % 2 4.996 1 0.025
0.447 0.025 (approx. sig)
%2 = 5.00; df = 1; p<0.05
(j> = 0.447; p<0.05
It can be concluded that there is a statistical association between adherence and a
systematising personality style. Based on the results, good adherers are statistically
more likely to have a systematising personality style.
No other statistical associations were discovered between adherence level and
personality style. However, the same statistical analysis was conducted across the
observed coping styles of the participants. The following significant results were
obtained:
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Adherence Good Count 7 2 9
Expected count 4.0 5.0 9.0
Poor Count 4 12 16
Expected Count 7.0 9.0 16.0
Total Count 11 14 25




Pearson \2 6.512 1 0.011
$ 0.510 0.011 (approx. sig)
X2 = 6.51; df = 1; p<0.05
$ =0.510; p<0.05
It can be concluded that there is a statistical association between adherence and a
nonconforming coping style. Based on the results, good adherers are statistically less
likely to have a nonconforming coping style.
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Adherence Good Count 5 4 9
Expected count 2.5 6.5 9.0
Poor Count 2 14 16
Expected Count 4.5 11.5 16.0
Total Count 7 18 25




Pearson X2 5.30 1 0.021
$ 0.460 0.021 (approx. sig)
X2 = 5.30; df = 1; p<0.05
<t> = 0.460; p<0.05
It can be concluded that there is a statistical association between adherence and a
forceful coping style. Based on the results, good adherers are statistically less likely
to have a forceful coping style.
Repeated use of the Chi-Square and Phi coefficient analyses on the relationship
between adherence and the Treatment Prognostics scales of the MBMD were carried
out. The results were as follows:
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Adherence Good Count 6 3 9
Expected count 3.6 5.4 9.0
Poor Count 4 12 16
Expected Count 6.4 9.6 16.0
Total Count 10 15 25




Pearson \2 4.167 1 0.041
$ 0.408 0.041 (approx. sig)
X2 = 4.17; df= 1; p<0.05
$ =0.41;p<0.05
It can be concluded that there is a statistical association between adherence and the
interventional fragility treatment prognostic. Based on the results, good adherers are
statistically less likely to have the interventional fragility factor.
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Adherence Good Count 6 3 9
Expected count 3.6 5.4 9.0
Poor Count 4 12 16
Expected Count 6.4 9.6 16.0
Total Count 10 15 25




Pearson X2 4.167 1 0.041
$> 0.408 0.041 (approx. sig)
X2 = 4.17; df = 1; p<0.05
<f> =0.41;p<0.05
It can be concluded that there is a statistical association between adherence and the
problematic compliance treatment prognostic. Based on the results, good adherers
are statistically less likely to have the problematic compliance factor.
As two treatment prognostic indicators were found to be associated with adherence,
an examination was conducted to evaluate any relationship between either of these
variables and the treatment regimen variables assessed in the semi-structured
interview. Only one association was found to be significant, the interventional
fragility indicator and the use of additional prescription medicines by individuals;
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Prescription Good Count 10 10 9
Drugs Expected count 12.0 8.0 9.0
Poor Count 5 0 16
Expected Count 3.0 2.0 16.0
Total Count 15 10 25




Pearson X2 4.167 1 0.041
0.408 0.041 (approx. sig)
X2 = 4.17; df= 1; p<0.05
<f> =0.41;p<0.05
It is concluded that individuals having to take additional prescription medication as
well as antiretroviral treatment, are more likely to express the interventional fragility
indicator.
The association discovered between level of adherence and the personality measures
was felt to warrant further investigation, in order to assess the presence of significant
differences between the means of each measure as they interact with level of
adherence. As the data was not normally distributed, as Table 7 (page 99) shows, it
was important to select a statistical method that was resistant to skewness. The
Mann-Whitney test for independent samples was therefore chosen.
98


















N 25 25 25 25 25 25




.464 .464 .464 .464 .464 .464
The original prevalence scores of each individual on each of the measures tested
were used in this analysis. The group statistics already demonstrated large
differences between group means of good and poor adherence and the personality-
defined measures (see Table 9).
Table 8: Group statistics for independent samples test
Adherence N Mean Standard Standard error
level deviation of mean
Accommodating Good 16 45.38 22.71 5.68
Personality Poor 9 81.89 16.11 5.37
style
Systematising Good 16 74.19 15.07 3.77
personality style Poor 9 27.44 28.85 9.62
Nonconforming Good 16 39.69 26.40 6.60
coping style Poor 9 69.89 19.20 6.40
Forceful coping Good 16 31.38 29.34 7.34
style Poor 9 59.56 26.81 8.94
Interventional Good 16 55.13 20.92 5.23
fragility Poor 9 88.56 20.91 6.97
indicator
Problematic Good 16 53.12 28.37 7.09
compliance Poor 9 94.00 17.31 5.77
indicator
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The results of the Mann-Whitney test clearly show that there are statistical
differences between the mean scores of good and poor adherers on the personality
variables measured. The significance of these results is shown in Table 10.
Table 9: Mann-Whitney test statistics
Accommodat Systematising Nonconforming Forceful Interventio Problematic
ing personality coping style coping n fragility compliance
personality style style indicator indicator
style
Mann- 12.000 13.500 23.500 30.500 15.500 12.500
Whitney
U
Z -3.398 -3.315 -2.750 -2.361 -3.200 -3.371
Asymp. .001 .001 .006 .018 .001 .001
Sig
(2-tailed)
The results are very significant and it is therefore concluded that good and poor
adherers show significant differences based on the following personality-related
variables variables:
i) Accommodating personality style
Z = 3.40; Significant; p<0.01
ii) Systematising personality style
Z = 3.32; Significant; p<0.01
iii) Nonconforming coping style
Z — 2.76; Significant; p<0.01
iv) Forceful coping style
Z = 2.36; Significant; p<0.05
v) Interventional fragility treatment prognostic
Z = 3.20; Significant; p<0.01
vi) Problematic compliance treatment prognostic
Z = 3.37; Significant;p<0.01
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4 Discussion
This chapter will introduce a discussion of the research findings based upon the
hypothesis. The ability of the study to answer the research question will be the
fundamental basis of this critique. Consideration as to how the findings of this study
fit into the framework set by previous research in this area will also take place. A
discussion of the qualitative elements of this research is also thought to be important.
Finally, after an examination of the possible limitations to this research,
consideration will be given to any implications of the study and the potential for
informing current clinical practice and future research in the area of adherence to
HIV treatment.
4.1 Comment on demographic data
The semi-structured interview schedule was the only instrument used to collect
information on demographic strata across the sample. Despite a considerable amount
of potential useful information being collected across several variables it is
disappointing that the statistical analysis did not yield any particularly significant
findings. However, the frequencies of individuals meeting various conditions of the
variables examined, do reflect some of the findings resulting from previous research
in this area. Mehta et al. (1997) cite a number of demographic characteristics found
to affect adherence with HIV therapy in a review of the literature on the subject. In
addition they considered psychosocial/behavioural characteristics, clinical aspects,
and healthcare administration and delivery. The Gordillo et al (1999) study identified
many variables which were statistically significant predictors of compliance in a
univariate analysis. Poorer adherence was commoner among younger individuals
with best adherence observed in those aged between 32 and 35 years. Most of the
sample used in the research reported here fell within this age range. However, due to
the small sample size, inferential statistics could not be applied to analyse for similar
findings reported in such previous literature. On first examination of previous
research findings, it becomes immediately apparent that their analyses are based
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upon research involving considerably larger sample sizes than examined within this
study. For example, Gordillo et al. (1999), who were able to produce results based
on a sample of 366 subjects. The Gordillo study included an extensive multivariate
analysis of the demographic characteristics associated with treatment adherence.
They discovered primarily that around three-quarters of their sample were able to be
classified as good adherers. A similar finding resulted from this current research
study. However, in the research reported in this thesis, no significant associations
were observed between adherence and demographic strata. The small number of
participants, also meant that a range of investigations could not be reliably
conducted, a conclusion reinforced by the fact that responses to the measures did not
represent a normal distribution. Many previous studies have enjoyed the advantage
of measuring adherence by HIV exposure category as their large response rates
allowed for such comparisons. For example, looking for differences between
homosexuals, heterosexuals, and within these groups also considering subgroups of
individuals who are or are not injecting drug users. Thus, the lack of significant
findings in the analysis of adherence by demographic strata in this study could
certainly be explained by the very low sample size. Other demographic findings
from previous research includes the finding that the male gender is associated with
decreased adherence, although many other studies have not found a significant
association in this interaction. Some studies, using frequency of appointment-
keeping as a measure of adherence, have found that females are less compliant (for
example, Kissinger et al., 1995). Many other associated demographic characteristics,
which given the sample size could not be accurately researched in this study, would
include: level of education, socio-economic status, and perception of social support.
It would appear that there are significant associations to be found between adherence
and demographic strata. However a reliable examination of them would appear to
rely heavily on large sample sizes, and the availability the researcher has in terms of
accessing relevant sub-populations based on such factors as employment, risk group,
education, and mental health.
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4.2 Comment on personality and adherence-related data
The adherence measures provide a basis for a more informing discussion than that
surrounding the demographic data. The adherence self-report measure was felt to be
a potentially reliable measure of compliance to antiretroviral medication. There are
three main reasons for drawing on this conclusion, based upon both the process of
data collection and the analysis of objective outcome measures. Firstly, it was
observed during the process of meeting with and interviewing participants that
perhaps more accurate information regarding their missed doses was being collected
tan would have been provided by a straight-forward self-report questionnaire. It is
believed the actual interview allowed a productive alliance to develop between the
respondent and interviewer, and the dialogue therein enabled open-ended
questioning of dosing lapses and regimen difficulties. Such a process would not
occur with the use of a self-completed questionnaire, and this may have increased
the risk of under-reporting of missed doses. The interview enabled an empathy to
develop surrounding the difficulties of treatment adherence and as such was a source
ofpotentially richer information.
The second reason for concluding that this self-report was a reliable avenue of data
collection, lies in the finding that the perusal of the physiological measures of viral
load indicated that four of the individuals identified as poor adherers via self-report
had detectable viral loads in the previous six months. Furthermore, three individuals
were demonstrating detectable viral loads in the previous three months. Fluctuations
in viral load have been discovered as statistically significant predictors of adherence
difficulties in previous studies (for example, Catz et al., 2000). The research reported
herein did not establish any statistical validity for the use of the past 3-month
measure of self-reported adherence. Furthermore, the decision to ground the good
and poor adherence boundary along a cut-off point of >1 missed dose per week, was
based upon previous methodology. However, the discovery that detectable viral
loads could only be traced to participants in the poor adherence group, suggested that
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the adherence cut-off point, and indeed the use of a retrospective 3-month self-
report, were appropriate elements in the methodology behind establishing an
adherence measure.
Finally, under a post hoc evaluation, it was discovered that one of the treatment
prognostic indicators being assessed within the MBMD, was significantly and
strongly associated with adherence. Although five other independent variables were
also found to be statistically significant with adherence, the fact that this scale
'problematic compliance', was designed to elucidate patients' disinclination to
follow medical advice such as adherence instructions, indicates that the measure of
adherence used in this study was reliable.
The finding that a positive correlation was discovered between the numbers of
different antiretroviral types taken, and the cumulative daily intake of pills, can be
approached as a reasonably obvious, and therefore expected, association. On the
basis of this statistically significant association, and given that that a strongly
significant association also occurs between adherence and the interventionalfragility
indicator, it is surprising therefore that no significant association was to be found
between either adherence or interventional fragility and cumulative pill intake or
regimen complexity. The interventional fragility indicator was designed to predict
whether patients will be able to adjust emotionally to the demands of physically and
psychologically stressful medical protocols. Based on the assumption that
increasingly complex regimens contribute to such emotional adjustment it is
surprising that more associations were not found between adherence and measures of
regimen complexity. For example, one could hypothesise that, given this
assumption, and the association between self-reported adherence and the
interventional fragility scale, one or other would be sensitive to higher dosing
requirements, more antiretrovirals in combination, more pills in total, and a
generally more complex treatment regimen. This did not prove to be the case in this
research and may indicate that there are other mediating variables or factors, that are
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not assessed by the measures used. Contextual and mediating factors may need
further investigation concurrent with personality characteristics.
Despite such conclusions, the evidence yielded in this research would point towards
self-report adherence as an essentially reliable measure. Other studies have also
found this to be the case, and self-report remains the most cited measure of
adherence in the literature on compliancy in life-threatening illnesses in general
(Haubrich et al., 1999; Besch et al, 1997; Caron et ah, 1985).
So far this discussion has identified that the demographic information yielded is
largely anecdotal in its relevance to the adherence issue, although previous research
has found statistical significance between adherence and such strata in surveys of
large samples. The low sample size meant that this study was unlikely to detect any
influences of demographic data even if they were present. The consideration of self-
reported adherence as a potentially reliable measure of compliance has also been
discussed using statistically significant findings, and further anecdotal observations,
to support such a claim. Before continuing with a critique of those specific
psychological elements that may or not have an influence on treatment adherence, it
would be prudent to re-visit the research hypothesis as a reminder of the main
objectives of this study:
Therapeutic and non-therapeutic levels of regimen adherence to HIV antiretroviral
therapy are associated with:
i) personality style
ii) coping styles
Hi) attitudes to, and beliefs about, healthcarefor HIV illness
iv) treatmentprognostic indicators
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The specific components of this hypothesis will now be considered in turn and either
endorsed or rejected based on an assessment of the evidence produced by the
research.
4.2.1 Hypothesis i) - Therapeutic and non-therapeutic levels of regimen
adherence to HIV antiretroviral therapy are associated with personality
style
As the introduction to this area of research has demonstrated (see section 1.3.4.2:
Psychological variables and adherence to antiretroviral therapy) explicit
personality characteristics have been studied very little in the context of adherence to
HIV treatment. Studies have tended to focus on aspects of mental health (for
example, depression; Singh et ah, 1994), cognitive barriers to treatment, self-
efficacy and social support. Rhodewalt & Fairfield (1990) suggest that patients
exhibiting the Type A behaviour pattern may be more likely to perceive medical
regimens as threatening to their personal freedom and react with nonadherence in an
attempt to regain perceived behavioural control. Christensen & Weibe (1996) in a
review of the limited literature, report that chronically ill patients with an internal
locus of control exhibit more favourable adherence. Most personality correlates of
health-related outcomes have been studied in relation to other life-threatening
conditions such as renal dialysis, and it is these investigations that must be consulted
in respect of this research study.
The findings of this study indicate that the hypothesis can be upheld with regard to
the relation between HIV treatment adherence and personality style. The results
support that there is a statistical association between an accommodating personality
style and adherence. Specifically, good adherers were more likely to possess this
characteristic. There was also evidence for a statistical association between a
systematising personality style and adherence. Good adherers were statistically more
likely to have a systematising personality style.
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An accommodating personality style describes an individual who,
"reacts to the passing scene, is accommodating to circumstances created by others,
but at times can appear acquiescent". (MIPS technical manual)
A systematising personality describes individuals who,
"are highly organised, and predictable in their approach to life's experiences. They
transform new knowledge in line with what is known and are careful, if not
perfectionistic, in arranging even minor details. As a result, they are often viewed by
others as orderly, conscientious, and efficient. " (MIPS technical manual)
Upon a consideration of these synopses of each personality style, it becomes
relatively effortless to begin associating such approaches to life to the context of an
individual who consistently adheres to treatment regimens. Having such attention to
detail and sense of order, routine and a willingness to adapt to the requests of others
would undoubtedly be advantageous pre-requisites for a good ability to live with the
demands imposed by combination therapy.
A conceptual examination of the five-factor taxonomy of personality dispositions
(Costa & McCrae, 1992) suggests that conscientiousness may be the most accurate
trait descriptor of those individual qualities important with regard to adherence
behaviour. Digman (1990) and Costa & McCrae (1987) have described this
personality dimension as reflecting
"a highly purposeful, well organised, self-disciplined style" or "a will to achieve,
dependability, and self-control
There would certainly appear to be a similarity between interpretations of the
accommodating and systematising personality styles of this study, and those of the
theorists above.
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Christensen & Smith (1995) observed that conscientiousness was a five-factor trait
significantly associated with adherence to medication regimens required during renal
dialysis. No other personality dimension was found to be significantly associated
with patient adherence.
This corroboration of support for the associative value of accommodating and
systematising personality styles with HIV treatment regimens, leads to the
conclusion that the hypothesis is endorsed in this respect. The findings of this study
would appear to provide some support for a relationship between therapeutic levels
of regimen adherence to HIV antiretroviral therapy and personality styles, coping
styles and indicators of treatment prognosis.
4.2.2 Hypothesis ii) - Therapeutic and non-therapeutic levels of regimen
adherence to HIVantiretroviral therapy are associated with coping style
The research base on coping styles and adherence to antiretroviral treatment is
slightly wider than that of personality characteristics. Sherbourne et al. (1992)
observed that avoidant coping behaviour has a negative association with medical
treatment adherence. Active coping preferences have been found to predict better
adherence outcomes in patients undergoing haemodialysis at home, where patient
involvement and control is greater. Problem-focused coping strategies have also
received some attention in the literature in relation to adherence. Folkman (1984)
proposes that problem-focused coping strategies oriented toward modifying some
aspect of the stressful situation may be associated with more positive outcomes only
if the stressful situation is amenable to efforts to control it. Pugliese et al. (1995)
studied adherence in cancer patients and discovered that a positive coping style was
related to treatment compliance, although the term 'positive' coping style is rather a
vague variable that requires elaboration.
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Conversely, Wiebe & Christensen (1996) review how there is little evidence to
suggest that the way an individual copes with a stressful encounter bears a
predictable relationship to that individual's well-being. They note how previous
research into coping may in part be due to a failure to consider contextual influences.
There may be further evidence in this for a stronger consideration of the illness or
treatment context as opposed to a single focus on the person in terms of the
adaptational value of a particular style of coping.
Catz et al. (2000) also considered the role of barriers to treatment adherence in
HAART. The findings in this study highlighted the need for interventions that help
patients organise and manage their medication regimens, and help them to plan and
problem-solve how they will handle regimens in the context of other life activities.
The study did not, however, identify any coping styles related to medication
adherence.
This research study found an association between nonconforming and forceful
coping styles and medication adherence.
The nonconforming scale of the MBMD describes a coping style characterised by
individuals who may be,
" somewhat sceptical about the motives of others, and they tend to act
insensitively and impulsively at time
The MBMD also advises that,
" such individuals should dealt with firmly and directly, with reassurance that
healthcare professionals are there to help them solve their physical problems
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High scorers on the forceful scale are characterised as,
"tending to be rather domineering and tough-minded the healthcare team should
try not to feel intimidated or provoked by these individuals. A straightforward
approach is most effective with these patients they may not follow treatment
regimens well extra effort will be necessary to encourage them to comply".
As with the descriptions of those personality styles found to be significantly
associated with adherence, it is not difficult to map individuals with difficulties
adhering to treatment within these contexts. Therefore it is concluded that the
hypothesis is also endorsed with respect to its prediction that treatment adherence
would be significantly associated with coping style.
4.2.3 Hypothesis iii) - Therapeutic and non-therapeutic levels of regimen
adherence to HIV antiretroviral therapy are associated with attitudes to,
and beliefs about, healthcare forHIV infection
The review of the literature uncovered that there was a research base in how negative
attitudes about healthcare and illness may also interfere with treatment adherence.
For example, Youssef (1984) reports on reasons cited by the mentally ill for not
taking medications, such as a fear of addiction, or a belief that medication use was a
sign of weakness. Among HIV-infected individuals, attitudes and beliefs related to
decreased adherence have been found to include the patient's perception and
acceptance of the disease, and a perceived lack of benefit (Norris et al., 1990). A
denial of the necessity of treatment has also been found to impede adherence.
The Gordillo et al. (1999) study evaluated patients' belief in antiretroviral therapy,
knowledge about the illness and satisfaction with their clinician. Although these
variables were well reported within their sample, none were found to be associated
with compliance.
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This research study used two scales of the MBMD to measure patient attitudes and
beliefs by proxy. These scales lay within the Stress Moderators domain of the
MBMD and consisted of illness apprehension versus illness acceptance and future
pessimism versus future optimism. Neither scale measured any significant
associations with adherence, and consequently, the relevant component of the
hypothesis was rejected.
4.2.4 Hypothesis iv) - Therapeutic and non-therapeutic levels of regimen
adherence to HIV antiretroviral therapy are associated with treatment
prognostic indicators
The use of indicators that could potentially inform the prognosis of a course of
illness in terms of treatment adherence would appear to be very rare. A literature
review revealed no specific working measure for determining patient adherence.
Perhaps this should be obvious, as if there were such a reliable instrument available,
there would be much less of a research base on adherence in chronic illnesses such
as HIV. For the purposes of this research, a Treatment Prognostics Domain within
the MBMD, was used to evaluate if any statistical association existed between
adherence by self-report and a range of scales designed to measure such treatment
adherence issues such as: interventional fragility, medication abuse, information
discomfort, excessive utilisation of services, and problematic compliance. To this
extent, such an evaluation was seen as particularly novel, especially as the MBMD
was a new assessment instrument despite being developed from the Millon
Behavioural Health Inventory (MBHI).
Two scales were found to be significantly associated with treatment adherence:
interventionalfragility and problematic compliance.
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The MBMD estimates that approximately 25-30% of all medical patients have
compliance problems. The scale describes individuals who,
"
are disinclined to follow homecare advice on treatment, and to keep and be on
timefor appointments "
The results indicated that good adherers are statistically less likely to have the
problematic compliance characteristic. This was potentially a very interesting result
as it could have implications for the credence of applying the MBMD as a screening
tool in HIV healthcare settings. The significant associations noted between
adherence and other scales on the assessment would certainly further support this
notion. Therefore it is felt that future research could concern itself with applying the
MBMD to a much larger HIV-infected sample, with the objective of avoiding the
limitations experienced with a sample size as low as the 25 participants assessed in
this current research.
The finding that interventional fragility was statistically associated with adherence
would give further strong evidence to suggest that the treatment prognostics
indicators of the MBMD are potentially very reliable in identifying those HIV-
infected individuals likely to be experiencing adherence difficulties, not only
currently, but also at some point in the future.
These findings enabled the hypothesis to be supported regarding its prediction of the
association of treatment prognostics indicators with treatment adherence.
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4.3 Limitations of the study and implications for clinical practice and
future research
Despite the significant statistical associations revealed by this study, it is still
believed that the extent of analysis and the exploration of inferential statistics was
impeded by the low sample size. In order to achieve statistical power = 0.8 (alpha =
0.05) and a medium effect size, a sample size of N = 67 was required. This would
undoubtedly have enabled more powerful multivariate analyses to be carried out.
However, the fact that statistical significance was achieved, and that self-reported
adherence was arguably a particularly reliable method of evaluating treatment
adherence, would all suggest that the measures used were especially sensitive at
tapping into the psychological factors considered.
Interpretation of the extent of statistical significance should also perhaps be
approached with caution. Level of probability for statistical significance was set at
p<0.05 in the analysis; this may have had an amplification effect on the frequency of
statistically significant results due to the multiple comparisons being made in the
chi- square analysis. It could be argued that the data should be analysed further with
some adjustment for p value taken as level of statistical significance. To summarise
the limitations of this research, the author concludes that interpretation of results
should be tempered by the small sample size, the low take-up during recruitment of
participants, the considerable number of comparisons made during the analysis, and
the implied potential for an undermined representation of the sample population.
Recruiting participants for a study such as this can become problematic when the
research population is an outpatient group, and contact between the researcher and
participants is determined by outpatient appointment times. Many of the potential
participants travelled considerable distances to attend the Lothian-based Regional
Infectious Diseases Unit, and with appointment frequency often as low as only once
every three months, the efficient distribution of information about the study was a
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cumbersome yet crucial task. It is also important to be aware that biases may also
have existed in the sample investigated. The researcher was aware that those
individuals who agreed to take part, may have represented a particularly motivated
subgroup of the sample. Working on the assumption that the more motivated
individuals were most likely to exhibit positive adherence behaviours, the potential
therefore existed of failing to obtain a truly representative sample in terms of
treatment adherence.
It is also noteworthy that there is still unfortunately some stigma attached to
HIV/AIDS, and this may have led to patients approaching the research with some
ambivalence.
Critics of the self-report method of collecting data may argue that there are inherent
problems in obtaining accurate and reliable responses from patients regarding what
can often be a contentious issue of treatment adherence. This argument may be more
applicable to the use of structured self-report questionnaires. However, the use of an
informal semi-structured interview to facilitate self-report was certainly believed to
enhance the accurate reporting of adherence variables among this HIV positive
population. Collection of accurate adherence data may also have been enhanced by
the fact that each respondent was being interviewed by someone they were
unfamiliar with, and with whom they could perhaps be more open and honest with in
their responses.
This research also suggested some evidence for the role of mediating factors in the
association between adherence, personality characteristics and coping styles.
Potential for future research may include the comparison of the application of similar
measures across individuals with other life-threatening illnesses requiring optimum
levels of treatment adherence.
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The process of application for ethical approval to undertake the research study is
summarised in the following steps. Please refer to the relevant correspondence as
indicated within the summary.
Step 1: An application form (appendix la) was forwarded to the Lothian Research
Ethics Committee on 5 February 2002. Attached to the application was a full
protocol (appendix lb) detailing the research objectives and methodology, a copy of
the research participant consent form (appendix lc), a research participant
information sheet (appendix Id), a consultant information sheet (appendixle).
Finally, copies of each questionnaire to be used in the research were also included
(refer to appendices 2, 3 &5).
Step 2: Simultaneously, verbal and written consent was obtained from each Lead
Consultant at the Regional Infectious Diseases Unit, Western general Hospital and
the Department of Genito-Urinary Medicine, Edinburgh Royal Infirmary (refer to
appendix If) for related correspondence.
Step 3: The application and research protocol were considered for ethical approval
by The Psychiatry/Clinical Psychology Research Ethics Sub-Committee at a meeting
held on 20 February 2002. Simultaneously, the application underwent a review of
resource and financial implications, which was subsequently approved by the
Research and Development Office, Royal Infirmary of Edinburgh. (Refer to
correspondence, appendix lg)
Step 4: On 26 February 2002 the Research Ethics Sub-Committee agreed to grant
ethical approval subject to the amendments stated in their correspondence (appendix
lh).
These amendments were then also forwarded.
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Step 5: At a meeting of the Research Ethics Sub-Committee held on 20 March
2002 ethical approval was granted to proceed with the research study. The researcher
received an official Certificate of Ethical Review on 12 April 2002 (appendix li).
The research protocol was then activated.
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Appendix la
Lothian Research Ethics Committee
Application form and notification of receipt
LOTHIAN RESEARCH ETHICS COMMITTEE
APPLICATION FORM
For official LREC Use Only
LREC/ / /
INSTRUCTIONS: Please complete in type. Please place a circle around Yes/No options as
appropriate. A version of this form is available on disc from the Secretary of the LREC or from
your Trust R&D Office. ONE COMPLETE COPY OF YOUR APPLICATION FORM AND
PROTOCOL SHOULD BESENT TO YOUR R&D OFFICE.
It is essential that this form is completed fully and sent with relevant enclosures. You should not
simply refer to the protocol but complete the form with the information requested. Please refer to
the accompanying Guidance Notes when completing the form and complete the checklist before
sending. Where a question is not applicable it is important to make this clear and not to leave it
blank. It is important that the language used in this application is clear and understandable to
lay members. All abbreviations should be explained.
Applicant's Checklist
Please indicate if the following have been enclosed by underlining or placing a circle round
Yes/No/Not applicable options.
Application Form (seventeen copies)
Full protocol (seventeen copies)
Application Fee of £500
Research subject consent form (seventeen copies)
Research subject information sheet (seventeen copies)
Advertisement for research subjects (seventeen copies)
GP/consultant information sheet or letter (seventeen copies)
Interview schedules for research subjects (seventeen copies)
Letters of invitation to research subjects (seventeen copies)
Questionnaire* Finalisod/Not yet finalised (seventeen copies)
Researchers brochure or data sheet for all drugs (one copy only)
Statement on compensation arrangements (seventeen copies)
CTX/CTC/DDX (one copy only)
Annexe A** (seventeen copies)
Annexe B*** (seventeen copies)
Annexe C**** (seventeen copies)
* Please indicate whether or not this is the final version
** Required if the study involves the use ofa new medicinal product or medical device, or the use
ofan existing product outside the terms of its product licence. Annexe A is attached to the
Application Form.
*** Required if the study includes the diagnostic use of ionising, radiation (radioactive materials
orX-Rays). Annexe B is attached to theApplication Form.
For official LREC Use Only
Yes No
Yes No Not applicable
Yes No -Not applicable
Yes No Not applicable
Yes No Not applicable
Yes No Not applicable
Yes No Not applicable
Yes No Not applicable
Yes No Not applicable
Yes No Not applicable
Yes No Not applicable
Yes No Not applicable
Yes No Not applicable
Yes No Not applicable
Yes No -Not applicable
Yes No Not applicable
Lothian Research Ethics Committee Application Form - October 2001 Page 1
**** Information concerning local researchers should always be given where possible at this stage.
Annexe C is attached to the Application Form. Please make additional copies as necessary.
Page 2
SECTION 1 Details of applicant(s)
1. Short title of project:
The role of personality factors in adherence to drug treatments for HIV
Full title:
An investigation into how normal and abnormal personality characteristics correlate with level
of adherence to antiretroviral therapy in individuals with HIV infection
2. Principal researcher (responsible for dealing with the LREC and the local R&D Office who







Present appointment of applicant:
Psychologist in Clinical Training
Qualifications:
Bsc Combined Honours (Psychology & Biology)
Address:
Studio Flat, 10 Boswall Road, Trinity, Edinburgh, EH5 3RH
Tel:
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3 Please give an approximate figure for the number of trials/studies in which the principal
researcher has been involved over the past year
One small-scale research project on a child psychology training placement
4. Names, titles and qualifications of other local researchers working on this project
N/A
5. Who is sponsoring the study?
Contact name:
Ms Ann Green (Line Manager)
Organisation:
East of Scotland Training Course in Clinical Psychology
Address:
C/o Nicole Tait










6. Drug Company Reference Number
N/A
Lothian Research Ethics Committee Application Form - October 2001 Page 4
7. Funding
Please give full details where applicable of:
a) Payment to subjects
N/A
b) Payment to Trust/practice/rcsearch funds, etc. (specify institution(s))
N/A





i) A block grant Yes
ii) Based on the number of research subjects recruited? Yes
If yes, how much per patient:
d) Details of other benefits, e.g. equipment
N/A
e) Details of NHS Trusts and hospitals/facilities to be used
Regional Infectious Diseases Unit, Western General Hospital, Edinburgh
f) Will the costs incurred by the institution be
covered by the payment? Yes No
8. What other researchers are/do you intend to be involved in this project? (Details of
researchers added subsequently must be notified to the LREC)
Please use the form attached atAnnexe C
N/A
Lothian Research Ethics Committee Application Form - October 2001 Page 5
SECTION 2 Details of project
This section must be completedfully. A copy ofthe protocol should be enclosed with the application
form, but it is not sufficient to complete questions by referring to the protocol.
9. Aims and objectives of project (Maximum. 250 words)
To attempt to identify correlates between normal/abnormal personality factors and level of adherence to
combination therapy in individuals with HIV positive status.
Sherr (2000), in a review of tire literature on adherence in HIV treatment, concludes that adherence can
be studied from four main perspectives:
• The patient or person
• The preparation/medication
• The provider
• The place or setting
She then describes how a number of psychological theories can be invoked to understand non-
adherence in terms of these four levels: Cognitive models, Psychodynamic models, Social concepts and
Personality concepts. This project aims to develop this principle further by studying how personality
specifically may influence a person's adherence to treatment regimens in HIV.
A review of the literature reveals an enormous amount of studies of adherence to HIV treatment.
However, very few of these studies explicitly examine the role of personality in adherence. The concept
underpinning the study is to investigate if it may be possible to predict likely adherence to HIV
combination therapy based on the presence (or absence) of certain personality characteristics. The end-
point to this research is to begin debating methods of improving adherence to antiretroviral therapy at
an individual level.
Sherr, L. Understanding adherence. LeadingArticle in Journal ofHIV Therapy, 2000, Vol. 5 No. 2 pp
30-35
10. Scientific background of study (Maximum. 250 words)
Studies on factors which influence adherence to HIV therapies are widespread. With HIV treatment, a
high level of adherence is vital if viral suppression is to be sustained. It is clear that non-adherence is
very common among patients treated for HIV infection. By understanding adherence factors in HIV,
interventions can be generated and evaluated to increase treatment adherence. Personality theory would
examine individual attributes in order to explain adherence. From the personal perspective, an
explanation would be related to ideas such as self-efficacy, self-esteem, resilience, commitment and
motivation. Personality variables may also affect the extent to which the physician can present
persuasive information and explanatory data thus influencing a variety of client-doctor relationships.
The role of personality factors in adherence to HIV treatment is not well documented in the literature.
There appears to be a paucity of research in this area. Personality variables and treatment adherence
have been more frequently researched in relation to other life-threatening conditions such as diabetes
and cancer. Results of these studies have identified personality variables characteristic of 'good' and
'poor' adherers to treatment.
Using a well documented and contemporary biopsychosocial theory of personality developed by
Theodore Millon (Davis 1999), this study will examine the personality styles of the participants and
attempt to identify correlations between certain personality variables and level of adherence to HIV
treatment. The personality assessments proposed to be used in the study have been developed as a result
ofMillon's dimensional conceptualisation of personality.
Davis R. D. (1999). Millon: Essentials ofjtis science, theory, classification, assessment and therapy.
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11. Brief outline of project including outcome measures (Maximum. 250 words)
To achieve statistical power around 70 participants will need to be recruited for this project. Individuals
attending the Infectious Diseases Unit, Western General Hospital and the GUM clinic at Edinburgh
Royal Infirmary will be approached with information about the study. Subject to their consent to take
part, each participant will meet with the researcher and be invited to complete a small battery of
questionnaires in 'pencil & paper' format. The battery of assessments will consist of:
• A short demographic questionnaire
• A brief self-report questionnaire on treatment adherence
• A questionnaire evaluating perceived quality of therapeutic relationship with consultant
• The Hospital Anxiety and Depression Scale (HADS)
• The Millon Index ofPersonality Styles (MIPS)
• The Millon Clinical Multiaxial Inventory -Third Version (MCMI-III)
It is estimated that the entire assessment battery will take lhr - lhr 15mins. to complete. The
researcher will be present during completion of the assessment.
The MIPS is designed for use by professionals looking for a comprehensive, well-rounded report of
general personality. It is a standardised psychological assessment containing 180 unobtrusive
True/False items organised into 3 groups of scales, together with 3 validity indicators or response sets:
Motivating Aims, Interpersonal Behaviours, Cognitive Modes, Response Sets.
The MCMI-III is a standardised instrument which assesses abnormal personality characteristics. It
specifically evaluates emotional, behavioural and interpersonal difficulties and can help to assess DSM-
IV related personality disorders and clinical syndromes. It consists of 175 True/False items grouped
into 14 personality pattern scales and 10 clinical syndrome scales.
Both tests draw from Dr T. Millon's widely accepted theory of personality.
Concurrent with personality assessment the researcher will also consult a computerised database of
patient information located at the Infectious Diseases Unit, Western General Hospital. This database
will reveal the level of adherence of each patient according to frequency of inpatient visits and viral
load over time (a physiological marker of adherence to treatment).
Correlations between personality variables and level of treatment adherence will be examined upon
statistical analysis of the data. Multiple regression will be used for statistical analysis.
12. Proposed start date and duration of project
Recruitment of participants data collection is proposed to take place during March, April and May
2002. Recruitment will commence immediately following ethical approval. Data Analysis and report
formulation will be on-going through June and July with a complete final report submitted by the end of
August 2002.
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13. Study design (e.g. Randomised Controlled Trial, cohort, case control, epidemiological analysis)
The study will, to some degree, constitute an epidemiological analysis of personality characteristics
common amongst the research sample. The study will be cross sectional in design. Concurrent with a
structured personality assessment, the researcher will also record a physiological measure of adherence
(from a computerised database of viral load over time). Correlations between personality variables and
level of treatment adherence will be examined upon statistical analysis of the data. Multiple regression
analysis will be used to examine the extent to which levels of regimen adherence is predictable from
variations in demographics, anxiety, depression, perceived quality of therapeutic relationship with
consultant, and a range of personality characteristics and clinical personality pathology. A between
groups design will examine the differences in variation of these variables across three levels of
treatment adherence.
14. Size of the study (including controls)
Will the study involve:
(a) Human Subjects Yes No
i) How many patients will be recruited?
Preliminary research suggests that this study will require around 70 participants in order to achieve
statistical power. See power analysis below.
ii) How many controls will be recruited?
N/A
iii) What is the primary end point?
The recruitment of at least 70 participants
iv) How was the size of the study determined?
Examination of previous similar studies on adherence and personality factors cited in a review of the
literature in this area. These studies concerned other life-threatening conditions where adherence was
an important factor.
v) What is the statistical power of the study?
For Power = 0.8 (alpha = 0.05) and a medium effect size, N = 67 for 2 independent variables.
(Cohen, 1992)
(b) Patient Records Yes No
i) How many records will be examined?
At least 70, ie. the case notes/computer database information of each participant will be reviewed.




iv) How was the size of the study determined?
See above
v) What is the statistical power of the study?
See above
15. Scientific critique
Has the protocol been subject to scientific critique? If so, please give the following information:
If the critique formed part of the process of obtaining funding, please give the name and address of the
funding organisation:
N/A
If the critique took place as part of an internal process, please give brief details:
The scientific critique of this protocol has taken place in collaboration with Dr Suzanne O'Rourke
(Research Academic Supervisor) and Dr Alison Richardson (Research Field Supervisor). The protocol
is entirely evidenced-based and was developed by consulting the most contentious literature available.
The psychological and theoretical framework behind this study is fully explained within the research
protocol attached.
If no critique has taken place, please explain why, and offer justification for this:
N/A
If you are in possession of any referees' or other scientific critique reports relevant to your
proposed research, please forward copies with your application form.
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SECTION 3 Recruitment of subjects
16. Local Recruitment of Subjects
a) How many subjects are being studied within Lothian?
70
b) Are any of these subjects involved in existing research
or have been involved in any recent research in the
last six months? ^0
Ifyes, please justify their use in thisproject
Some participants have been involved in drugs trials in the past. Their use in this project is justified
because the study is strongly linked to their experience of taking drugs.
c) Will any of the subjects involved be in a dependent
relationship with the researcher? Yes
Ifyes, please ensure you comply with local recruitment arrangements
d) Local independent adviser details:
Mike Henderson, Senior Clinical Tutor, Doctorate of Clinical Psychology, Kennedy Tower, Royal
Edinburgh Hospital
I confirm that I am willing to act as an Independent Adviser.
) Signature of Independent Adviser: L^}..
Date: 1.1^.1%.
e) Will any of the subjects involved be medical students? Yes (No\
Ifyes, please obtain signed agreement ofthe Dean ofthe Faculty ofMedicine:
Signature the ofDean of the Faculty ofMedicine
or equivalent if medical students are research subjects:
17. How will the subjects in the study be:
a) selected?
Participants will have an HIV positive status. They will be currently receiving antiretroviral medication
and will have been in attendance at the Regional Infectious Diseases Unit, Western General Hospital
during at least the preceeding six months.
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b) recruited?
A letter will be sent to each consultant physician at the Unit to request their consent to approach his or
her patients with regard to taking part in the study. Each consultant will also be sent an information
sheet explaining the study's objectives and methodology. Pending consent from each consultant,
potential participants will be approached with information and a letter inviting them to consider taking
part in the study. They will have at least 24 hours to consider this. Willing participants will then be sent
an appointment to meet with the researcher to obtain formal written consent and complete
questionnaires.
Patients will also be approached with information on the wards following consent from their consultant.
This will involve the distribution of information amongst nursing staff on wards. The researcher will
also be in attendance at the Unit should any patients wish to approach him about the research.
c) what inclusion criteria will be used?
Participants must currently be in receipt of antiretroviral medication and have been in attendance at the
Unit within at least the previous six months.
d) what exclusion criteria will be used?
Those patients under the influence of illegal drugs during psychological testing will be excluded from
the study.







c) what inclusion criteria will be used?
d) what exclusion criteria will be used?
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SECTION 4 Consent
19. Is written consent to be obtained? ^°
Ifyes, please attach a copy ofthe consent form to be used. Enclosed
Ifno written consent is to be obtained, please justify.
Patients will have at least 24 hours time in which to consider whether or not to consent.
20. How long will the subject have to decide whether to take part in the study?
If less than 24 hours please justify.
N/A
21. Please attach a copy of the written information sheet or letter to be given to the subject.
(See Guidelines page 3 andAppendixA.) Enclosed
Ifno Information Sheet is to be given, please justify.
N/A
22. Have any special arrangements been made for subjects
for whom English is not a first language? Yes No \N/AJ
Ifyes, give details.
Ifno, please justify.
23. Will any of the subjects or controls be from one of the following vulnerable groups?
Children under 16
People with learning difficulties
Unconscious or severely ill
Other vulnerable groups e.g. mental illness, dementia
Yes ) No
Ifyes, please specify andjustify:
Participants will have an HIV positive status and may possibly be facing a life-threatening illness.
Justification resides in the research outcome of debating methods of improving treatment adherence.
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24. What special arrangements have been made to deal with the issues of consent for the
subjects above? (Please see Guidelines.)
Patients unable to give informed consent will be excluded from the study.
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SECTION 5 Details of interventions
25. Does the study involve the use of a new medicinal product
or medical device, or the use of an existing product outside
the terms of its product licence? (Please see Guidelines.) Yes (Tvjo)
Ifyes, please complete Annexe A ofthe Application Form.
26. Will any additional diagnostic tests using ionising radiation
(radioactive materials or X-Rays be administered? Yes (No)
(NB Please ensure information in Question 17 includes exclusion criteria with regard to ionising
radiation if appropriate.)
Ifyes, please complete Annexe B ofthe Application Form.
27. Please list those procedures in the study to which subjects will be exposed indicating those
which will be part of normal care and those that will be additional (e.g. taking more
samples than would otherwise be necessary). Please also indicate where treatment is
withheld as a result of taking part in the project
Participants will be required to complete two structured paper and pencil personality assessments each
lasting 25-30 minutes. They will also be asked to complete a short demographic questionnaire, a short
screening questionnaire for anxiety and depression symptoms, and brief questionnaires relating to their
own self-report of medication adherence and their perception of the quality of the therapeutic
relationship with their consultant. The above procedures are in addition to normal care. The study does
not involve the with-holding of any treatment.
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SECTION 6 Risks and ethical problems
28. Arc there any potential hazards? Yes (fyo)
Ifyes, please give details, and give the likelihood and details ofprecautions taken to meet them,
and arrangements to deal with adverse events.
29. Is this study likely to cause any discomfort or distress? Yes (No)
Ifyes, please give details andjustify. '
It is possible, but very unlikely, that some participants may experience some discomfort in answering
items about themselves within the personality questionnaires. The researcher will be present during
completion of these questionnaires to talk through any possible discomfort with the participant should it
become apparent.
30. Safety Requirements
a) Medical support and other facilities available:
N/A
b) Local emergency contact details:
N/A
c) If you are going to administer drugs what arrangements have
you made to store, code and administer them? (See Annexe A)
N/A
I confirm that I am aware of and approve of these arrangements.
Signature of Hospital Pharmaceutical Officer:
Date:
d) Are you going to administer radioactive materials? Yes (Ncf
(See Annexe B)
i) If yes, do you have a separate ARSAC certificate for
this particular research study? Yes No
ii) Have you informed the Radiation Protection Adviser? Yes No
I confirm that I am aware of and approve of these arrangements.
Signature of Radiation Protection Adviser:
Date:
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31. What particular ethical problems or considerations do you consider to be important or
difficult with the proposed study?
Please give details.
N/A
32. Will information be given to the patient's General Practitioner? Yes (Nof)
Please note: permission should always be sought from research subjects before doing this.
Ifyes, please enclose an information sheet/letter for the GP.
Ifno, please justify:
Justified on the grounds that permission will be sought from the responsible medical consultant.
33. If the study is on hospital patients, will permission of all consultants
whose patients are involved in this research be sought? No
Ifno, please justify:
34. Are you free to publish the results of this study?
(ftw) No
Ifno, please expand:
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SECTION 7 Compensation and confidentiality
Product liability and consumer protection legislation make the supplier and producer (manufacturer)
or any person changing the nature of a substance, e.g. by dilution, strictly liable for any harm
resulting from a consumer's (subject or patient) use ofa licensedproduct.
A
35. Have arrangements been made to provide indemnity and/or compensation in the
event of a claim by, or on behalf of, a subject for non negligent harm?
(Please indicate N/A ifnot applicable) „ „
Yes No @
Ifyes, please give details ofcompensation arrangements with this application.
For pharmaceutical company sponsored research, the company should confirm that it will abide
by the most recent ABPI guidelines (Manual V. 14.1.1)
36. In cases of equipment or medical devices, have appropriate arrangements been made with
the manufacturer to provide indemnity?
(Please indicate N/A ifnot applicable) Yes No (n/A)
Ifyes, please give details and enclose a copy ofthe relevant correspondence with this
application.




i) How are confidentiality and anonymity to be ensured?
ii) What arrangements have been made to obtain consent for these procedures?
38. Will medical records be examined by research worker(s)
outside the employment of the NHS?
Ifyes, please see Guidelines.
39. What steps will be taken to safeguard confidentiality of personal records?
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All information provided by participants will be treated in the strictest confidence. Medical records
(either hard copy or computer database held) will be viewed by the researcher only. Information leaving
the Unit will have all identifiers removed. Participant consent forms will be kept separately from
completed questionnaires and individual participant numbers will be allocated to ensure anonymity.
Participants could not and would not be identified in any subsequent report or publication.
40. What steps will be taken to safeguard the information relating to specimens and the
specimens themselves?
N/A
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SECTION 8 Management Details
41. Can this project be included in the NRR (National Research Register) ? Yes (a/?)
42. Is this research carried out as part of a: Undergraduate Degree? Yes
Student Special Study Module? Yes
Postgraduate Degree? (Key) No
If YES which one?
Doctorate of Clinical Psychology - University ofEdinburgh
43. Is the host Trust the Lead Institution for this project? Yes (No)
IfNo, please indicate Lead Institute
Doctorate of Clinical Psychology - University of Edinburgh
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Ref. No.






























46. Who has vetted the contract? Commercial Development Unit (CDU)
University (Edinburgh Research and Innovation)
Trust
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Not Applicable
SECTION 9 NHS Resource Implications/Costs
47. Time Resources N/A
a) Staff involved in execution of project (including principle researcher)
Name Grade of Staff Hours on project
(specify per week or per patient or overall)
Please estimate as accurately as possible,
you should include hours outside your
contracted hours
Funded by:
Please state the fonder of the
research time,
(e.g. Trust/Univ/funds


















48. a) Could this activity be carried out within the Wellcome Trust Clinical Research
Facility (WT-CRF), with centralised research nursing, tracking and administration?
Yes No
b) If yes, are you intending to apply to the WT-CRF Scientific Committee?
(if yes, contact the WT-CRF office on 0131 537 2591)
Yes No
49. Service Costs
a) Is your study likely to incur excess treatment/investigation costs? Yes No
b) Additional Service Costs (including contact person)
Location of research Quantity per patient Contact Person
Additional Ward Days
Additional Outpatient Visits
Additional hours/procedures in Theatre
Additional GP time
_Other - please give details
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50. What additional Investigations are involved per patient? (Please discuss the NHS
resources needed with the relevant departments and obtain their agreement)
NOTE FOR SIGNATORIES
IF YOU ARE UNSURE AS TO WHETHER THIS WILL BE ACCEPTABLE TO YOUR
PATIENT SERVICES DIRECTOR/HEAD OF DEPARTMENT, THEN PLEASE DISCUSS
WITH THEM BEFORE SIGNING.
(a) Nursing
Grade of staff & Hours involved
Description of activities involved
Additional no. of contracts
Funded from: This grant Yes No
Department Yes No
Commercial/other sources Yes No




Grade of staff & Hours involved
Additional cost of drug therapy
Additional dispensing requirements and
storage & costs
Funded from: This grant Yes No
Department Yes No
Commercial/other sources Yes No
Agreed by Chief Pharmacist/Departmental Pharmacist (see list of authorised Trust signatories):
Signature: Designation: Date:
(c) PROFESSIONS ALLIED TO MEDICINE (PAMS e.g. Occupational Therapists, Speech
Therapists, Physiotherapists, Dieticians, Chiropodists)
Grade of staff & Hours involved
Description of activities involved
Additional no. of contracts
Funded from: This grant Yes No
Deriartment Yes No
Commercial/other sources Yes No
Agreed by Divisional Therapy Services Co-ordinator (see list of authorised Trust signatories):
Signature: Designation: Date:
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(d) Anaesthctics/Thcatres/ITU/HDU/Day Surgery
Description of activities involved
Grade of staff & hours involved
Funded from: This grant Yes No
Department Yes No
Commercial/other sources Yes No
Agreed by site-based Operational Manager (see list of authorised Trust signatories):
Signature: Designation: Date:
(c) Cardiac Laboratory Testing (e.g. ECG/Exercise Testing/Lung Function Test)
Name of Test
Number per patient
Grade of staff & hours involved
Funded from: This grant Yes No
Department Yes No
Commercial/other sources Yes No
Agreed by site Chief Technician (see list of authorised Trust signatories):
Signature: Designation: Date:
(f) Radiology/Imaging Procedures
Description of activities involved
Grade of staff & Hours involved
Number per patient
Funded from: This grant Yes No
Department Yes No
Commercial/other sources Yes No
Agreed by site-based R&D Consultant for Radiology (see list of authorised Trust signatories):
Signature: Date: Rev'd by Radiology Ops Mgr: (Initials)
(g) A&E/ Acute Receiving Unit/ Medical Assessment Unit/ MOPD
Description of activities involved
Grade of staff& Hours involved
Number per patient
Funded from: This grant Yes No
Department Yes No
Commercial/other sources Yes No
Agreed by site-based Operational Manager (see list of authorised Trust signatories):
Signatured, Designation: .T.,,.. Date:
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(h) Haematology Laboratory Investigations
Name of Test
Grade of staff & hours involved
Number per patient
Funded from: This grant Yes No
Department Yes No
Commercial/other sources Yes No
Agreed by Head of Site Laboratory (see list of authorised Trust signatories):
Signature: Date: Rev'd by Haematology Ops Mgr: (Initials)
(i) Clinical Biochemistry Laboratory Investigations
Name of Test
Grade of staff & hours involved
Number per patient
Funded from: This grant Yes No
Department Yes No
Commercial/other sources Yes No
Agreed by Head of Site Laboratory (see list of authorised Trust signatories):
Signature: Date: Rev'd by Biochemistry Ops Mgr: (Initials)
(j) Pathology Laboratory Investigations
Name of Test
Grade of staff & hours involved
Number per patient
Funded from: This grant Yes No
Department Yes No
Commercial/other sources Yes No
Agreed by Head of Site Laboratory (see list of authorised Trust signatories):
Signature: Date: Rev'd by Pathology Ops Mgr: (Initials)
(k) Other Laboratory Investigations (e
Cytogenetics/Molecular Genetics/Mec




Grade of staff & hours involved
Number per patient
Funded from: This grant Yes No
Deoartmctft Yes No
Commercial/other sources Yes No
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Agreed by Head of Site Laboratory (sec list of authorised Trust signatories):
Signature: Date: Rev'd by relevant Ops Mgr: (Initials)





Funded from: This grant Yes No
Department Yes No
Commercial/other sources Yes No
Agreed by Directorate Operational Manager (see list of authorised Trust signatories):
Signature: Designation: Date:
(m) Additional equipment purchased specifically for study
Type of equipment
Cost of equipment
Funded from: This grant Yes No
Department Yes No
Commercial/other sources Yes No
Agreed by Directorate Operational Manager (see list of authorised Trust signatories):
Signature: Designation: Date:
51. What additional Trust Administration support is involved? N/A
Secretarial/clerical (Grade of Staff) Hours per week on R&D
Medical Records
Please state the number of case notes to be retrieved At least 70
Who will retrieve the Medical Records?
(Medical records staff/researcher/student etc)
The Researcher
PLEASE ENSURE THAT YOU COMPLETE THE CHECKLIST ON THE FRONT
COVER OF THE APPLICATION FORM AND ENCLOSE ALL RELEVANT
ADDITIONAL DOCUMENTS.
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SECTION 10 Declaration
DECLARATION
The information in this form is accurate to the best of my knowledge and belief and I take
full responsibility for it.
I understand it is my responsibility to obtain management approval where appropriate
from the relevant NHS body before the project takes place.
I agree to supply interim and final reports on the pro forma provided, and to advise my
sponsor, the LREC from which approval was granted for this proposal and any other
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Annexe C Local Researchers
OTHER RESEARCHERS INVOLVED IN THIS STUDY
Please provide the name and contact details of other researchers involved in this study. Please
include your own name and centre if you are also a local researcher.
(Please copy and complete this page for each researcher. You must inform the LRECAdministrator
by means ofa copy ofthisform as each new researcher is recruited.)
LREC Reference Number:

















Telephone: 0131 -537 8300 0131 - 537 6502 or 01555 - 840293 x539
Fax:
E-Mail:
Please retain a blank copy of this form, complete it and send to the LREC Administrator
whenever other local researchers become involved in the future.
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Telephone 0131 536 9000









Date 07 February 2002
Your Ref
Our Ref LREC//2002/7/6
Enquiries to Annette Harris
Extension 89050
Direct Line 0131 536 9050
Email annette.harris@lhb.scot.nhs.uk
Dear Mr Ferguson,
AN INVESTIGATION INTO HOW NORMAL AND ABNORMAL PERSONALITY
CHARACTERISTICS CORRELATE WITH LEVEL OF ADHERENCE TO
ANTIRETROVIRAL THERAPY IN INDIVIDUALS WITH HIV INFECTION
Thank you for submitting the above protocol for ethical approval. The Psychiatry/Clinical
Psychology Research Ethics Sub-Committee will consider this protocol at its next meeting
to be held on 20 February 2002. I will notify you of the outcome of this consideration as
soon as possible.
Under the terms of the Scottish Office Home and Health Department Guidelines on Local
Research Ethics Committees a copy of your request has been sent to the NHS body under
the auspices of which the research is intended to take place. It is that NHS body which has
the responsibility of deciding whether or not the research should go ahead taking account
of the advice of the Research Ethics Sub-Committee and from whom you must obtain
management approval before any work on the study can proceed.
Details of the Lothian Research Ethics Committee and its documentation can be found on





Deaconess House 148 Pleasance Edinburgh EH8 9RS
INVESTOR IN PEOPLE ^Jj|»Vs
Chair Brian Cavanagh
Chief Executive James Barbour O.B.E.
Lothian NHS Board is the common name of Lothian Health Board
NHS
Lothian
cc Ms Ann Green
c/o Nicole Tait






Lothian Primary Care NHS Trust
Draft Research Protocol
John S Ferguson
Psychologist in Clinical Training
Full Title
Personality correlates of adherence to HIV antiretroviral therapy
Research Objectives
This study aims to profile the personality characteristics and psychosocial factors of
individuals with HIV who are in receipt of antretrivoral therapy. Individual adherence profiles
will also be examined in order to investigate the existence of a possible relationship between
these two main variables (personality profile & level of adherence).
Additionally, further variables will be measured in terms of how they interact with both
personality characteristics and adherence among HIV infected individuals. These will include
gender, age, route of infection, depression/anxiety symptomatology, coping with illness and
attitudes to general healthcare.
In summary, the research objective is to explicitly examine and begin to understand the role,
if any, of personality and psychosocial factors in predicting level of adherence to treatment
regimens. The end point of this research is to begin debating methods of improving adherence
to antiretroviral therapy at an individual level.
Rationale and scientific background to the research
The proposal for this research has been born out of a literature review of those general factors
considered to influence medication adherence. Most of the limited psychological research in
this area cites such factors as poor social support networks, poor coping skills, dysfunctional
cognitions and memory problems as indicative of poor levels of adherence. Medically driven
research is widespread and appears to focus primarily on the side effects of drug therapy with
antiretrovirals and the role of motivational factors in establishing a particular pattern of
adherence. In HIV treatment, a high level of adherence is vital if viral suppression is to be
sustained. It is clear that non-adherence is very common among patients treated for HIV
infection. By understanding adherence factors in HIV, interventions can be generated and
evaluated to increase treatment adherence. A running theme within the research from both
disciplines is the acknowledgement of the role of personality as an inevitable influential factor
in an individual's level of adherence to antiretroviral medication. Very few studies to date
have expanded on this theme and research approaching possible internally-driven personality
characteristics predictive of positive adherence tends to arise within the context of life-
threatening illnesses in general. For example the role of motivational factors and adherence to
strict therapeutic regimens has been documented in the literature in relation to conditions such
as cancer, renal disease, diabetes, multiple sclerosis and hypertension (see Pyszczynski et al,
1995; Sosa et al, 1991; Zeldow et al, 1988; Oldridge & Rogowski, 1990). Personality theory
would examine individual attributes in order to explain adherence. Explanations would be
related to ideas such as self-efficacy, self-esteem, resilience, commitment and motivation.
Personality variables may also be used to explain the extent to which the physician can
present persuasive information and explanatory data thus influencing a variety of doctor-
Headquarters:
St. Roque, Astley Ainslie Hospital, 133 Grange Loan, Edinburgh EH9 2HL
NHS
Lothian
Chairman Garth Morrison CBE
Chief Executive David Pigott
client relationships. The doctor-client relationship has been found to be particularly important
for adherence to treatment to occur.
Sherr (2000), in a review of the literature on adherence in HIV treatment, concludes that
adherence can be studied from four main perspectives:
• The patient
• The preparation (or medication)
• The provider
• The place or setting
'The patient' and 'preparation' perspectives would appear to have come under most scientific
scrutiny to date.
Sherr also goes on to describe how a number of psychological theories can be invoked to





Available research would appear to indicate that research has tended to apply more of a
'social' and 'cognitive' model to help explain adherence from the perspectives of the 'patient'
and the 'provider'. It is the intention of this research project to apply a model of personality to
the patient perspective (and to some extent the provider also) in an attempt to understand
treatment adherence in antiretroviral therapy. This study is therefore being informed by
previous research but with a focus on how normal personality characteristics and
psychosocial indicators may or not be related to objective and subjective measures of
treatment adherence.
Inherent in this research proposal is an acknowledgement that many other possible factors
typically affect an individual's ability to adhere to drug regimens in HIV, as the literature
clearly indicates. Such factors cannot realistically be isolated and controlled for within the
limitations placed on this study. However, this proposal is also developed with a working
assumption that by virtue of the natural rigidity of human personality, combined with a
thorough analysis of the outcomes of both personality structure and adherence in the research
sample, the study will allow meaningful inferences to be drawn about their relationship in the
specific context ofHIV antiretroviral therapy.
The integrity of this study is also enhanced by drawing from a well documented and
contemporary biopsychosocial theory of personality developed by Theodore Millon, PhD
(Davis 1999). This uniformity is further maintained by applying two personality measures,
both developed by Millon, to the assessment of normal range personality and psychosocial
strengths and weaknesses. These assessments, while being based upon the trait approach to
personality, also take into account the cognitive and motivational aspects of individual
differences. The study will examine in detail the personality styles of participants and attempt
to identify correlations between various personality variables and levels of adherence to
antiretroviral therapy.
2
Research questions and hypotheses
1. What is the overall profile of individuals on antiretroviral therapy in terms of; general
personality style, attitudes to healthcare, ability coping with illness, and self-reported
level of adherence? Do they differ from the normative sample?
2. What is the overall personality/psychosocial profile of individuals on antiretrovirals
who may need more communication and support in order to comply with prescribed
medical regimens?
3. Do particular types of profile become differentiated based upon a breakdown of
objective and subjective measures of adherence? In other words based on the above
variables, is there a particular profile indicative of each of the following three levels
of adherence:
• Individuals who have never reached a sustained level of therapeutic adherence
• Individuals who have reached a sustained therapeutic level of adherence which
then declined
• Individuals who have consistently achieved a therapeutic level of adherence
4. There is no evidence for a predictable association between personality characteristics
and regimen adherence in antiretroviral therapy.
5. Individuals experiencing significant personality adjustment problems do not differ
from the remaining sample on measures of personality characteristics, psychosocial
factors affecting attitude to healthcare, level of regimen adherence, depression and
anxiety symptomatology.
6. Regimen adherence is not positively associated with anxiety and depression
symptomatology.
7. Patient self-report measures of regimen adherence do not differ significantly from




To achieve statistical power around 70 participants will need to be recruited for this project.
Individuals attending the Infectious Diseases Unit, Western General Hospital and the GUM
clinic at Edinburgh Royal Infirmary will be approached with information about the study.
Subject to their consent to take part, each participant will meet with the researcher and be
invited to complete a small battery of questionnaires in 'pencil & paper' format.
Obtaining consent:
The following procedure will be strictly adhered in order to ensure that consent is appropriately
and responsibly obtained:
• A letter will be sent to each consultant physician at the Infectious Diseases Unit/ GUM
Dept. requesting consent to approach his or her patients with regard to taking part in the
study. Each consultant will also be sent an information sheet explaining the objectives and
methodology of the project.
• Pending their own consent to approach and recruit patients, each consultant will then
distribute a further information sheet to each patient within a letter inviting them to take
part and to obtain the direct consent of each patient (including consent to view case notes).
• Additional consent will be sought from consultants in order to approach in-patients and
information sheets will be distributed to nursing staff and throughout in-patient wards.
Outcome measures:
The battery of assessments will consist of:
• A short demographic questionnaire
• A brief self-report questionnaire on treatment adherence
• The Millon Index of Personality Styles (MIPS)
• The Millon Behavioural Medicine Diagnostic (MBMD)
It is estimated that the entire assessment battery will take lhr - lhr 15mins. to complete. The
researcher will be present during completion of the assessment.
The MIPS is designed for use by professionals looking for a comprehensive, well-rounded
report of general personality. It is a standardised psychological assessment containing 180
unobtrusive True/False items organised into 3 groups of scales, together with 3 validity
indicators or response sets: Motivating Aims, Interpersonal Behaviours, Cognitive Modes,
Response Sets. The MBMD was developed to aid clinicians including consultant physicians
and clinical/health psychologists who work with physically ill and behavioural medicine
patients. The test aids in the psychological understanding of these patients. The MBMD can
help pinpoint personal and social assets that may facilitate adjustment to lifestyle changes. It
can also help identify individuals who may need more communication and support on order to
adhere to treatment regimens. It is a standardised instrument that assesses negative health
habits, psychiatric indicators, coping styles, stress moderators, treatment prognostics and
adjustment difficulties. The MBMD norms are based on extended research with patients with a
wide variety of medical conditions including HIV/AIDS. It consists of 165 True/False items
grouped into 38 content scales. Both tests draw from Dr T. Millon's widely accepted theory of
personality.
Design:
The study is cross-sectional in design. Concurrent with a structured personality assessment the
researcher will also consult a computerised database of patient information located at the
Infectious Diseases Unit, Western General Hospital. This database will reveal the level of
adherence of each patient according to frequency of inpatient visits and viral load over time (a
physiological marker of adherence to treatment). Correlations between personality variables
and level of treatment adherence will be examined upon statistical analysis of the data.
Multiple regression will be used for statistical analysis in order to examine the extent to which
levels of regimen adherence (dependent variable), is predictable from variations in
demographics, anxiety, depression, psychosocial indicators, and a range of personality
characteristics and clinical personality pathology. 4
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The role of individual personality characteristics in predicting levels of
therapeutic adherence to antiretroviral therapy
I would like to invite you to take part in a research study that aims to explore the role
ofpersonality in determining how well individuals manage to adhere to antiretroviral
treatment for HIV.
Before you decide whether or not you wish to take part, it is importantforyou to
understand why the research is being done and what it will involve. Please take time
to read the following information carefully and discuss it with others ifyou wish.
Your consultant has given permission for me to approach you with this
information. Please contact me if there is anything that is not clear, or ifyou would
like more information. Take time to decide whether or notyou wish to take part.
Thank you for reading this.
Why is the study taking place?
• Non-adherence is very common among patients treated for HIV infection. During
treatment it is already known that a high level of adherence to antiretroviral
therapy is vital if viral suppression is to be sustained. Research has shown that
many factors may influence treatment adherence. Not much is known about the
role of personality factors. By understanding how personality may or may not
affect adherence, it may be possible to help people adhere to antiretroviral therapy
more effectively.
What is the purpose of the study?
• To provide a profile of people on antiretroviral therapy in terms of general
personality characteristics and to investigate if there is any relationship between
these characteristics and a person's ability to adhere successfully to treatment.
• The study is taking place between March and August 2002.
Headquarters:
St. Roque, Astley Ainslie Hospital, 133 Grange Loan, Edinburgh EH9 2HL
Chairman Garth Morrison CBE
Chief Executive David Pigott
Why have I been chosen?
You have been invited to take part in this research because you are currently receiving
antriretroval therapy and have direct experience of the difficulties involved in
managing your medication. You also attend regular reviews at the Western General
Hospital and it might be convenient for you to take part in this Edinburgh based study.
Do I have to take part?
No. It is entirely up to you whether or not to take part. If you do decide to take part
you will be given this information sheet to keep and be asked to sign a consent form.
By signing the consent form you are agreeing to take part in the study and also giving
the researcher permission to view your medical records held by the hospital.
What will happen to me if I take part?
Once you have returned your consent form to the researcher, the researcher will
contact you by letter to offer an appointment to meet in order to complete the
following questionnaires:
• A short questionnaire relating to your gender, age, route ofHIV infection etc
• A questionnaire relating to how well you think you adhere to treatment
• A questionnaire relating to your particular personality style
• A questionnaire relating to your general health, how you cope with stress &
illness, and your attitudes to issues ofyour general healthcare
These questionnaires should take approximately lhr - lhr 15 mins. to complete.
The questions are short and will mostly only require 'true/false' answers.
Are there any disadvantages in taking part?
There should be no ill effects in taking part in this study. However, some people do
experience discomfort when responding to questionnaires about themselves. It is
unlikely that this will be the case. However, if you have any questions about the study
and wish to discuss them then please do not hesitate to contact me.
Confidentiality
All information you give about yourselfduring the course ofthis research will be
strictly confidential. Any information about you which leaves the hospital will have
your name removed so that you cannot be identified from it. The consent form will
be kept separately front the completed questionnaires and vou will be allocated an
individual participant number to ensure anonymity. You will not be identified in
any subsequent report or publication as a result ofthis research study.
Withdrawal
Your participation in this research is entirely voluntary. If you decide to take part you
are still free to withdraw at any time and without giving a reason. A decision to
withdraw at any time, or a decision not to take part, will not affect any of the care you
receive.
What will happen with the results?
A detailed summary of the research results and implications will be sent to your
consultant for their interest. If interested you will be able to receive a copy of the
results from either the researcher or your consultant after September 2002.
Further Information
If you require any further information about the study, or have any questions or
comments, please feel free to contact me.
Thank vou very much for taking the time to consider and/or participate in this
research




Psychologist in Clinical Training
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Title of Project: LothiSfl
The role of individual personality characteristics in predicting levels of therapeutic
adherence to antiretroviral therapy
Name of Researcher: Mr John Ferguson
1. I confirm that I have read and understood the information sheet which I have
been given about this research study.
2. 1 understand that my participation is voluntary and that I am free to withdraw
at any time, without giving any reason, without my medical care or legal rights
being affected.
3. I understand that sections ofmy medical notes may be looked at by the
researcher where it is relevant to my taking part in this research. I give
permission for the above named researcher to have access to my records.
4. I agree to take part in the above research study.
It would be preferable to contact you by telephone to arrange a time to meet.
If possible please enter your contact number
Please also sign & print your name below:
Signature of Patient Date
Printed Name of Patient
Signature ofPerson taking consent Date
(if different from researcher)
Printed Name of Person taking consent
Signature of Researcher Date
Headquarters:
St. Roque, Astley Ainslie Hospital, 1 33 Grange Loan, Edinburgh EH9 2HL
Chairman Garth Morrison CBE








Dr Researcher: John Ferguson
Regional Infectious Diseases Unit
Western General Hospital
Edinburgh
Psychologist in Clinical Training
Doctorate in Clinical Psychology
University of Edinburgh/
East of Scotland Health Boards
Training Course in Clinical Psychology






1 write to ask if you may consider approaching your patients regarding a research study 1 am
undertaking. The research will examine the relationship between personality characteristics /
psychosocial factors and level of adherence to antiretroviral therapy. The study will be presented
as a thesis in part fulfilment of the degree of Doctorate in Clinical Psychology at the University of
Edinburgh. I am a final year trainee clinical psychologist on a specialist year-long placement with Dr
Alison Richardson at the Spittal Street Centre.
I would be grateful if you could approach your patients to determine if they would be interested in
opting to participate in the study.
For your information I enclose a research protocol which outlines the objectives and methodology
behind my proposed piece of research.
I require a sample of participants who fulfil the following inclusion criteria:
Individuals who have HIVpositive status and are currently in receipt ofantiretroviral medication or
have been on antiretrovirals and in attendance at the Infectious Diseases Unit within the last six
months.
I also enclose patient information leaflets and consent forms for you to distribute to your patients to
facilitate their decision whether or not to participate. Once an individual opts in by returning their
consent form to me, 1 will then approach them by letter with the offer of an appointment to meet and
complete the measures involved in the research.
I am very grateful for your consideration of this. Please do not hesitate to contact me if you would like
any further information. 1 look forward to hearing from you in the near future regarding this project.
Yours sincerely
John Ferguson
Psychologist in Clinical Training
Headquarters:
St. Roque, Astley Ainslie Hospital, 133 Grange Loan, Edinburgh EH9 2HL
Chairman Garth Morrison CBE










Clinical Tutor/D. Clin. Psych. Training course, Edinburgh
C.c.
For Consultant information: Research Protocol
For Patient Information: Information Sheet
Consent Form
Return Envelope




Dr G R Scott Researcher: John Ferguson
Consultant Physician
Dept ofG U Medicine
Level 1, Lauriston Building
The Royal Infirmary Edinburgh
Psychologist in Clinical Training
Doctorate in Clinical Psychology
University of Edinburgh/
East of Scotland Health Boards
Training Course in Clinical Psychology






1 write to ask if you may consider approaching your patients regarding a research study I am
undertaking. The research will examine the relationship between personality characteristics /
psychosocial factors and level of adherence to antiretroviral therapy. The study will be presented
as a thesis in part fulfilment of the degree ofDoctorate in Clinical Psychology at the University of
Edinburgh. I am a final year trainee clinical psychologist on a specialist year-long placement with Dr
Alison Richardson at the Spittal Street Centre.
I would be grateful if you could approach your patients to determine if they would be interested in
opting to participate in the study.
For your information I enclose a research protocol which outlines the objectives and methodology
behind my proposed piece of research.
I require a sample of participants who fulfil the following inclusion criteria:
Individuals who have HIVpositive status and are currently in receipt ofantiretroviral medication or
have been on antiretrovirals and in attendance at the Dept. ofGU Medicine within the last six months.
1 also enclose sample patient information leaflets and consent forms for your perusal. Once an
individual opts in by returning their consent form to me, I will then approach them by letter with the
offer of an appointment to meet and complete the measures involved in the research. Upon your
consent, I will contact you again shortly in order to supply information packs for distribution to your
patients. I have already begun distributing same information to the medics at R1DU.
I am very grateful for your consideration of this. Please do not hesitate to contact me if you would like
any further information. I look forward to hearing from you in the near future regarding this project.
Yours sincerely
John Ferguson
Psychologist in Clinical Training
Headquarters:
St. Roque, Astley Ainslie Hospital, 1 33 Grange Loan, Edinburgh EH9 2HL
Chairman Garth Morrison CBE










Clinical Tutor/D. Clin. Psych. Training course, Edinburgh
C.c.








THE ROYAL INFIRMARY OF EDINBURGH
Lauriston Place, Edinburgh EH3 9YW
Dept of G U Medicine
Level 1, Lauriston Building
Tel: 0131 536 2098
Mr John Ferguson GRS/CE
Clinical Psychology Student 22 March 2002
HARM Reduction Team




With regard to your research on adherence to HIV medication, I have had a request from the R & D
Department in the Trust to send a letter giving my agreement to you undertaking research with our
patients. This is fine, but I have managed to mislay the letter that you sent me about the study. Could
you please give me a few details and I shall send a formal letter to the Trust.
Kind regards.
Yours sincerely
G R SCOTT FRCP
Consultant Physician
The Lothian University Hospitals NHS Trust provides a comprehensive range of first class acute adult and paediatric care to the people of Edinburgh, Lothian and beyond from the
following locations: Chalmers Hospital, City Hospital, Liberton Hospital, Princess Alexandra Eye Pavilion, Princess Margaret Rose Orthopaedic Hospital, Royal Hospital for Sick Children,
Royal Infirmary of Edinburgh, Royal Victoria Hospital, Simpson Memorial Maternity Pavilion, Western General Hospital.
The Lothian University &
Hospitals NHS Trust A
THE ROYAL INFIRMARY OF EDINBURGH
Lauriston Place, Edinburgh EH3 9YW
Dept ofG U Medicine
Level 1, Lauriston Building
Tel: 0131 536 2098
CONFIDENTIAL GRS/CE
Alison Craig 4 April 2002
Research & Development Department
RIE
Dear Alison
Research Study On The Relationship Between Personality Characteristics/Psychosocial Factors
and Level of Adherence to Antiretroviral Therapy
I have reviewed the application for this research study, and am happy to confirm that we give





cc. John Ferguson, Psychologist in Clinical Training, Kennedy Tower, Royal Edinburgh Hospital.
The Lothian University Hospitals NHS Trust provides a comprehensive range of first doss acute adult and paediatric care to the people of Edinburgh, Lothian and beyond from the
following locotions: Chalmers Hospital, City Hospital, Liberton Hospital, Princess Alexandra Eye Pavilion, Princess Margaret Rose Orthopaedic Hospital, Royal Hospital for Sick Children,
Royal Infirmary of Edinburgh, Royol Victoria Hospital, Simpson Memorial Maternity Pavilion, Western General Hospital.
Appendix Ig
Notification of approval by research & development office
136
ROYAL INFIRMARY OF EDINBURGH













An investigation into how normal and abnormal personality
characteristics correlate with level of adherence to antiretroviral
therapy in individuals with HIV infection
The above project has undergone a review of resource and financial implications by the R&D
Office and I am satisfied that all the necessary arrangements have been set in place.
On behalf of the Trust Chief Executive and Medical Director, I am happy to give Trust
management approval to allow the project to commence, subject to the approval of the
appropriate Research Ethics Sub-Committee having also been obtained.
We would ask you to note that under Section 7, question 34, The Lothian University Hospitals
NHS Trust provides indemnity for negligence for NHS and honorary clinical staff wherever
research involves patients attending the hospitals. It is not empowered to provide non



































Women & Children /Clinical
Support
Dr Rhian Hunter
Dr Heather A Cubie
R&D Director
cc Secretary, Research Ethics Sub-Committee
Mr John Ferguson, Psychologist in Clinical Training Kennedy Tower, Royal Edinburgh
Hospital
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Telephone 0131 536 9000









Date 26 February 2002
Your Ref
Our Ref LREC//2002/7/6
Enquiries to Annette Harris
Extension 89050
Direct Line 0131 536 9050
Email annette.harris@lhb.scot.nhs.uk
Dear Mr Ferguson,
AN INVESTIGATION INTO HOW NORMAL AND ABNORMAL PERSONALITY
CHARACTERISTICS CORRELATE WITH LEVEL OF ADHERENCE TO
ANTIRETROVIRAL THERAPY IN INDIVIDUALS WITH HIV INFECTION
Thank you for submitting the above protocol for ethical approval. The Psychiatry/Clinical
Psychology Research Ethics Sub-Committee has discussed this protocol and has agreed
that it is prepared to grant ethical approval subject to the following amendments,
delegating authority to the Chairman to approve them on receipt:
/ /» The signature of the independent adviser is required
v/ • The initial approach to patients asking them if they are interested in being approached
by the researcher, must be made by the consultant in charge of their clinical care.
Patients must opt to participate in the study before being contacted by the researcher
and this should be reflected in the letter from the consultant.
Once these amendments have been received by me and approved by the Chairman
a formal Certificate of Approval will be issued. Only then can management approval
be given and the research proceed.
The next meeting of the Sub-Committee will be held on 20 March 2002. It would be





Deaconess House 148 Pleasance Edinburgh EH8 9RS
Chair Brian Cavanagh
Chief Executive James Barbour O.B.E.
Lothian NHS Board is the common name of Lothian Health Board
NHS
Lothian
Should you have any queries regarding the above, please contact myself on the number
below.
Details of the Lothian Research Ethics Committee and its documentation can be found on




cc Ms Ann Green
c/o Nicole Tait
Level 4, Kennedy Tower
Royal Edinburgh Hospital
Edinburgh















I was sorry to hear that you had not received these amendments already. However I
now enclose them again and also copy to Mr Neil Feltham (R&D, Edinburgh Royal
Infirmary) who has requested the same information for his records.
Please do contact me if there is any further information that you require, and many
thanks for your consideration ofmy proposal.
Yours Sincerely
John Ferguson
Psychologist in Clinical Training





St. Roque, Astley Ainslie Hospital, 1 33 Grange Loan, Edinburgh EH9 2HL
Chairman Garth Morrison CBE
Chief Executive David Pigott
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Telephone 0131 536 9000









Date 12 April 2002
Your Ref
Our Ref LREC//2002/7/6
Enquiries to Annette Harris
Extension 89050
Direct Line 0131 536 9050
Email annette.harris@lhb.scot.nhs.uk
Dear Mr Ferguson,
AN INVESTIGATION INTO HOW NORMAL AND ABNORMAL PERSONALITY
CHARACTERISTICS CORRELATE WITH LEVEL OF ADHERENCE TO
ANTIRETROVIRAL THERAPY IN INDIVIDUALS WITH HIV INFECTION
Thank you for submitting the amendments or additional information requested by the Sub-
Committee for the above protocol. The Chairman of the Psychiatry/Clinical Psychology
Research Ethics Sub-Committee has now agreed to confirm the Sub-Committee's ethical
approval under its delegated authority. An official Certificate of Ethical Review is enclosed
together with a list of members present at the meeting.
Under the terms of the Scottish Office Home and Health Department Guidelines on Local
Research Ethics Committees this decision has been notified to the NHS body under the
auspices of which the research is intended to take place. It is that NHS body which has the
responsibility of deciding whether or not the research should go ahead taking account of
the advice of the Research Ethics Sub-Committee and from whom you must obtain
management approval before any work on the study can proceed.
Details of the Lothian Research Ethics Committee and its documentation can be found on







H K A I. T H
A T
W O H K
Headquarters
Deaconess House 148 Pleasance Edinburgh EH8 9RS
Chair Brian Cavanagh
Chief Executive James Barbour O.B.E
Lothian NHS Board is the common name of Lothian Health Board
NHS
Lothian
cc Ms Ann Green
c/o Nicole Tait





Wednesday 20 February 2002
Present
Dr A Richardson (Consultant Psychologist) (Chairman)
Mr J Oliphant (Nursing Member)
Mr R Beasley (Lay Member)
Dr D Morrison (Consultant Psychiatrist)
Dr I McKee (GP Representative)
Ms F Barry (Consultant Psychologist)
Mr N Grier (Lay Member)
Dr T White (Consultant Psychiatrist)
LOTHIAN RESEARCH ETHICS COMMITTEE
CERTIFICATE OF ETHICAL REVIEW
LREC Reference Number: LREC/2002/7/6
Title: An investigation into how normal and abnormal personality characteristics
correlate with level of adherence to antiretroviral therapy in individuals with HIV infection
Researcher: Mr John Ferguson
The Psychiatry/Clinical Psychology Research Ethics Sub-Committee reviewed this proposed
study and has agreed that it is ethical and appropriate to be carried out in the Lothian Area.
This opinion encompasses all aspects of the application including the Patient/Subject
Information Sheet and all other accompanying documentation provided.
The LREC application form, protocol, subject information sheet, information on compensation
arrangements, payments to researchers and the provision of expenses to subjects (where
appropriate) were reviewed and approved.
The membership of the Psychiatry/Clinical Psychology Research Ethics Sub-Committee is
shown on the attached sheet.
It is a condition of this opinion that you must obtain appropriate management approval from the
relevant NHS body under the auspices of which the research is intended to take place before
starting the study. It is that NHS body which has the responsibility of deciding whether or not
the research should go ahead taking account of the advice of the Local Research Ethics
Committee. It is also a condition that you are required to notify the Psychiatry/Clinical
Psychology Research Ethics Sub-Committee and the relevant NHS body, in advance, of any
significant proposed deviation from the original protocol or application form. Reports to the Sub-
Committee and the relevant NHS body are also required once the research is underway if there
are any unusual or unexpected results which raise questions about the safety of the research.
Researchers are also required to report on success, or difficulties, in recruiting subjects in order
to provide useful feedback on perceptions of the project among patients and volunteers.
Peter Reith
Secretary






The Psychiatry/Clinical Psychology Research Ethics Sub-Committee is fully compliant with the International
Committee on Harmonisation/Good Clinical Practice (ICH) Guidelines for the Conduct of Trials Involving the
Participation of Human Subjects as they relate to the responsibilities, composition, function, operations and records
of an Independent Ethics Committee/Independent Review Board. To this end it undertakes to adhere as far as is
consistent with its Standing Orders, to the relevant clauses of the ICH Harmonised Tripartite Guideline for Good
Clinical Practice, adopted by the Commission of the European Union on 17 January 1997. The Membership List,
Standing Orders and Statement of Compliance were included on the computer disk containing the guidelines and
application form and are available on request.
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Date ofHIV Diagnosis: AIDS Diagnosis? Yes No 2.
Illegal Drug Use
Heroin 1. Cocaine 7.
DHC 2. Crack 8.
Other Opiate 3. Amphetamine 9.
Diazepam 4. LSD 10.
Temazepam 5. MDMA etc 11.
Other Benzo 6. Cannabis 12.
Other 13.
Legal Prescription Drug Use







Yes 1. No 2.
Permission for Medical Notes to be consulted for test results.
Yes 1. No 2.
No. Units Per Week :
Adherence Questionnaire
Knowledge of Cell CD4 Counts
Note:
Knowledge of Viral Load
Note:












x 2 daily 1 or 2 hours
before or after meals
x 3 daily 1 or 2 hours
before or after meals
7
Other
How many tablets do you/did you take each day?
Are you taking them at all? Yes 1. No 2.
IfNo-why not?
Note:
In the last month have you missed any doses? How often have you missed a dose?
Yes 1. No 2. > 1 per day 1.
> 1 per week 2.
> 1 per month 3.
Other 4.










Do you ever take any of the drugs at a different time specified? Yes 1. No 2.
If so - how often per week?
Do you stick to the advice about food? Yes 1. No 2.
If not - how often per week?
What are your reasons for taking Combination Therapy?
List:
What do you think about Combination Therapy?
What do you understand about resistance to antiretrovirals?
Why is it important to adhere to treatment?
Viral Load CD4 Count
Now Now
Highest Ever Lowest Ever
Appendix III
Millon Index of Personality Styles
Test Booklet
140
Copyright © 1993 by Dicandrien, Inc.
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Directions: The following pages contain a list of
statements. Read each statement and decide
whether or not it describes you. If you agree with
a statement or believe that it is true about you,
blacken the T circle for true on the Answer Sheet.
If you disagree with a statement or believe that it is
not true about you, blacken the F circle for false on
the Answer Sheet. Be sure to answer either true or
false for every statement. There are no right or
wrong answers.
1 like to follow instructions and do what others
expect of me.
25 So little of what 1 do is appreciated by others.
26 Almost anything 1 try is easy for me.
I've become more drawn into myself in recent
years.
1 am a dramatic and showy sort of person.
29 1 always try to do what is proper.
30 1 don't depend much on other people for friend¬
ship.
£g' 1
31 I've never overstayed my time at a parking
meter.
1 1 am a quiet and cooperative person.
2 1 have always done things my way and taken the
consequences.
Punishment hasn't stopped me from doing what¬
ever 1 wanted.
33 1 like to arrange things to the last detail.
3 1 like to be the one to take charge. 34 1 am often annoyed by others.
4 1 have always had a regular way of doing things
so 1 can avoid mistakes.
35 1 never broke any rule my parents expected me
to follow.
5 1 respond the same day to letters 1 get. 1 get what 1 want even if 1 have to bully others.
6 Every now and then 1 ruin the good things that
happen to me.
Nothing is more important than protecting one's
moral reputation.
7 1 don't get excited about much any more.
8 1 would much rather be a follower than be a
leader.
Opportunities don't work out for me the way they
do for others.
1 don't show much feeling any more.
9 1 go out of my way to make myself popular with
others.
What 1 have to say is not likely to interest others.
10 1 have always had a talent for being successful. 1 go out of my way to meet exciting people and
to have adventures.
11 1 often find that I've been treated unfairly. 1 don't take many of my responsibilities too
seriously.12 1 feel uncomfortable when people are good to
me. I'm a tough, unsentimental sort of person.
13 1 often feel self-conscious and tense at social
gatherings.
Few things in life seem to stir me very much.
45 1 become very tense when 1 have to talk to
people 1 don't know.14 Police take too much advantage of the power
they have. I'm a cooperative person who gives in to others.
15 Sometimes 1 have had to be pretty rough with
people.
1 like to act on the spur of the moment.
1 think ahead and then actively follow through.
Children should always obey the rules of their
elders.
1 have often been restless and wanted to move
on to almost anywhere else.
1 7 1 often feel disgusted with the way things are
going.
It is best to tightly control one's emotions.
18 1 often expect the worst to happen to me. 1 wish people would not blame me when things
go wrong.19 1 wouldn't mind not having many friends.
20 1 am a shy and socially inhibited person. I'm probably my own worst enemy.
1 have very few close ties with others.
Even when 1 disagree, 1 usually let others have
their way.
No one should be expected to always tell the
truth.
1 feel anxious with people 1 don't know very well.
It's all right to get around the law, if you don't
break it.
1 do a lot for others, but little is done for me.
1 make nasty remarks to people if they deserve I've always believed that others don't think well
them. of me.
58 1 am very confident.
59 1 very systematically arrange my papers and
records.
60 From past experience 1 know that good things
don't last.
61 Some people say 1 enjoy being a martyr.
62 1 am most comfortable when I'm alone.
63 1 become much more tense than others do in new
situations.
64 1 always try to avoid disagreements, no matter
how strongly 1 feel about the subject.
65 1 look for opportunities that are exciting and new
to me.
66 There were times when my parents had trouble
keeping me in line.
67 1 always finish my work before 1 relax.
68 Others get breaks 1 don't get.
69 1 sometimes feel 1 deserve to be unhappy.
70 1 wait for events to take their course before
deciding what to do.
71 1 try to take care of others before 1 take care of
myself.
72 1 often feel that my life goes from bad to worse.
73 1 am inspired simply by being around people.
74 1 always check the speed limit and never drive
faster than what's posted.
75 1 use my head, not my heart, to make decisions.
76 1 usually follow my hunches, not the information
1 may have.
77 I'm never envious of the achievement of others.
78 1 preferred school subjects that were factual
rather than theoretical.
79 1 plan ahead and then act decisively to make my
plans happen.
80 My heart seems to rule my head.
81 1 can always see the bright side of life.
82 1 often wait for someone else to solve my
problems.
83 1 do what 1 want without worrying about the
effects on others.
84 1 react quickly to anything that might become a
problem to me.
85 1 feel good about myself only when I'm helpful to
others.
86 When something little goes wrong, my whole
day can be spoiled.
87 1 enjoy daydreams more than everyday realities.
88 I'm content to sit back and let life take its course.
89 1 try to be logical rather than emotional.
90 1 prefer things that 1 can see and touch rather
than things 1 just imagine.
91 Talking with someone whom I've just met is
difficult.
92 Being kindhearted is much more important than
being cool and logical.
93 Guesses about the future are more interesting to
me than facts about the past.
94 It's very easy for me to enjoy myself.
95 1 don't seem able to influence the world around
me.
96 1 live in terms of my own needs, not the needs of
others.
97 1 never wait for things to happen; 1 make them
happen my way.
98 1 never voice a curse-word even when I'm furious
with someone.
99 My life is guided by a need to help others.
100 1 often feel on edge, waiting for something to go
wrong.
101 Even when 1 was a youngster 1 would never cheat
on a test.
102 1 am always cool and objective when dealing
with others.
103 I'd rather learn how to run a machine than
speculate on why it works.
104 I'm not an easy person to get to know.
105 1 spend a lot of time thinking about the mysteries
of life.
106 1 cope very easily with emotional ups and
downs.
107 1 am somewhat passive and slow about
organizing my life.
108 1 do what 1 want without worrying about pleasing
others.
109 No matter what the temptation may be, 1 would
never do something wrong.
110 Friends and family turn to me first for warmth and
support.
111 Even when life is going well, 1 usually expect it
will soon get worse.
112 1 carefully plan and organize my work before
1 begin.
113 1 am impersonal and objective when 1 try to solve
a problem.
114 1 am a realistic person who does not like to
speculate about things.
115 Some of my best friends don't know how 1 really
feel.
116 Others consider me cool-headed rather than
warmhearted.
117 My sense of reality is better than my sense of
imagination.
118 1 look out for myself first and then think of others.
119 1 spend a lot of effort to see that life works out
well for me.
120 1 always keep my composure, no matter
what's happening.
121 I show a great deal of warmth toward my
friends.
Very few things have worked out well for me.
123 | like to meet new people and learn about their
[ives.
124 I can ignore personal and emotional matters in
my work.
125 I prefer to deal with realities, not with possibili¬
ties.
126 I seem to need a lot of time to be alone with my
thoughts.
127 Feelings of the heart are of greater value than the
logic of the mind.
128 | like dreamers more than I do realists.
129 I'm able to laugh at problems more easily than
most people are.
130 There's not much I can do, so I just wait to see
what happens.
131 I never get into arguments, no matter how angry
I am.
I express my thoughts openly and freely.
133 Hook at the job to be done, and not at the
feelings of the people involved.
134 Working on creative ideas would be ideal
for me.
135 I'm the kind of person who takes life easy and
prefers to watch the passing scene.
136 I dislike depending on anyone in my work.
137 I see to it that things come out the way I want
them to.
I enjoy everyday realities more than daydreams.
139 Lots of small things upset me.
140 | learn best by watching and talking to people.
141 I'm not content to sit back and let life take its
course.
142 Meeting new people is not something I look
forward to.
143 I seldom know how to keep a social conversation
going.
I I always take others' feelings into account.
145 I trust my hunches more than my observations.
146 I tend not to act until I know what others are
going to do.
147 I prefer to make decisions on my own, with little
or no advice from others.
148 I often feel miserable for no good reason.
149 I like being popular and doing lots of social
activities.
150 I rarely express my inner thoughts to others.
151 I am enthusiastic about almost all of the activities
I do.
152 I make it a practice to depend on myself and not
on others.
153 Most of the time I'm actively involved in
arranging the events in my life.
154 There's nothing like the warm feeling of being
with a group of relatives.
155 Sometimes I am tense or depressed, and I don't
know why.
156 I really enjoy discussions about myths and
mystical events.
157 I decide my priorities and then take fi
to achieve them.
rm action
158 I don't hesitate to direct people to do what I think
is best for them.
159 proud that I am efficient and organized.
160 I really dislike people who become leaders for
no good reason.
161 I am ambitious.
162 I know how to charm people.
163 Others can always rely on me to do my work
diligently.
164 Others consider me warmhearted rather than
cool-headed.
165 I'd be willing to work for years to become some¬
one of importance.
166 I would enjoy selling new ideas or products to
people.
167 I usually persuade others to do exactly what
I want them to do.
168 I enjoy work that requires careful attention to
details.
169 I'm very introspective, always trying to under¬
stand my thoughts and emotions.
I have great confidence in my social abilities
I quickly size up situations and then act to make
them turn out the way I want.
172 I can persuade almost anyone to switch to my
side of an argument.
173 I will get any job done no matter what the
obstacles may be.
174 Like a good salesperson, I can successfully
influence people in a socially pleasing manner.
175 Meeting new people is something I look forward
to.
176 The welfare of those affected should be the
primary consideration when a decision about
them is made.
177 I have the patience to attend to work that must be
highly accurate.
178 My sense of imagination is better than my sense
of reality.
179 I'm motivated to become one of the best in my
field.
I have a pleasing social style that makes people
easily like me.
Appendix IV
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ABC D
1. I feel very tense when I think about the
day's events.
2. I am not a very spiritual person.
3. I get extremely anxious when I don't know
what the doctors are going to do to me.
4. I am a dramatic kind of person.
5. Sometimes I can't remember what
medications to take and when to take them.
6. I often get confused about what is
happening to me.
7. I can no longer do things I enjoyed doing in
the past.
8. I've felt sad much of my life.
9. The idea of being left alone in life really
frightens me.
10. Sometimes I take medications that were
prescribed for others on the chance that
they'll help me.
11. I wish other people were more accepting of
me.
12. I can get nasty with people who deserve it.
13. My best years are behind me.
14. I feel jumpy and under strain, but I don't
know why.
15. I get great comfort from my religious
beliefs.
16. I begin to cry when the smallest things go
wrong.
17. I seem to fit in right away with any group of
people I meet.
18. I like to follow instructions and do what
others expect of me.
19. Most people wouldn't care much if I were
sick.
20. Medical instruments really frighten me.
21. Loss of memory has been a big problem for
me.
22. I can't move around and do things as well
as I could in the past.
23. I want my doctor to review with me the
results of all my medical tests.
24. I've found that this society is too hard on
people who don't conform.
25. I've felt all alone for a very long time now.
26. I'll stop anyone who tries to boss me
around.
27. I would much rather follow someone than
be the leader.
28. I get very anxious when I think about my
medical problems.
29. I deserve many of the misfortunes I've
suffered.
30. I think things will get much worse in the
coming months.
31. I can't take care of myself as well as I used
to.
32. I try to learn as much as I can about the
treatments available for my medical
condition.
33. Faith and prayer always get me through my
troubles.
34. I have a lot of confidence in myself.
35. I'm trying to be as open as I can in my
responses to these questions.
36. I protect myself by not letting people know
much about my life.
37. I guess I've always been a fearful and
inhibited person.
38. If you don't have something good to say
about yourself, you should keep quiet.
39. I would do anything to stop the pain I feel.
40. I seem to need a lot of advice in order to
get things done.
Please go to the next page
41. If I have to go through another medical
procedure, I think I'll just go crazy.
42. My health seems to be failing faster than
that of most people my age.
43. Life will never be the same again for me.
44. No matter what, seeing a doctor is
reassuring.
45. I rarely find the time to exercise.
46. I feel so jittery and restless that I'm worn
out at night.
47. I've always preferred to have a quiet and
inactive life.
48. I have a habit of making my problems
sound worse than they really are.
49. I have been having serious thoughts about
suicide.
50. I like to arrange things down to the last
detail.
51. There's little emotional support within my
family.
52. I have always had a talent for being
successful.
53. I have told lies to my family to conceal my
use of drugs.
54. Very few people appreciate just how hard
my life really is.
55. I seem to be losing my ability to
concentrate.
56. Answering questions like these helps me
take a good honest look at things in my life.
57. I watch out for people trying to cheat me.
58. The pain I'm in has made my life feel very
hopeless.
59. In this world you either push or get shoved.
60. I'm very erratic, changing my feelings all
the time.
61. When people are bossy, I usually do the
opposite of what they want.
62. I've had nightmares about medical
procedures I may have to endure.
63. I worry a lot that the people I depend on will
leave me.
64. I'm my own worst enemy.
65. I sometimes exaggerate how poorly I am
feeling.
66. For some unknown reason, I suddenly get
very panicky.
67. My emotions don't seem to be as strong as
other people's.
68. It makes me very uncomfortable when
other people know about my problems.
69. Physical pain is a big part of my life.
70. I am constantly worried about my health.
71. It is good to have a routine for doing things
in order to avoid mistakes.
72. There is someone close to me who truly
understands my feelings.
73. Many people respect and envy me.
74. Taking drugs has been a regular part of my
social life.
75. I believe something is wrong with my head.
76. Most people in my life eventually disappoint
me.
77. I feel particularly resentful when I am
refused medical benefits I know I am
entitled to.
78. It's all right to bend the law as long as you
don't break it.
79. I never let anyone get the better of me.
80. I know from the past that good things don't
last.
Please go to the next page
81. I can handle the worst medical news about
myself, no matter how upsetting it may be.
82. I am afraid that I may suddenly die from an
illness.
83. I am quickly losing hope that I will ever
regain my health.
84. I make sure that I'm on time for all my
doctor's appointments.
85. Pain makes it very difficult for me to work
now.
86. I have found very few things in life to be
pleasurable.
87. I have many very good and close friends.
88. I always finish my work before I take time
out for leisure.
89. I have friends who will listen to any problem
I have.
90. Everything I try comes easily to me.
91. I'm making myself seem healthier in my
responses here than I really am.
92. My life has always gone from bad to worse.
93. I think it's best not to trust anyone.
94. Pain is the worst part of my medical
condition.
95. I often resent doing things that others
expect of me.
96. I am mistreated most by close friends and
relatives.
97. I quickly consult my doctor whenever I have
new symptoms.
98. I'm on edge a lot lately.
99. I am never alone as long as God is with
me.
100. I think I'm a very sociable and outgoing
person.
101. It is always best to follow the rules that
those in authority have made.
102. A lot of my answers on this test have been
affected by my current bad mood.
103. I sometimes take medications that are
prescribed for other people.
104. I often set myself up to fail.
105. I feel guilty most of the time.
106. I flew across the Atlantic more than 30
times last year.
107. My feelings toward my relatives often swing
back and forth from love to hate.
108. I want my doctors to be as detailed as
possible in telling me about my medical
problems.
109. I don't think I'll live as long as I should.
110. I make my life worse than it has to be.
111. I smoke about a pack of cigarettes a day.
112. I've never had as much interest in sex as
most people my age.
113. I'm too embarrassed to admit my problems
as frankly as I should.
114. I can charm people into doing almost
anything I want.
115. I've been overweight ever since I was a
child.
116. If I don't get relief from medicine, I may
increase the dosage on my own.
117. In the past year, I've really gone downhill
mentally.
118. I think I am making my life look worse than
it really is by my responses here.
119. I spend much of my time brooding about
things.
120. Too many rules get in the way of people
doing what they want to do.
Please go to the next page
121. No one needs to know my business.
122. I've always felt that most people think
poorly of me.
123. I'm considered a tough and unsentimental
person.
124. I was on the front cover of several
magazines recently.
125. I get very annoyed when others put
pressure on me.
126. My body is constantly giving me worrisome
signals.
127. It is difficult for me to get through the day
without a few drinks.
128. I never put off seeing the doctor if I feel I
need to.
129. Being in touch with my spiritual self helps
me deal with life's burdens.
130. I often feel sad and unloved.
131. I start feeling crazy when medical problems
turn out badly for me.
132. I am holding back when I respond to many
of these statements.
133. I feel entitled to all my sick days each year.
134. I'd rather not know the details of an illness I
might have.
135. I get very irritable if I haven't had a cup of
coffee for a few hours.
136. The quality of my life has gotten much
worse because of my illness.
137. I rarely feel a sense of joy these days.
138. I usually do what I want without worrying
about how it affects others.
139. I'm a yo-yo dieter; my weight goes up and
down.
140. My head often hurts so much that I need to
take time off from work.
141. This is a very lonely world.
142. I've tried to quit smoking many times, but I
always start again.
143. I would change my lifestyle on my doctor's
advice.
144. Without God in my life, I could never get
through a serious illness.
145. My pain is on my mind constantly.
146. I always overeat when I'm depressed or
under stress.
147. My future looks like it will be full of
problems and pain.
148. It's okay to take advantage of gray areas in
the law.
149. I've tried exercise programs, but I just can't
seem to stick with them.
150. I'm unable to organize my life the way I
want.
151. Members of my family have complained
recently about my drinking.
152. I really don't understand human feelings
like others do.
153. I need plenty of caffeine to get me through
the day.
154. I almost always put other people's needs
above my own.
155. I often feel overwhelmed by minor
responsibilities.
156. I've lost interest in things that I used to find
pleasurable.
157. I now need to follow routines so that I don't
get confused.
158. My medical condition has made daily tasks
much more difficult.
159. I know I should exercise, but I just can't get
started.
160. I cannot count on anyone to support me
during times of illness.
Please go to the next page
161. I feel very depressed.
162. I am a very emotional person.
163. I like to flirt with members of the opposite
sex.
164. I get irritable if I go too long without a
cigarette.
165. I have no deep religious beliefs.
Appendix VI
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Definitions of MIPS Scales
144
The 24 MIPS scales are organised into three major areas: Motivating Aims, Cognitive Modes, and
Interpersonal Behaviours. A brief definition of each of the 24 MIPS scales follows:
Motivating Aims
Enhancing Persons scoring high on this scale tend to look for the bright side of life, are optimistic
about future possibilities, find it easy to enjoy themselves, and face the ups and downs of life with
equanimity.
Preserving Persons scoring high on this scale focus on and intensify the problems of life.
Perceiving the past as having been personally troubling, they always seem to be waiting for
something else to go wrong, and feel that things are likely to go from bad to worse. They are easily
upset by minor concerns and disappointments.
Modifying Persons scoring high on this scale take charge of their lives and make things happen
rather than wait for them to occur. They are busily involved in modifying their environments and
arranging events to suit their needs and desires.
Accommodating Persons scoring high on this scale undertake little to shape or alter their lives.
They react to the passing scene, accommodating to circumstances created by others; they seem
acquiescent, are unable to rouse themselves, lack initiative, and do little to generate the outcomes
they desire.
Individuating Persons scoring highly on this scale are oriented to actualise their own needs and
wishes, that is, they seek to fulfil themselves first, worry little about the impact of their behaviour on
others, and tend to be both independent and egocentric.
Nurturing Persons scoring high on this scale are motivated to meet the needs of others first; to
attend to other people's welfare and desires at the expense of themselves. They are seen as nurturant
and protective taking care of others before taking care of themselves.
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Cognitive Modes
Extraversing High scorers turn to others to find stimulation and encouragement. They draw upon
friends and colleagues for ideas and guidance, inspiration and energy, as well as garnering
assurances of self-worth from them and taking comfort in their presence.
Introversing High scorers prefer to use their own thoughts and feelings as resources, gaining
inspiration and stimulation primarily from themselves rather than from others. By contrast with
extraverts, introverts experience greater serenity and comfort by distancing themselves from external
sources, preferring to heed the prompting that comes from within.
Sensing High scorers gather their knowledge from the tangible and concrete, trusting direct
experience and observable phenomena over the use of inference and abstraction. The practical and
'real', the literal and factual are what give these individuals comfort and confidence.
Intuiting High scorers prefer the symbolic and unknown to the concrete and observable. They are
open to the intangibles of life and are inclined to seek out and enjoy the more mysterious
experiences and speculative sources of knowledge.
Thinking High scorers prefer to process the knowledge they have by means of logic and analytical
reasoning. Decisions are based on cool, impersonal, and 'objective' judgements, rather than on
subjective emotions.
Feeling High scorers form their judgements by heeding their own affective responses to
circumstances, by evaluating subjectively the impact of their actions upon those involved, and by
following their personal values and goals.
Systematising High scorers are very organised and predictable in their approach to life's
experiences. They transform new knowledge in line with what is known and are careful, if not
perfectionistic, in arranging even minor details. As a result, others see them as orderly,
conscientious, and efficient.
Innovating High scorers are inclined to be creative and to take risks, ready to alter and recast
whatever they come upon. They seem discontented with the routine and predictable; spontaneously
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modifying what is given by following their hunches and seeking to effect novel, unanticipated
consequences.
Interpersonal Behaviours
Retiring Persons scoring high on this scale are characterised by their lack of affect and their social
indifference. They tend to be quiet, passive, and uninvolved; they may be viewed by others as quiet
and colourless, unable to make friends, as well as apathetically disengaged.
Outgoing High scorers seek social stimulation, excitement and attention. They often react
dramatically to situations around them, but typically, they lose interest very quickly. Colourful and
charming socialites, they can also be demanding and manipulative.
Hesitating High scorers are usually shy, timid and nervous in social situations, strongly wanting to
be liked and accepted, yet often fearing rejection. At the same time they are sensitive and
emotionally responsive, they are mistrusting, lonely, and isolated.
Asserting High scorers tend to feel that they are more important and gifted than the people around
them. They are often ambitious and egocentric, self-assured and outspoken. Others may see them as
arrogant and inconsiderate.
Dissenting High scorers tend to act out in an independent and non-conforming manner. They often
resist following traditional standards, displaying an audaciousness that may be seen either as
reckless or as spirited and enterprising.
Conforming High scorers are likely to upstanding and self-controlled. They relate to authority in a
respectful and co-operative manner, tend to behave in a formal and proper manner in social
situations, and are unlikely to be self-expressive or to act spontaneously.
Yielding High scorers are their own worst enemies: They are accustomed to suffering rather than
pleasure, are submissive, and tend to act in self-demeaning ways. Their behaviour renders
ineffective the efforts of others to assist them, and causes the yielders to bypass opportunities for
rewards and to fail repeatedly to achieve despite possessing abilities to do so.
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Controlling High scorers are forceful and often domineering and socially aggressive. They tend to
see themselves as fearless and competitive. To them, warmth and gentleness are signs of weakness,
which they avoid by being strong-willed and ambitious.
Complaining High scorers are characterised by their tendency to be passive-aggressive, sullen, and
generally dissatisfied. Their moods and behaviour are highly changeable: At times, they relate to
others in a sociable and friendly manner: on other occasions, they are irritable and hostile,
expressing the belief that they are misunderstood and unappreciated.
Agreeing High scorers tend to be highly likeable socially, often relating to others in an amenable
manner. They form strong loyalties and attachments to others. They cover any negative feelings,






The MBMD is comprised f seven domains. Each domain contains a series of scales. The domains
are: Response Patterns, Negative Health Habits, Psychiatric Indications, Coping Styles, Stress
Moderators, and Treatment Prognostics. A brief description of those scales used in the research
follows:
Response Patterns:
Validity The validity indicator is composed of two highly improbable items (Items 106 & 124 -
refer to Appendix). Endorsements on the validity indicator may indicate inadequate reading skills,
confusion, or random responding. In this research no respondents endorsed either item.
Disclosure The scale is designed to determine whether the patient is inclined to be overly frank or
self-revealing. No respondents obtained scores that may have signified a troublesome level of
disclosure.
Desirability This scale identifies the degree to which the respondent's results may have been
affected by his/her desire to appear socially attractive, morally virtuous, or emotionally well
composed. High scores indicate a greater likelihood that the respondent is concealing important
psychological stressors or behavioural problems. No respondents obtained any suggestive scores on
this scale.
Debasement This scale assesses the respondent's tendency to present many minor and major
symptoms, sensations, and experiences in his/her communication with the healthcare provider. The
scale reflects tendencies that are the opposite of those detected by the Desirability scale. High scorers
are inclined to devalue themselves by reporting more troublesome emotions or medical problems
than are likely to be uncovered in an objective review. No respondents obtained any significant
scores on this scale.
Negative Health Habits
The indicators included in this domain cover lifestyle behaviours that have been shown to have the




Anxiety-Tension High scorers may suffer from numerous somatic disorders, especially those
associated with the cardiovascular and digestive systems.
Depression High scorers tend to interpret life as a series of troubles and misfortunes and are likely
to intensify the discomfort of their real physical and psychological problems.
Cognitive Dysfunction This scale assesses the capacity to recall past experiences, to think
abstractly, and to represent events and interrelate and process them symbolically.
Emotional Lability This scale assesses the experience of intense endogenous moods and
respondents may exhibit recurring periods of dejection, and apathy, often interspersed with spells of
anger, anxiety, or euphoria. They are typified by dysregulation of their affect and instability in their
moods, perhaps at one extreme, manifested in repetitive suicidal thoughts or self-harm.
Guardedness This scale aims to identify medical patients who display mistrust and an edgy
defensiveness against those they see as hostile and deceptive. They may exhibit irritability and
suspiciousness, and they often provoke annoyance, if not exasperation, on the part of healthcare
providers.
Coping Styles
Introversive High scorers tend to be rather colourless, emotionally subdued, and quiet. Typically,
they lack energy, are communicatively vague, and are difficult to pin down regarding their
symptoms. Some may have become withdrawn as a way of coping with a chronic illness.
Inhibited High scorers tend to be shy, ill at ease, and hesitant with others. They may be sensitive
and are often concerned that others may do them harm. Because they may fear that others take
advantage of them, they may try to keep their physical discomfort to themselves. Their isolation may
also stem from a loss of self-esteem consequent to persistent illness. Despite their hesitation, they do
want understanding and attention. With a sympathetic clinical attitude, they can become quite co¬
operative.
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Dejected High scorers are inclined to be persistently and characteristically disheartened, unable to
experience the pleasures or joys of life. They are easily disposed to give up trying to work through
their emotional or physical problems. Their disconsolate and somewhat hopeless orientation will
call for greater effort than usual from healthcare staff.
Co-operative High scorers tend to be eager to attach themselves to a supportive healthcare
professional, and will follow medical advice closely. However, they may not take the initiative to
seek treatment and will need to be told exactly what to do. Healthcare personnel may have to probe
carefully and ask explicit questions to get the information they need. They become overly dependent
on their carers.
Nonconforming High scorers tend to be somewhat unconventional if not arbitraiy and occasionally
inconsiderate in their manner. They are somewhat sceptical about the motives of others, and they
tend to act insensitively and impulsively at times. Healthcare professionals should assure them that
they are there to help them solve their physical problems in a professional way.
Forceful High scorers tend to be rather domineering and tough-minded. The healthcare team
should try not to feel intimidated or provoked by these individuals. A straightforward approach is
most effective with these patients. They may have a tendency to be mistrustful, and may not follow
treatment regimens well. It will be necessary for the healthcare team to exert extra effort to
encourage them to comply.
Respectful High scorers are likely to be responsible, conforming, and co-operative. They keep
their feelings to themselves and try to appear controlled, diligent, and serious-minded. These
patients usually take their medication and follow therapeutic recommendations. However, they are
very likely to hide their symptoms, and they may resist disclosing their problems. They do not like to
be seen in the patient role because it signifies weakness and inefficiency to them.
Oppositional High scorers are often unpredictable and difficult. They may be erratic in following a
treatment plan - overmedicating and under medicating without consulting their attending
healthcare worker. They often seem displeased and dissatisfied with their physical and psychological
state. At times, they will complain about their treatment, but this may quickly switch to expressions
of regret and contrition. They often have mood changes for no obvious reason, and rapport may be
easy on some days but difficult on others.
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Denigrated High scorers habitually focus on the most troublesome aspects of their lives, behaving
as if they deserve to suffer. They may feel that they deserve the infirmities and ailments they
experience, and they may actively and repetitively recall past troubles and afflictions.
Stress Moderators
Illness Apprehension vs. IllnessAcceptance The Illness Apprehension scale reflects patients' focus
on and awareness of changes in their bodies such as tension/relaxation and arousal/fatigue. They
may either have an ability to monitor and report significant changes in symptoms, or attend to less
important sensations in a way that they ruminate excessively about their medical state and medical
services. Illness Acceptance reflects the behavioural assets of self-possession and imperturbability.
Social Isolation vs. Social Support This scale assesses respondents' perceptions of the social
support in their lives. High scorers are more likely to suffer physical and psychological ailments
than low scorers. Poor adjustment to hospitalisation is also common.
Future Pessimism vs. Future Optimism This scale is designed to assess patients' outlook toward
their future health status. This patient characteristic may influence a number of medical outcomes
including adherence to and confidence in medical regimens, emotional reactions to diagnostic test
results, and probably the actual physical course of disease. A high score may reflect a patient's
response to his/her current medical problems rather than a lifelong tendency to be pessimistic.
Treatment Prognostics
Interventional Fragility vs. Interventional Resilience The Interventional Fragility scale predicts
whether patients will be able to adjust emotionally to the demands of physically and psychologically
stressful medical protocols. This is most useful in a medical/surgical context.
Medication Abuse vs. Medication Conscientiousness This scale predicts the likelihood that
patients will have problems with or will misuse prescribed medication. This might take the form of
changing dosages, combining medications inappropriately, or using outdated prescriptions. These
behaviours can be dangerous and should be identified at the earliest point in the treatment process.
Information Discomfort vs. Information Receptivity This scale assesses patients' lack of
receptivity to specific details about diagnostic, prognostic, and treatment procedures and outcomes.
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Some patients want to know as much as they can about their medical condition and prognosis.
Others do not, sometimes to the point of not wanting to know the name of their disorder much less
its character or prognosis.
Problematic Compliance vs. Optimal Compliance A major problem for healthcare professionals
is patients who either inadvertently or intentionally resist following medical recommendations. This
scale assesses compliance problems and identifies the disinclination to follow home-care advice, to
adhere to medication instruction, and to be and keep on time for appointments.
Management Guides
The Management Guides domain includes two summary scales: Adjustment Difficulties and Psych
Referral. These scales integrate and summarise a patient's major problem areas. They were not
consulted within this research.
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The 24 MIPS scales are organised into three major areas: Motivating Aims, Cognitive Modes, and
Interpersonal Behaviours. A brief definition of each of the 24 MIPS scales follows:
Motivating Aims
Enhancing Persons scoring high on this scale tend to look for the bright side of life, are optimistic
about future possibilities, find it easy to enjoy themselves, and face the ups and downs of life with
equanimity.
Preserving Persons scoring high on this scale focus on and intensify the problems of life.
Perceiving the past as having been personally troubling, they always seem to be waiting for
something else to go wrong, and feel that things are likely to go from bad to worse. They are easily
upset by minor concerns and disappointments.
Modifying Persons scoring high on this scale take charge of their lives and make things happen
rather than wait for them to occur. They are busily involved in modifying their environments and
arranging events to suit their needs and desires.
Accommodating Persons scoring high on this scale undertake little to shape or alter their lives.
They react to the passing scene, accommodating to circumstances created by others; they seem
acquiescent, are unable to rouse themselves, lack initiative, and do little to generate the outcomes
they desire.
Individuating Persons scoring highly on this scale are oriented to actualise their own needs and
wishes, that is, they seek to fulfil themselves first, worry little about the impact of their behaviour on
others, and tend to be both independent and egocentric.
Nurturing Persons scoring high on this scale are motivated to meet the needs of others first; to
attend to other people's welfare and desires at the expense of themselves. They are seen as nurturant
and protective taking care of others before taking care of themselves.
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Cognitive Modes
Extraversing High scorers turn to others to find stimulation and encouragement. They draw upon
friends and colleagues for ideas and guidance, inspiration and energy, as well as garnering
assurances of self-worth from them and taking comfort in their presence.
Introversing High scorers prefer to use their own thoughts and feelings as resources, gaining
inspiration and stimulation primarily from themselves rather than from others. By contrast with
extraverts, introverts experience greater serenity and comfort by distancing themselves from external
sources, preferring to heed the prompting that comes from within.
Sensing High scorers gather their knowledge from the tangible and concrete, trusting direct
experience and observable phenomena over the use of inference and abstraction. The practical and
'real', the literal and factual are what give these individuals comfort and confidence.
Intuiting High scorers prefer the symbolic and unknown to the concrete and observable. They are
open to the intangibles of life and are inclined to seek out and enjoy the more mysterious
experiences and speculative sources of knowledge.
Thinking High scorers prefer to process the knowledge they have by means of logic and analytical
reasoning. Decisions are based on cool, impersonal, and 'objective' judgements, rather than on
subjective emotions.
Feeling High scorers form their judgements by heeding their own affective responses to
circumstances, by evaluating subjectively the impact of their actions upon those involved, and by
following their personal values and goals.
Systematising High scorers are very organised and predictable in their approach to life's
experiences. They transform new knowledge in line with what is known and are careful, if not
perfectionistic, in arranging even minor details. As a result, others see them as orderly,
conscientious, and efficient.
Innovating High scorers are inclined to be creative and to take risks, ready to alter and recast
whatever they come upon. They seem discontented with the routine and predictable; spontaneously
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modifying what is given by following their hunches and seeking to effect novel, unanticipated
consequences.
Interpersonal Behaviours
Retiring Persons scoring high on this scale are characterised by their lack of affect and their social
indifference. They tend to be quiet, passive, and uninvolved; they may be viewed by others as quiet
and colourless, unable to make friends, as well as apathetically disengaged.
Outgoing High scorers seek social stimulation, excitement and attention. They often react
dramatically to situations around them, but typically, they lose interest very quickly. Colourful and
charming socialites, they can also be demanding and manipulative.
Hesitating High scorers are usually shy, timid and nervous in social situations, strongly wanting to
be liked and accepted, yet often fearing rejection. At the same time they are sensitive and
emotionally responsive, they are mistrusting, lonely, and isolated.
Asserting High scorers tend to feel that they are more important and gifted than the people around
them. They are often ambitious and egocentric, self-assured and outspoken. Others may see them as
arrogant and inconsiderate.
Dissenting High scorers tend to act out in an independent and non-conforming manner. They often
resist following traditional standards, displaying an audaciousness that may be seen either as
reckless or as spirited and enterprising.
Conforming High scorers are likely to upstanding and self-controlled. They relate to authority in a
respectful and co-operative manner, tend to behave in a formal and proper manner in social
situations, and are unlikely to be self-expressive or to act spontaneously.
Yielding High scorers are their own worst enemies: They are accustomed to suffering rather than
pleasure, are submissive, and tend to act in self-demeaning ways. Their behaviour renders
ineffective the efforts of others to assist them, and causes the yielders to bypass opportunities for
rewards and to fail repeatedly to achieve despite possessing abilities to do so.
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Controlling High scorers are forceful and often domineering and socially aggressive. They tend to
see themselves as fearless and competitive. To them, warmth and gentleness are signs of weakness,
which they avoid by being strong-willed and ambitious.
Complaining High scorers are characterised by their tendency to be passive-aggressive, sullen, and
generally dissatisfied. Their moods and behaviour are highly changeable: At times, they relate to
others in a sociable and friendly manner: on other occasions, they are irritable and hostile,
expressing the belief that they are misunderstood and unappreciated.
Agreeing High scorers tend to be highly likeable socially, often relating to others in an amenable
manner. They form strong loyalties and attachments to others. They cover any negative feelings,






The MBMD is comprised f seven domains. Each domain contains a series of scales. The domains
are: Response Patterns, Negative Health Habits, Psychiatric Indications, Coping Styles, Stress
Moderators, and Treatment Prognostics. A brief description of those scales used in the research
follows:
Response Patterns:
Validity The validity indicator is composed of two highly improbable items (Items 106 & 124 -
refer to Appendix). Endorsements on the validity indicator may indicate inadequate reading skills,
confusion, or random responding. In this research no respondents endorsed either item.
Disclosure The scale is designed to determine whether the patient is inclined to be overly frank or
self-revealing. No respondents obtained scores that may have signified a troublesome level of
disclosure.
Desirability This scale identifies the degree to which the respondent's results may have been
affected by his/her desire to appear socially attractive, morally virtuous, or emotionally well
composed. High scores indicate a greater likelihood that the respondent is concealing important
psychological stressors or behavioural problems. No respondents obtained any suggestive scores on
this scale.
Debasement This scale assesses the respondent's tendency to present many minor and major
symptoms, sensations, and experiences in his/her communication with the healthcare provider. The
scale reflects tendencies that are the opposite of those detected by the Desirability scale. High scorers
are inclined to devalue themselves by reporting more troublesome emotions or medical problems
than are likely to be uncovered in an objective review. No respondents obtained any significant
scores on this scale.
Negative Health Habits
The indicators included in this domain cover lifestyle behaviours that have been shown to have the




Anxiety-Tension High scorers may suffer from numerous somatic disorders, especially those
associated with the cardiovascular and digestive systems.
Depression High scorers tend to interpret life as a series of troubles and misfortunes and are likely
to intensify the discomfort of their real physical and psychological problems.
Cognitive Dysfunction This scale assesses the capacity to recall past experiences, to think
abstractly, and to represent events and interrelate and process them symbolically.
Emotional Lability This scale assesses the experience of intense endogenous moods and
respondents may exhibit recurring periods of dejection, and apathy, often interspersed with spells of
anger, anxiety, or euphoria. They are typified by dysregulation of their affect and instability in their
moods, perhaps at one extreme, manifested in repetitive suicidal thoughts or self-harm.
Guardedness This scale aims to identify medical patients who display mistrust and an edgy
defensiveness against those they see as hostile and deceptive. They may exhibit irritability and
suspiciousness, and they often provoke annoyance, if not exasperation, on the part of healthcare
providers.
Coping Styles
Introversive High scorers tend to be rather colourless, emotionally subdued, and quiet. Typically,
they lack energy, are communicatively vague, and are difficult to pin down regarding their
symptoms. Some may have become withdrawn as a way of coping with a chronic illness.
Inhibited High scorers tend to be shy, ill at ease, and hesitant with others. They may be sensitive
and are often concerned that others may do them harm. Because they may fear that others take
advantage of them, they may try to keep their physical discomfort to themselves. Their isolation may
also stem from a loss of self-esteem consequent to persistent illness. Despite their hesitation, they do
want understanding and attention. With a sympathetic clinical attitude, they can become quite co¬
operative.
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Dejected High scorers are inclined to be persistently and characteristically disheartened, unable to
experience the pleasures or joys of life. They are easily disposed to give up trying to work through
their emotional or physical problems. Their disconsolate and somewhat hopeless orientation will
call for greater effort than usual from healthcare staff.
Co-operative High scorers tend to be eager to attach themselves to a supportive healthcare
professional, and will follow medical advice closely. However, they may not take the initiative to
seek treatment and will need to be told exactly what to do. Healthcare personnel may have to probe
carefully and ask explicit questions to get the information they need. They become overly dependent
on their carers.
Nonconforming High scorers tend to be somewhat unconventional if not arbitrary and occasionally
inconsiderate in their manner. They are somewhat sceptical about the motives of others, and they
tend to act insensitively and impulsively at times. Healthcare professionals should assure them that
they are there to help them solve their physical problems in a professional way.
Forceful High scorers tend to be rather domineering and tough-minded. The healthcare team
should try not to feel intimidated or provoked by these individuals. A straightforward approach is
most effective with these patients. They may have a tendency to be mistrustful, and may not follow
treatment regimens well. It will be necessary for the healthcare team to exert extra effort to
encourage them to comply.
Respectful High scorers are likely to be responsible, conforming, and co-operative. They keep
their feelings to themselves and try to appear controlled, diligent, and serious-minded. These
patients usually take their medication and follow therapeutic recommendations. However, they are
very likely to hide their symptoms, and they may resist disclosing their problems. They do not like to
be seen in the patient role because it signifies weakness and inefficiency to them.
Oppositional High scorers are often unpredictable and difficult. They may be erratic in following a
treatment plan - overmedicating and under medicating without consulting their attending
healthcare worker. They often seem displeased and dissatisfied with their physical and psychological
state. At times, they will complain about their treatment, but this may quickly switch to expressions
of regret and contrition. They often have mood changes for no obvious reason, and rapport may be
easy on some days but difficult on others.
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Denigrated High scorers habitually focus on the most troublesome aspects of their lives, behaving
as if they deserve to suffer. They may feel that they deserve the infirmities and ailments they
experience, and they may actively and repetitively recall past troubles and afflictions.
Stress Moderators
Illness Apprehension vs. Illness Acceptance The Illness Apprehension scale reflects patients' focus
on and awareness of changes in their bodies such as tension/relaxation and arousal/fatigue. They
may either have an ability to monitor and report significant changes in symptoms, or attend to less
important sensations in a way that they ruminate excessively about their medical state and medical
services. Illness Acceptance reflects the behavioural assets of self-possession and imperturbability.
Social Isolation vs. Social Support This scale assesses respondents' perceptions of the social
support in their lives. High scorers are more likely to suffer physical and psychological ailments
than low scorers. Poor adjustment to hospitalisation is also common.
Future Pessimism vs. Future Optimism This scale is designed to assess patients' outlook toward
their future health status. This patient characteristic may influence a number of medical outcomes
including adherence to and confidence in medical regimens, emotional reactions to diagnostic test
results, and probably the actual physical course of disease. A high score may reflect a patient's
response to his/her current medical problems rather than a lifelong tendency to be pessimistic.
Treatment Prognostics
Interventional Fragility vs. Interventional Resilience The Interventional Fragility scale predicts
whether patients will be able to adjust emotionally to the demands of physically and psychologically
stressful medical protocols. This is most useful in a medical/surgical context.
Medication Abuse vs. Medication Conscientiousness This scale predicts the likelihood that
patients will have problems with or will misuse prescribed medication. This might take the form of
changing dosages, combining medications inappropriately, or using outdated prescriptions. These
behaviours can be dangerous and should be identified at the earliest point in the treatment process.
Information Discomfort vs. Information Receptivity This scale assesses patients' lack of
receptivity to specific details about diagnostic, prognostic, and treatment procedures and outcomes.
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Some patients want to know as much as they can about their medical condition and prognosis.
Others do not, sometimes to the point of not wanting to know the name of their disorder much less
its character or prognosis.
Problematic Compliance vs. Optimal Compliance A major problem for healthcare professionals
is patients who either inadvertently or intentionally resist following medical recommendations. This
scale assesses compliance problems and identifies the disinclination to follow home-care advice, to
adhere to medication instruction, and to be and keep on time for appointments.
Management Guides
The Management Guides domain includes two summary scales: Adjustment Difficulties and Psych
Referral. These scales integrate and summarise a patient's major problem areas. They were not
consulted within this research.
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